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For Kate
'Tis strange — but true; for truth is 
always strange;
Stranger than fiction
Lord George Gordon Byron
How often have I said to you that when 
you have eliminated the impossible, 
whatever remains, however improbable, 
must be the truth ?
Sir Arthur Conan Doyle
ABSTRACT
Phenformin (N1-phenethylbiguanide) is an oral hypoglycaemic 
agent which has been in use in the U.K. since 1959 for the treatment 
of some forms of diabetes. In recent years there have been reports 
of lactic  acidosis associated with phenformin therapy, particularly  
in patients with renal or hepatic diseases.
M e t a b o l i c  and pharmacological studies in the rat and guinea-pig 
have shown that a number of factors are involved in the differences 
in response to phenformin in these species. Following a low oral 
dose of [ 2 '- 1IfC]phenformin rats excreted the radioactivity more rapidly 
than guinea-pigs and metabolised the drug more extensively. The rat 
eliminated almost 88% of a 7 mg/kg dose in the urine and faeces in 
24h and the urine contained almost entirely 4-hydroxyphenformin (free  
and conjugated with glucuronic acid) which had no effects on blood 
lactate or glucose concentrations in this species. The guinea-pig 
excreted only 57% of a 25 mg/kg dose and 50% of the urinary radio­
activ ity  (18.5% of the dose) was unchanged phenformin.
The ra t actively eliminated a large proportion (26% in 6h) of a 
20 mg/kg intraduodenal dose of [2' - llfC]phenformin in the b ile , most 
of the radioactivity being attributable to the parent compound. In the 
guinea-pig b ilia ry  excretion was in it ia l ly  rapid but declined so that 
only 6% of the same dose was eliminated in 6h. The possibility that 
active b ilia ry  excretion of phenformin is inhibited by the pharmacological 
effects of the drug in the guinea-pig is discussed.
After oral administration of [ 2 '- llfC]phenformin guinea-pig urine 
contained no 4-hydroxyphenformin but small amounts were detected a fter  
intraperitoneal administration. After both routes of administration 
guinea-pig urine contained a novel metabolite and its glucuronideo 
After oral administration a second novel metabolite was detected in
guinea-pig faeces. These metabolites have not been completely 
characterised but in both cases the biguanide portion of the metabolites 
had been modified. The urinary metabolite is probably the product of 
aliphatic hydroxylation rather than aromatic hydroxylation. The 
identification and pharmacological properties of these metabolites 
remain to be determined. .
Preliminary in vitro studies using isolated rat and guinea-pig 
hepatocytes showed a faster rate of metabolism of [2‘ - ll+C]phenformin 
in rat cells . Rat cells produced significant amounts of 4-hydroxy- 
phenformin and its  glucuronide but guinea-pig cells did not. ; ,
In the rat the time taken to eliminate the dose and the extent to 
which phenformin was excreted unchanged in the urine increased with 
larger doses of the drug. After a high oral dose (100 mg/kg) 24% 
of the urinary radioactivity (12.5% of the dose) was attributable to 
unchanged phenformin.
Pharmacological studies showed that the rise in blood lactate 
concentrations and fa ll in blood glucose concentrations associated 
with phenformin were dose related in the ra t. The relationship between 
this observation and the increased elimination of unchanged drug in 
rat urine after high doses is discussed in terms of a f ir s t1pass 
effect for phenformin in the ra t. The dose-response data indicated 
a c ritica l dose in rats in the region of 120 mg/kg intraperitoneally, 
at which point marked increases in the pharmacological effects of the 
drug were seen. Normal and fasted guinea-pigs were more susceptible 
than rats to both pharmacological actions of phenformin. 4-Hydroxy- 
phenformin produced hyperlactataemia in guinea-pigs without affecting 
blood glucose levels.
The possibility that the guinea-pig may produce a biologically
active metabolite has not been resolved, but the differences in 
pharmacological response to phenformin in the ra t and guinea-pig 
have been explained by the results in the thesis, which show a 
slower rate of metabolism and excretion of the drug in the guinea- 
pig, together with the established biochemical differences in the 
mechanisms of carbohydrate regulation in these species.
Sodium dichloroacetate was effective in reducing phenformin- 
associated hyperlactataemia in rat and guinea-pig and prevented 
the increase in blood lactate levels caused by 4-hydroxyphenformin 
in guinea-pigs.
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CHAPTER 1 
INTRODUCTION
1.1 HISTORICAL REVIEW
The development of biguanides as a treatment of diabetes stemmed
from the reports that parathyroidectomy produced hypoglycaemia which
*
was accompanied by an increase in blood levels of guanidine (Underhill 
et aj_., 1914; Paton et a/L, 1917). This led to the suggestion that 
guanidine might have potential as a hypoglycaemic agent (Watanabe, 1918) 
and to a number of pharmacological and metabolic studies using guanidine
Unfortunately, guanidine its e lf  (see FIG. 1.1) is a highly toxic 
substance, its  lethal dose in mice being 4-5 mg/kg (Sterne, 1969), and 
so attempts were made to modify the molecule to obtain a less toxic 
material which retained the blood sugar-lowering capability. Early 
investigators concluded that for the hypoglycaemic e ffect, i t  was 
necessary to avoid substitution at both ends of the guanidine moiety.
Of the so-called "mono-guanidines" which were synthesised, only iso-amyl 
guanidine (Galegin) showed even a slight possibility of being effective  
in the treatment of diabetes (Mehnert and Sadow, 1969).
The diguanidines (see FIG.1 .1 ), however, were quite effective as 
hypoglycaemic agents and less toxic than the monoguanidine derivatives. 
The f ir s t  of these, Synthalin A, was introduced in 1926, and an improved 
version two years later (Frank jet aj_., 1926, 1928), Although these 
compounds were used for a number of years reports of their toxic ity , 
primarily gastrointestinal reactiv ity , were prevalent. There v/ere 
also reports of other toxic si de-effects which were not assessed 
accurately since pharmacological methods of testing were not highly 
developed at this time. The long methylene chain breaks releasing 
fragments of guanidine which exert a toxic effect upon the liv e r  and
kidneys. The recording of a number of digestive, hepatic and renal 
complications led to discontinuance of this therapy. In fact the 
reports of complications have been questioned by many of the leading 
diabetologists of the Synthalin era (Mehnert and Sadow, 1969), and 
inadequate monitoring of patients along with a poor understanding of 
the true diabetic state in each of the diabetic classes treated 
undoubtedly contributed to.the ultimate failure of the diguanidines.
In 1929 Slotta jet _a]_. reported the preparation of a number of 
alkyl biguanides and found that they had hypoglycaemic activ ity as well 
as an apparently lower toxicity than the guanidines. Although the alkyl 
biguanides seemed to be useful, a combination of factors essentially 
closed down research in this area for nearly 25 years; namely the advent 
of insulin, increasing reports o f guanidine toxicity and the assumption 
that since guanidines were highly hepatotoxic, biguanides were also 
hepatotoxic.
Ambiguity in nomenclature was evident at this time. The Synthalins 
are diguanidines with two discrete 3-nitrogen groupings, whereas the 
biguanides contain one 5-nitrogen moiety (see F IG .l.1 ).
The hypoglycaemic effects of the biguanides were not re-examined 
until 1957, when Ungar reported the hypoglycaemic effect of 3-phenethyl- 
biguanide (Ungar _et jH .,  1957). Since that time a number of biguanides 
have been prepared and evaluated as hypoglycaemic agents. The relative  
effectiveness of various substituted biguanide compounds is discussed 
in SECTION 1.2.
NH
h2n- c—NH2 guanidine
NH . NH
H2N-C-NH ~C—nh2 guanylguanidi ne 
(biguanide)
NH NH
ii
H2N— C—NH—(lGH2)~NH—C—NH2 the diguanidines
n = 10, Synthalin A 
n = 12, Synthal in B
NH NH
II II
~C—NH-—C—NH2 $-phenethy Ibiguamde
(phenformin)
F IG .l.1 Structure of guanidine derivatives
.2 CHEMISTRY OF THE BIGUANIDES
Structure and hypoglycaemic activity
A number of biguanides have been synthesised and pharmacologically 
tested in animals (Hesse and Taubman, 1929; Ungar 1957; Shapiro
et aj_., 1959a,b, c ,d ). These possess the general formula (1 ). Biguanide 
i ts e lf  has about the same blood sugar-lowering effect as simple 
guanidine (2 ).
Substitution on N1 produces a number of effective preparations but 
the choice of substituents is very lim ited. Aralkyl substitution is also 
very effective when the aliphatic portion consists of one or two carbons. 
Substitution on the alkyl chain by hydroxy, methoxy or mercapto groups 
gives inactive compounds.
Di-substitution on N1 appears to produce effective compounds only 
i f  one of the groups is methyl, and is most effective when the other 
group is methyl or benzyl.
According to Shapiro et al_.(1959a,b,c,d) substitution on N5 only 
forms effective compounds i f  the total of the C atoms of the substituents 
does not exceed five and only three of the four radicals are substituted. 
In contrast, Osterloh (I960) has reported that tetra-substitution with
R
\ /
'N^C-NH-C-N5 ( 1)
II II \
NH NH R
butyl radicals produces an effective hypoglycaemic compound, and N1- 
butyl-N5,N5-dimethylbiguanide has also been shown to be active.
The relative effectiveness of various substituted biguanides
%
is summarised in TABLE 1.1.
The structure of the three biguanide derivatives in clinical use 
at the present time are shown below, (3-5).
Reactions of the biguanides
Although the structures of biguanides are conventionally 
represented as shown above, the biguanide moiety may also be 
represented by a number of tautomeric forms, which in turn may also 
exist in several resonant forms (Elpern,.1968) some of which are 
shown in FIG.1.2.
In addition i t  has been suggested by Shapiro et al_. (1959b) that 
the effective biguanide derivatives under physiological conditions 
exist in ring form as monobasic, conjugated hydrophilic cations.
This ring structure (6) is readily formed by biguanides under a number 
of conditions.
PHENFORMIN (3)
N1 - p h e n e t  hy 1 b i g u a n i d e
BUFORMIN (4) 
N1-buty1biguanide
METFORMIN (5)
N1,N1-dimethyIbiguanide
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Wickramasinghe and Shaw (.1972) have reported the thermal in s tab ility  of 
phenformin hydrochloride to gas chromatographic conditions. Analysis
Elpern (1968) has described a number of condensation reactions of 
biguanides -which lead to the formation of triazine structures. One of 
these, acylation, has recently been used as a means of preparing 
derivatives of phenformin, buformin and metformin which are suffic iently  
volatile  to allow g .l.c . determination of the biguanides. Derivatisation 
with trifluoroacetic anhydride (Sterling Winthrop Research Laboratories, 
personal communication, 1974) or monochlorodifluoroacetic anhydride 
Matin e t ^ . ,  1975) forms the corresponding diamino-s-triazine. The 
reaction products are structurally stable on volatilisation and possess 
electron capture activ ity . An example of the reaction scheme is shown 
in FIG. 1.3.
by mass spectrometry of the single GC peak seen at 225° showed signals 
consistent with the s-triazine structure (7) shown below.
/ <:::s>-'CH2CH2-N H ^ / n ^ p N H 2
n^ n
NH2
NH NH 
H II R—NB-C-NH—C-NH2
^  “ NH NH 
+ I II
R -M =C -N B -C -N H 2
n h 2 nh
I I!
r- nh- c = n- c- nh2
“ NH “ NH 
+ . 1 + 1
R—NH=0-^H=G~NH o
” N NH
+ II li
Rr-NH 2—C-NH—C-N H2
“ NH “ NH 
R~+NH==C-NH-o4iH9
NH
R^ NH^ -NH2Ji-NH2
N -H ..N H  
II i! 
R -N H -C -N H -G -N H 2
FIG.1.2 Resonant and tautomeric forms of the biguanide moiety
nh nhf f  ' ^ 2  2
II II
NH NH
phenformin
R - C - O - C — R
li II
O 0
R = CFs
or
CF2 C1
ff ^ s ^ r^ CH2CH2NH ■NH.
substituted
diamino~l,3,5-tri azine
FIG. 1.3 Acylation reaction of phenformin with acetic anhydrides 
to form triazine derivatives.
1.3 BIGUANIDES IN THE TREATMENT OF DIABETES MELLITUS
Clinical experience with the biguanides has shown that the drugs 
can lower blood sugar extrapancreatically and reduce excessive, delayed, 
post-prandial insulin release. Biguanides cannot increase endogenous 
insulin release, suppress lipolysis or promote lipogenesis. Thus in 
the insulin-dependent diabetic total insulin replacement is impossible 
since the lowering of blood sugar is almost certainly less important 
than the suppression of the excessive lipolysis which can lead to 
ketoacidosis.
The overweight, ketoacidosis-resistant diabetic is usually an 
over-secretor of insulin in response to hyperglycaemia. Excessive body 
weight and hyperinsulinaemia seem to have a tendency to go hand-in-hand.
In this case the use of biguanides to lower blood sugar without calling 
upon more endogenous insulin permits a reduction in the hyperinsulinaemic 
response and avoids lipogenesis without further suppressing lipolysis.
Accordingly, because of the gradual and persistent reduction in 
body weight and serum cholesterol levels produced by the drugs (M ille r, 
I960;'Brown and Gabert, 1962; McKendry, 1962; Patel and Stowers, 1964; 
Alterman and Lopez-Gomez, 1968; Craig et a1_., 1968; Gershberg et al_., 1968; 
Meinert and Schwartz, 1968) the biguanides are considered by many to be 
the drug of choice in the stable adult-onset, ketoacidosis-resistant 
diabetic who has a strong tendency towards becoming overweight.
Biguanides have also been used sucessfully in the treatment of some 
unstable adult-onset diabetics (Krall et al_., 1958) particularly in cases 
of insulin resistance (Roush et al_., 1961; Gold, 1962).
The combination of a biguanide with a suTphonlyurea (usually phenformin 
and chlorpropamide) has been found effective in maintaining diabetic 
control in patients over 50 years of age particularly in view of the 
high incidence of secondary sulphony]urea failures, where the pancreatic 
0-cells become less capable of regenerating insulin in response to 
repeated doses of the drug. There are numerous reports of fu ll recovery 
of control of diabetes by combined therapy in patients who responded 
poorly to either drug alone (Bradley, 1959; Bloom e ta l_ ., 1961; Clarke 
et al_., 1965; Gibbs, 1966). Combined therapy provides maximal hypoglycaemic 
effect and tends to avoid si de-effects as dosage of each drug is reduced, 
but the risk of hypoglycaemia is increased.
1.4 PHARMACOLOGY AND MODE OF ACTION OF THE HYPOGLYCAEMIC BIGUANIDES
Despite a large amount of data on the effects of biguanides both 
in vitro and in vivo, the mechanism by which hypoglycaemia is produced 
has not yet been fu lly  elucidated. A very important aspect is the 
relationship between the mode of action of the biguanides and lactate 
metabolism. There is no doubt, from clinical and experimental evidence, 
that lactate metabolism is influenced by the biguanides, and that in 
special circumstances, when lactate metabolism is disturbed, the drugs 
can exert a toxic action. This problem is discussed in more detail in 
SECTION 1.5.
Hypoglycaemic effects
The hypoglycaemic dose of a ll biguanides differs considerably from 
one drug to another, and there is a widely varying response to the same 
drug in different species. The nutritional state of the animals also 
has considerable bearing on the hypoglycaemic activ ity  (Ungar, 1961)
and in the same species may vary by 100% of the lowest dosage depending 
upon the individual susceptibility.
Hypoglycaemia appears in non-diabetic animals only after administration 
of very large doses, far higher than therapeutic doses and even as high 
as 50% of the lethal dose. In non-diabetic humans a number of authors 
have reported insensitivity to doses of phenformin which cause a 
pronounced reduction of blood sugar in diabetics (Fajans et a/[., I960; 
Madison and Ungar, 1960). This specific antidiabetic action has also 
been reported with metformin (Rambert et a l . ,  1961) and buformin 
(Osterloh, 1960; Sbling and Creutzfeldt, 1960). The biguanides can 
lower blood sugar in experimentally-induced diabetic animals. Although 
there have been conflicting reports on this effect by various authors 
these are almost certainly due to the d ifficu lty  in defining the exact 
nature of the diabetic state produced. In streptozotocin-induced diabetic 
rats the blood glucose concentration was significantly reduced by doses 
of phenformin (30 to 100 rng/kg, intraperitoneally) which were v irtua lly  
inactive in normal rats (Polacek and Ouart, 1974). Beckmann (1961) 
succeeded in maintaining the blood sugar at a normal level in alloxan- 
induced diabetic rats with 100-150 mg/kg of buformin ora lly , the 
glucose concentration dropping from 366 to 60 rng/100 ml in 3 days.
Similar effects in alloxan diabetic rats given 700 mg/kg of metformin 
orally have been reported by Sterne (1969).
Experiments in animals after surgical pancreatectomy have produced 
conflicting results, probably due to differing experimental procedures 
and varying degrees of trauma. In the partia lly  eviscerated guinea-pig 
from which the pancreas, stomach and intestines were removed and in which
the live r was excluded from the circulation, phenformin produced a 
marked hypoglycaemia even in the presence of a dextrose infusion (Nielsen 
et a L , 1958). On the other hand Kflhler and Lippmann (1963) found that 
blood sugar in pancreatectomised dogs was not affected by phenformin. 
Metformin (50 mg/kg, orally) administered to pancreatectomised dogs 
caused a reduction in blood glucose according to Hesse and Taubmann (1929), 
but Sterne (1969) was unable to reproduce these findings and concluded 
that the presence of some pancreatic islets was essential for the 
biguanides to act effectively. In view of the varying degrees of 
surgical trauma and the d ifficu lty  of ensuring a total pancreatectomy 
in some species (Sterne, 1969) the results of these experiments are 
d iff ic u lt  to interpret.
Toxic effects
These have been carefully studied, partly because the biguanides 
are given for prolonged periods and partly because earlier oral 
antidiabetic agents such as the diguanidines had created adverse 
impressions.
The toxic dose varies from species to species and, as death 
generally results from hypoglycaemia, there is considerable variation 
depending on the nutritional state and individual susceptibility of the 
animal. The Rhesus monkey and the guinea-pig are both exquisitely 
sensitive to the hypoglycaemic effects of phenformin, while the rat 
and mouse are resistant. A comparison of the LD^ q values of phenformin 
and metformin in a number of laboratory animal species is shown in 
TABLE 1.2. Equally extensive data on the acute toxicity of buformin does
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not appear to have been published.
Investigation of chronic toxicity of phenformin in laboratory 
animals has been studied, although the problem of fatal hypoglycaemia at 
large doses has caused some d iffic u ltie s . In rats given 100 mg/kg orally  
each day for 6 months no harmful effects were seen on growth, blood 
sugar, nitrogen, cholesterol, protein, or electrolytes. Organ weights 
and histology in the treated group were indistinguishable from control 
animals. In the same study guinea-pigs given 10 or 20 mg/kg orally for 
6 months showed no harmful effects (Ungar, cited by Sterne, 1969), and 
no untoward effect on blood chemistry other than a fa ll in blood sugar.
Some minor necrosis of hepatic cells and histological changes in the 
renal tubules was reported in guinea-pigs after administration of 25 mg/kg 
sub-cutaneously (Creutzfeldt and Moench, 1958).
Chronic toxicology studies with metformin in the rat (125 mg/kg, 
orally) and rabbit (100 mg/kg, orally) given the drug daily for one year, 
failed to detect any abnormalities in blood chemistry or tissue histology 
(Sterne, 1969). After 5 months treatment with buformin (50 mg/kg, daily) 
in the ra t, a number of hepatic lesions including some sclerosis developed 
and fatty  deposits were found in the renal epithelium (Georgii, 1960).
The extent of the lesions, particularly fibrosis and glycogen depletion, 
was more pronounced in rats with experimentally induced cirrhosis.
In the human diabetic in the absence of other illnesses and at 
therapeutic doses, the biguar.ides are non-toxic (Mehnert and Sadow, 1969; 
Hermann, 1973). Recently, Graeber et al_. (1976) described the occurrence 
of severe pancreatitis in an elderly diabetic patient receiving phenformin 
(50 mg ora lly , twice a day). The implication of phenformin as the aetiological
agent was based primarily on the absence of other causes of pancreatitis 
at laporotomy, and the fact that the patient had not suffered a recurrence 
of the condition since termination of biguanide therapy. In previously 
published cases cessation of the drug terminated relapsing,bouts of 
pancreatitis (Wilde, 1972; Levitan, 1973; Goodley ejt al_., 1973).
In the presence of other complicating disorders biguanides can give 
rise to lac tic  acidosis. The causal connection between biguanide therapy 
and the development of lactic acidosis in diabetic patients is a 
contraversial issue at present. Although a slight elevation of blood 
lactate is common in phenformin treated diabetics (Craig et al_., 1960; 
Fajans et al_., 1960; Mattrass et al_., 1977) a significant increase is 
unlikely to occur except in cases where some other factor is present, 
such as poor renal function (Cohen et a]_., 1973; Ball et-al_» 1974;
Heuclin et al_., 1975; Conlay and Loewenstein, 1975; Searle and Siperstein, 
1975; Assan e ta j_ ., 1976; Thimme et al_., 1976; Williamson, M., 1976;
Wise et al_., 1976), live r disease (Cohen ert a l . ,  1973; Ass an et a l . ,  1975; 
Heuclin et al_., 1975; Assan et al_., 1976), reduced circulatory efficiency, 
which in turn would affect renal function (Assan et al_., 1975; Dembo 
et a l - , 1975; Assan et a]_., 1976; Thimme et. ah 9 1976; Wise et _al_., 1976), 
severe infections (Dembo et al_., 1975; Heuclin et al_., 1975; Romankiewicz, 
1975; Thimme et a l . , 1976; Williamson, M., 1976) and acute alcoholosis 
(Johnson and Waterhouse, 1968; Heuclin et , 1975; Assan et al_., 1976). 
Lactic acidosis also occurs in diabetic patients treated with metformin 
(Lebacq and Tirzmalis, 1972; Hayat, 1973; Heuclin e t 'a K , .1975; Bismuth 
et cH., 1976; Assan et al_., 1977) and buformin (Clavadetscher et ^1 ., 1976 
Thimne et_ cfL, 1976). Although the incidence of lactic  acidosis with
metformin and buformin is lower than that in phenformin treated patients, 
the existence of the same predisposing conditions has been reported 
(Clavadetscher et al_. ,  1976; Thimme et aV., 1976; Assan et a l. , 1977).
While there have been some reports of lactic acidosis in diabetic patients 
receiving biguanides in whom nooknown causes of lactate accumulation were 
detected (Blumenthal and Streeten, 1975; Fulop and Hoberman, 1976) the 
weight of evidence is strongly in favour of regarding the biguanides as 
having a contributory rather than a causal, role. This evidence is 
discussed in more detail in SECTION 1.5.
The effect of phenformin on diabetic patients has been studied under 
s tr ic t balance conditions, (Geldermans et a1_., 1975). In a ll five patients 
there was a lowering of blood glucose and decreased glycosuria. Other 
metabolic effects included a positive nitrogen, phosphorus and calcium 
balance and a slight increase in body weight, possibly due to a positive 
caloric balance mainly caused by the diminished glycosuria. No change 
in the basal metabolic rate or respiratory quotient was seen, but phenformin 
treatment did result in a drop in cholesterol and total lip id  levels in 
the blood. A slight loss of appetite was reported by most of the patients, 
and a strong feeling of anorexia accompanied by vomiting in one subject.
No toxic effects were observed in the 15 days of therapy, nor in the 
subsequent period of observation.
Metabolic effects and mode of action
Although the mechanism of action of the biguanides is not yet clear, 
a number of theories have been proposed to explain the hypoglycaemic 
action based on laboratory studies in enzyme systems, isolated animal 
tissue and several species of laboratory animals, as well as clin ical
i n v e s t i g a t i o n s  i n  man.
The earliest theory of biguanide action proposed that the fa ll  in 
blood sugar arose from an inhibition of tissue respiration with an 
increase in peripheral anaerobic glycolysis producing lactic  acid (Steiner 
and Williams, 1958). Other workers have attributed the hypoglycaemic 
and hyperlactataemic effects of the biguanides to an inhibitory  
action on gluconeogenesis (Tyberghein and Williams, 1957; Patrick, 1966}; 
Meyer et a l. ,  1967; Altschuld and Kruger, 1968; Jangaard et a l . ,  1968;
Toews et a l. , 1970; Haeckel and Haeckel, 1972; LIoyd et a^., 1975). I t  
has also been suggested that intestinal absorption of sugars may be 
inhibited by the biguanides, which have been shown to accumulate in the 
intestine (Biro et a]_., 1961; Arvanitakis et a h , 1973).
Sterne (1969) has proposed that the activity of the drugs in the 
body is related in some way to the presence of insulin, even though the 
biguanides have been shown to exert a hypoglycaemic effect in 
pancreatectonri.sed animals (Nielsen et a h , 1958; Steiner and Williams, 
1959a; Sterne 1969).
Other workers have proposed that the metabolic effects of the
v
biguanides can be explained by the effects of the drugs on fatty  acid 
oxidation (Stone and Brown, 1968; Muntoni et al_., 1970; Muntoni, 1974).
Attempts to explain the different effects of the biguanides, 
particularly the enhanced hypoglycaemic activ ity  in the diabetic subject 
compared to the non-diabetic, have produced a number of apparently 
conflicting results. Animal experiments have further complicated the 
interpretation of these findings because of the considerable species
d i f fe r e n c e s  in  p h a rm a c o lo g ic a l s u s c e p t i b i l i t y  t o  the  d rugs .
In this section, a b rie f consideration of the experimental and 
clinical evidence relating to the mechanism of action of the biguanides 
is presented, along with an attempt to evaluate these findings in order 
to arrive at a comprehensive view of the metabolic effects of the compounds.
(a) E ffe c ts  on carbohydrate metabolism
Tyberghein and Williams (1957) showed that phenformin administered 
to guinea-pigs (20 mg/kg) caused a lowering of blood glucose, depletion 
of liv e r glycogen and a significant rise in blood lactate levels.
Incubation of isolated rat hemidiaphragm preparations with phenformin 
resulted in an increased uptake of glucose which was accounted for by 
lactic  acid production, not by glucose oxidation (Williams £ t a h , 1957).
The glycogen content of the muscle decreased in the presence of phenformin.
Steiner and Williams (1958) studied the effect of several biguanides 
on the respiration of rat and guinea-pig isolated diaphragm and liv e r  
slices. Phenformin inhibited oxygen consumption by the muscle preparations 
and increased glucose uptake and lactic  acid production. Significant
-3
effects were only seen at high concentrations such as 1 x 10 M phenformin. 
In vivo administration of phenformin (40 mg/kg, subcutaneously) to rats 
caused a subsequent depression in oxygen uptake in liv e r slices in v itro .
The authors also showed that phenformin (25 mg/kg, subcutaneously) in 
giliinea-pigs resulted in hypogjycaemia 2-3 h after dosing, and elevated 
lactic acid and inorganic phosphate levels in the blood. These findings 
were similar to tissue anoxia reported following the adminstration of 
the respiratory inhibitors cyanide, fluoride and malonate (Handler, 1945).
Accordingly, Steiner and Williams studied rat and guinea-pig live r  
mitochondrial respiration and found a small degree of inhibition  
of succinate dehydrogenase and a larger inhibition of cytochrome 
oxidase with phenformin (3 x 10 ^-6.7 x 10 ^M).
The exact site  of respiratory inhibition appeared to d iffe r
according to the.tissue being studied. In rat epididymal fa t
preparations a number of enzymes of the tricarboxylic acid cycle
were inhibited by 2.1 x 10 phenformin (Wick et al_., 1958), the
point of inhibition being between succinate dehydrogenase and reduced
cytochrome C. Similar results were obtained with rat kidney homogenate
-3incubated with 2.1 x 10 M phenformin (Kruger ^ t al_., 1960).
These data led Steiner and Williams (1958) to suggest that the 
hypoglycaemia experienced after biguanide administration may be due 
to tissue anoxia, caused by inhibition of tissue respiration. They 
suggested that the primary inhibitory effect of the drugs on oxidative 
phosphorylation leads to a lowering of ATP levels which increases 
peripheral anaerobic glycolysis and decreases gluconeogenesis.
This explanation has lost favour but according to Cohen and 
Woods (1976) its  implications regarding lactate metabolism are s t i l l  
widely accepted. The greatest criticism is that the hypothesis is 
based upon the results of experiments using high phenformin 
concentrations. The plasma level in humans following a therapeutic 
dose of 50 or lOOmg normally does not exceed 0.1-0.2yg/ml, i . e . ,
0.5-1.0 x 10"^M (Beckmann, 1968; Mehnert, 1969a; Karam et al_., 1974: 
Sterling Winthrop Research Laboratories, personal communication, 1974; 
Alkalay et a l . ,  1975; Matin et a l . ,  1975). This represents the peak
(2-3h) level and is short lived, and while i t  is possible that certain 
organs may experience concentrations higher than that in plasma, 
there is no evidence in the literature to indicate that levels ever
_3
reach the 1.0 - 2.1 x 10 M used in in vitro experiments. 4 The tissue 
concentrations of phenformin (Hall et aj_., 1968) , buformin (Beckmann, 1965) 
and metformin (Cohen and Costerousse, 1961) after administration to 
animals are discussed in SECTION 1.6.
As man is reportedly like the rat in metabolising and eliminating 
phenformin as the phenol (Beckmann, 1968) i t  would seem unlikely that 
particularly high concentrations of the unchanged biguanide occur in 
the tissues.
Therefore, in interpreting the in vitro actions such as glycogen 
depletion in rat liver slices (Steiner and Williams, 1958; Sdling, 1969) 
i t  should be remembered that the effects have only been observed with 
high concentrations of biguanides, and even the lower levels (4 x 10 tM 
phenformin) used by Altschuld and Kruger (1968) to inh ib it gluconeogenesis 
and oxidative phosphorylation in isolated, perfused guinea-pig liv e r  
are considerably greater than those measured in the plasma of patients 
after therapeutic doses.
No reduction in live r glycogen nor any indications of inhibition
of oxidative phosphorylation was observed in patients treated effectively
with biguanides (Sterne, 1969). Sdling (1969) found no evidence'of
glycogen depletion or reduced oxidative phosphorylation in rat liv e r
-5perfused in v itro with biguanides at a dose level (2.5 x 10 M) which 
does not greatly exceed the plasma concentration for therapeutic doses 
in man.
In the guinea-pig phenformin produced hypoglycaemia at a dose of
lOmg/kg subcutaneously while 1OOmg/kg had no effect on blood sugar in the
ra t (Altschuld and Kruger, 1968). However, the absence of hypoglycaemia
in the normal rat does not indicate a lack of effect on carbohydrate
14 umetabolism, since the production of C02 from [U-14C] glucose was increased
by doses of phenformin which did not lower blood sugar (Losert et a l .,
1971). The guinea-pig was also more sensitive than the ra t to the
hypoglycaemic actions of hypoglycin (methylene cyclopropylalanine) and
cyclopropanecarboxylic acid (Sherratt, 1969). I f  the dose of biguanide
was adjusted according to the sensitivity of the animal the guinea-pig
responded sim ilarly to the ra t. Thus, while 25mg/kg phenformin produced
marked hypoglycaemia, 2.5 mg/kg did not. This lower dose, however, did
14stimulate the production of CO^  from JU- C] glucose in the guinea-pig 
(Losert £ t  al_0, 1971 ) 0 This suggests that there are two effects of 
biguanides in the non-diabetic; enhancement of glucose oxidation at lower 
doses, and hypoglycaemia associated with inhibition of oxidative 
phosphorylation, reduction of hepatic ATP levels and inhibition of 
gluconeogenesis at high doses of the drugs.
I t  may be that the hypoglycaemia produced in non-diabetic animals 
is a toxic effect which is produced by large doses of biguanides. The 
considerable difference between the hypoglycaemic dose in normal, non­
fasted subjects and the dose which is therapeutically effective in 
appropriate forms of diabetes in man supports this proposal. I t  seems 
like ly  that in man, as well as in laboratory animals, the mechanism 
responsible for the antidiabetic action is different from the one causing 
the toxic effects,
Davies e^aJL(1971) showed that pretreatment with phenformin and
buformin increased glucose turnover and recycling in the normal rat and 
dog without changes in glucose oxidation or live r glycogen concentration.
In contrast Losert et £]_. (1971) reported that the oxidation of [U-14C] 
glucose to 14C02 in the normal rat was increased by phenformin, metformin 
and buformin with a dose-effect ratio , and that each biguanide produced 
an increase in blood lactic  acid concentrations.
In the normal, non-diabetic human therapeutic doses (100-150 mg/day)
of phenformin produced an increase in the glucose turnover rate (Searle 
and Cavalieri, 1968; Kreisberg, 1968b) accounted for by increased gluconeo- 
genesis from lactate and other substrates (Kreisberg, 1968b; Searle et al 
1969). Blood glucose levels were unchanged (Searle et a V .jl966; Searle 
and Cavalieri, 1968) while blood lactate levels were elevated (Searle and 
Cavalieri, 1968; Kreisberg, 1968b). Glucose oxidation after phenformin 
administration, determined as 14C02 production, was enhanced with [6 -14C] 
glucose as substrate (Searle et a1_., 1969) but was reduced when [ l - 14C]glucose 
was used. A possible reason for this discrepancy is discussed la te r.
In the non-diabetic obese subject, whose resting glucose kinetics
were similar to those in normal man except that glucose recycling ( i .e .  
glucose to lactate to glucose) was increased, phenformin administration 
appeared to exert a varying influence, perhaps depending upon the degree 
of obesity (Muntoni, 1974). Kreisberg (1968a) reported an increased 
recovery o f[14C]lactate from [1-14C]glucose in phenformin-treated obese 
patients, but later found that the drug also caused an increase in glucose 
turnover due to glucose recycling, with a rise in both the rate and amount 
of conversion of lactate to glucose (Kreisberg, 1968b; Kreisberg et a l . ,  
1970,1972).
In diabetic patients phenformin administration resulted in a fa ll in
blood glucose levels accompanied by an increased glucose turnover and 
14C02 production from [U-14C]glucose (Searle and Cavalieri, 1968). In 
a la ter study with a diabetic patient receiving chlorpropamide, alone 
or in addition to phenformin (50-150 mg/day), Searle and.Siperstein 
(1975) showed that although lactate oxidation was increased under the 
influence of phenformin this increase was not in balance with the increase 
in anaerobic metabolism. They suggested that aerobic metabolism in the 
presence of phenformin did not keep pace with the increased level of 
anaerobic metabolism, and that this imbalance accounted for the hyper- 
lactataemia associated with phenformin therapy. I t  was further suggested 
that the increased gluconeogenesis noted with phenformin treatment in 
both normal and diabetic subjects (Kreisberg, 1968b; Searle et al_., 1969; 
Kreisberg et aj_. ,1972; Searle and Siperstein, 1975), represents a 
compensatory mechanism . Kreisberg (1968b) has proposed that oxidative 
metabolism is inhibited by phenformin resulting in enhanced anaerobic 
glycolysis with no inhibition of gluconeogenesis.
The disagreement regarding the effect of phenformin on the aerobic 
metabolism of glucose may arise from the different radio-isotopes used 
in the various studies. This possibility has been dealt with in some 
detail by Muntoni (1974). The experiments in which the production of 
14C02 was increased were carried out with [U-14C]glucose (Searle and 
Cavalieri, 1968; Losert et al_., 1971), [U-l4C]lactate (Searle and
Siperstein, 1975) or [6 -14C]glucose (Searle _et a h , 1969). Those in 
which glucose oxidation was reduced or unchanged used [1 - 1UC]glucose 
(Kreisberg, 1968a, b; Kreisberg _et crt., 1970). The degree of glucose 
oxidation in the c itr ic  acid cycle is best estimated with [U-14C]glucose 
where there is a higher probability that 14C02 w ill be formed directly
from the entry of pyruvate into the cycle. I t  is well established that 
the f ir s t  atoms to appear in C02 are C3 and Ci*, followed by C2 and C5 
and lastly Cx and C6 (Mahler and Cordes, 1971). As i t  is possible that 
intermediates containing 14C may leave the cycle and enter synthetic 
pathways (e.g. ami no-acids and porphyrins) only [U-14C]glucose (or 
lactate) is sure to give rise to 14C02 . The finding that there is a 
smaller increase in 14C02 production from [6-14C]glucose than from 
[U-14C]glucose (Searle et al_., 1969) and that there is a reduction in 
[ l - 14C]glucose oxidation in phenformin treated subjects (Kreisberg, 1968b) 
may be a result of the inhibition of the pentose phosphate pathway which 
occurs with phenformin (Wick et al_., 1958; Sflling et al_., 1967). As Cx 
of glucose is oxidised to C02 by this pathway, inhibition by phenformin would 
be expected to lower the 1!|C02 production from [1-14C]glucose. Sim ilarly, 
as the direct oxidative pathway produces a higher proportion of triose- 
phosphate compounds incorporating C ,^ C5 and C6 than Cx (which is oxidised 
to C02) or C2 and C3 (which may be condensed onto other sugars) phenformin 
may reduce the production from [6 -14C]glucose of triose-phosphates which 
would subsequently be oxidised to give 14C02 (Muntoni, 1974).
Thus the overall effect of phenformin at therapeutic levels appears 
to be to stimulate both anaerobic and aerobic metabolism of glucose and to 
increase gluconeogenesis. The increase in blood lactate levels in the 
presence of biguanides therefore, is not attributable to an inhibition of 
oxidative phosphorylation, as the lactate concentration is also raised when 
the increase in glucose oxidation is marked (Searle and Cavalieri, 1968; 
Losert et ajk, 1971). However, Searle and Siperstein (1975) have found 
that the increased oxidation of lactate does not keep pace with its  
production, and the overall effect is a relative inhibition of oxidative 
metabolism.
While these findings are at variance with much of the animal work 
previously mentioned, the large differences in the drug levels used 
in the in v itro  and in vivo studies in animals and in the, therapeutic 
management of human patients make comparison very d if f ic u lt .  Such 
comparisons also raise great d ifficu lties  because of species differences. 
However, Losert ejt a_l_. (1971, 1972b) have shown that at very low doses of 
biguanides which do not produce hypoglycaemia in animals, the production 
of 14C02 from [U-14C]glucose and the blood lactate concentrations are 
increased.
Cb) E ffe c ts  on gluconeogenesis
Gluconeogenesis is the process responsible for the formation of 
glucose from various non-carbohydrate precursors, such as amino acids, 
lactic  acid or glycerol, and plays an important role in the maintenance 
of the pptimal concentration of the sugar in the blood. The available 
carbohydrate reserves which can be used to support body function are 
stored primarily in the liv e r, and can account for no more than 8 to 
10 hours of glucose requirement by peripheral tissues such as the brain 
and the blood cells. Thus during starvation gluconeogenesis plays a key 
role in replenishing the blood glucose concentration (Hanson and Mehlman,
1976). This process is confined to the live r and, under some physiological 
conditions, the renal cortex.
The finding that administration of biguanides in animals produces 
an increase in blood levels of lactic  acid, together with the b e lie f that 
the compounds are concentrated in the liv e r, led to a number of investigations 
into the effects of the drugs on gluconeogenesis.
There is l i t t le  evidence, however, to support the be lie f that the 
hypoglycaemic biguanides are substantially concentrated in hepatic 
tissue, and the statement that 'phenformin is concentrated in the liv e r '
i
(Cohen and Woods, 1976) is not supported by the meagre data in the 
lite ra tu re . This data is discussed in more detail in SECTION 1.6.
However, there is evidence to suggest that higher blood concentrations 
of the drugs do arise in certain diabetic patients with other serious 
illnesses such as impaired renal or hepatic function (see SECTION 1 .5 ), 
and the effects on hepatic gluconeogenesis seen in animal studies using 
'moderate' concentrations of the biguanides may be relevant in these 
conditions.
Administration to fasted guinea-pigs of phenformin (Tyberghein 
and Williams, 1957; Steiner and Williams, 1958; Altschuld and Kruger,
1968; Losert et al_.,l972b) or buformin (Losert et  aK , 1972b) at a 
dose level of 20-25 mg/kg subcutaneously caused a reduction in blood 
glucose concentrations of 70-95% in 2~3h. Similar reductions were seen 
after 300 mg/kg doses of metformin in the guinea-pig (Losert et  a K , 1972b). 
Liver glycogen levels were almost to ta lly  depleted, even in non-fasted 
animals (Tyberghein and Williams, 1957), and hepatic ATP levels were 
reduced by some 40% (Altschuld and Kruger, 1968) . An elevation of blood 
lactate concentrations was produced ranging from 70% (Tyberghein and 
Williams, 1957) to 800% (Steiner and Williams, 1958) after subcutaneous 
doses of 20-25 mg/kg phenformin, and was also seen after intraperitoneal 
injections.of 12-15 mg/kg (Stork and Schmidt, 1970; Haeckel and Haeckel,
1972).
In the ra t, however, no significant changes in blood glucose or
hepatic ATP concentrations were produced by phenformin even at a dose of 
100 mg/kg subcutaneously (Altschuld and Kruger, 1968). Losert et al.
(1972b) have shown that doses of buformin of greater than,50 mg/kg in tra - 
peritoneally were necessary to produce a fa ll in blood glucose levels in 
the ra t.
Studies using guinea-pig liv e r slices showed that lactate output was
-.3
increased and glycogen levels were diminished by phenformin (2.1 x 10 M),
but no change in glucose output was produced (Tyberghein and Williams,
1957). Patrick (1966) has reported that rat kidney slices are more
sensitive to inhibition of glucose production and ATP depletion by phenformin
-4than rat liv e r slices; concentrations of 6.7 x 10 M phenformin in live r
-4slices and 2.0 x 10 M phenformin in kidney slices were required to produce 
a 50-60% inhibition of gluconeogenesis from pyruvate. Buformin also
diminishes gluconeogenesis from pyruvate in rat live r slices; concentrations
-4 -3of 10 M caused a 20% reduction, while 10 M reduced the rate to less than
50% of controls (Losert et al_., 1972b).
According to Altschuld and Kruger (1968) phenformin (4.1 x 10 ^M)
lowered ATP levels in the isolated, perfused guinea-pig live r by approximately
40% and reduced the uptake of glucose and its  synthesis from lactate and
glycerol, but had l i t t l e  effect in the rat liv e r even at the higher con-
-3centration of 2.1 x 10 M. This lack of effect has not been confirmed by
subsequent workers. Toews et al_.(1970) found that gluconeogenesis in the
perfused rat liverwas i n h i b i t e d  by phenformin with lactate, pyruvate or
-4alanine as substrate, with an inhibition constant of 5.0 x 10 M. A 
differential effect of phenformin in the isolated, perfused livers of
normal“fed and fasted, non-diabetic rats and streptozotocin-induced
diabetic rats has been reported (Connon, 1973). A dose-effect response
in the inhibition of gluconeogenesis from pyruvate was seen in a ll
-3three groups with complete inhibition occurring at 1.7 x *10 M phenformin. 
Reducing the phenformin concentration resulted in an increase in gluconeo­
genesis u n til, at 5.0 x 10 Si the rate of glucose synthesis in the normal- 
fed, non-diabetic rat was similar to that in the control group. In the
livers from 48h fasted or diabetic rats 80-85% inhibition of gluconeogenesi
-4s t i l l  occurred with 5.0 x 10 M. However, although an increase in 
gluconeogenesis both in diabetes arid during fasting has been reported 
(Weber et al_., 1965; Forbath and Hetenyi, 1966; Foster et al_., 1966;
Owen et a1_., 1976) i t  should be noted that the rate of glucose production 
in the livers from the three groups in the absence of phenformin was very 
similar.
The effects of both phenformin and metformin on gluconeogenesis from
lactate in the isolated, perfused rat liv e r have been studied by Woods
and Alberti (1973). At high drug concentrations (2.0 x 10 M) lactate
uptake and glucose output were completely inhibited by phenformin and
-5partia lly  inhibited by metformin. Inhibition s t i l l  occurred at 10 M 
although to a lesser extent (phenformin, 45%; metformin, 30%). These 
results are of interest as they were obtained with concentrations of 
phenformin which might exist in the blood of man after therapeutic doses 
in situations v/here excretion or metabolism are impaired (see SECTION 1 ,5 ).
The inhibition of gluconeogenesis has been variously attributed to 
effects such as lowering of the ATP levels (ATP/ADP ratio) and inhibition  
of individual enzyme systems. A decrease in hepatic and renal ATP
concentrations (Patrick, 1966; Altschuld and Kruger, 1968) would be
expected to lead to a decrease in gluconeogenesis; 6 moles of ATP are required
for the production of one mole of glucose from lactate and ATP is required
for the phosphorylation of glycerol which is the in it ia l step in the
synthesis of glucose from glycerol. In addition, decreased ATP concentrations
lead to increased levels of ADP and AMP which may lead to inhibition of
pyruvate carboxylase and fructose 1,6-diphosphatase respectively (Pontremoli
and Grazi, 1968). The causal relationship between the reduction in the
ATP/ADP ratio and the inhibition of hepatic gluconeogenesis in the presence
of phenformin has been questioned by Haeckel and Haeckel (1972). In isolated,
perfased guinea-pig livers studied 2h after administration of phenformin in vivo
(12 mg/kg, intraperitoneally) the ATP/ADP ratio was halved while glucose
formation from lactate was unaffected. Subsequent addition of phenformin
-5to the perfusate (2 x 10 M) led to a significant reduction of gluconeogenesis 
without further affecting the ATP/ADP ratio . As the 3-hydroxybutyrate/ 
acetoacetate ratio was increased, both in the perfusate in v itro  and in the 
blood after in vivo doses of phenformin (12 mg/kg, intraperitoneally),
Haeckel and Haeckel (1972) suggested that phenformin had an effect on the 
mitochondrial redox state causing an increase in the NADH/NAD* ratio which 
raises the concentration of malate with respect to oxaloacetate, thus 
decreasing the ava ilab ility  of oxaloacetate for gluconeogenesis. Other 
workers have reported that the production of malate in isolated mitochondria 
is stimulated and the synthesis of both citrate and phosphoenolpyruvate is 
decreased when the NADH/NAD* ratio is elevated (Garber and Ballard, 1970; 
Williamson, J ., 1976).
After determining the concentrations of the intermediates of the 
gluconeogenic sequence in the absence and presence of phenformin, Toews et al«
0970) proposed that the drug exerted an inhibitory action at either the 
level of glyceraldehyde 3-phosphate dehydrogenase or 3-phosphoglycerate 
kinase, and that glutamate-alanine transaminase may also be inhibited.
Lloyd et al. 0975) have shown that the decrease in Icictate consumption 
and glucose output by the isolated, perfused guinea-pig liv e r in the 
presence of phenformin is associated with a fa ll in the in tracellu lar pH.
A correlation between lactate uptake and intracellu lar pH was observed 
which may indicate that the rate of lactate uptake and metabolism is a 
major factor in the control of hepatic cell pH, and suggests that the low 
in tracellu lar pH values in phenformin-perfused livers could be due to an 
inhibition of lactate uptake, either due to inhibition of lactate metabolism 
or to interference with lactate transport into the c e ll. Previously 
Lloyd etal_. 0973) showed that above a hepatic intracellu lar pH of about 
7.1 there was no obvious effect on lactate consumption, while at values 
below 7.1 lactate uptake was rapidly diminished and production of lactate 
occurred. Low intracellu lar pH may reduce lactate uptake by its  influence 
on the gluconeogenesis enzyme pyruvate carboxylase (Cohen and Woods, 1976; 
Ile s 'e t al_., 1977). The pH optimum of this enzyme lies between 7.4 and
8.0 (Pontremoli and Grazi, 1968). The total in tracellu lar oxaloacetate 
concentration is reduced in isolated rat livers perfused with lactate under 
conditions simulating metabolic acidosis (pH 6 .7 -6 .8 ), leading to a 
decrease in gluconeogenesis due to substrate lim itation of phosphoenolpyruvate 
carboxykinase (lies et aK , 1977). Whether the decreased ava ilab ility  of 
oxaloacetate is a result of inhibition of pyruvate carboxylase, or a rise 
in the malate/oxaloacetate ratio due to an increase in the NADH/NAD ratio  
which accompanies the fa ll in intracellu lar pH is not clear (lies  et a l ., 
1977). The significance of the effects of pH on gluconeogenesis in the 
development of lactic  acidosis is discussed in SECTION 1.5.
The studies of the effects of phenformin on carbohydrate metabolism 
and gluconeogenesis in man have been discussed earlie r. At therapeutic doses of 
phenformin gluconeogenesis is not inhibited and may even be stimulated 
QCreisberg, 1968b; Searle et a K , 1969; Kreisberg et aJL, 1972; Searle and
Siperstein, 1975). This may be a result of a direct effect of phenformin
on the gluconeogenic sequence, or may occur as a compensatory mechanism 
for the enhanced anaerobic u tilisation  of glucose which provides increased 
quantities of lactate as a substrate for gluconeogenesis.
This interpretation is not accepted by Muntoni (1974) who has stated 
that biguanides do not inh ib it gluconeogenesis in normal live r but 
selectively inh ib it gluconeogenesis induced by fasting, cortisol, obesity 
or diabetes. The author has proposed that this occurs by a single 
mechanism, namely inhibition of fa tty  acid oxidation. Such an action of 
biguanides on fa tty  acid oxidation would reduce the supply of acetyl-CoA 
necessary for the adequate functioning of the gluconeogenic enzyme 
pyruvate carboxylase (Utter and Keech, 1963; Utter and Scrutton, 1969).
This mechanism, according to Muntoni (1974), functions in diabetes, 
obesity, hypercortisol ism and in other pathological conditions 
characterised by a high free fatty-acid supply to the liv e r .
Despite the elaborate reasoning of Muntoni (1974) there is l i t t l e
evidence to suggest that a specific inhibition of gluconeogenesis 
occurs in the diabetic or obese human. The findings of Searle and 
Siperstein (1975) that phenformin administration to a diabetic patient 
increases the proportion of glucose derived from lactate, and of Kreisberg 
et al_* (1970, 1972) that significant rises in the rate and amount of 
lactate conversion to glucose occur in the phenformin treated obese 
patient bring this theory into question.
(c) E ffe c ts  on in te s t in a l  abso rp tion  o f  glucose
The biguanides may interfere with the intestinal absorption of 
glucose and other sugars in man and in animal species. All three 
hypoglycaemic biguanides inhibited in vitro absorption of glucose 
and galactose in rings of hamster intestine with minimum inhibitory
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concentrations of 10 "M phenformin, 2 x 1 0  M buformin and 6 x 1 0 1  
metformin (Caspary and Creutzfeldt, 1971). In the rat, in vivo 
administration of phenformin (5-150 mg/kg) inhibited the subsequent 
in vitro transport of glucose in everted intestinal sacs with a log 
dose-response relationship in the range studied (Kruger et a l .,1970).
Biro et al_.(1961) reported a reduced intestinal absorption of glucose 
in the phenformin treated rat, while Czyzk et al_. (1968) have shown 
the same effect in the dog after a single dose of buformin (10 mg/kg).
In contrast, some workers have fa iled to observe an inhibitory  
effect of biguanides on glucose absorption. Creutzfeldt et a1. (1962) 
found that buformin (50-100 mg/kg) in the glucose-filled rat intestine 
in situ did not decrease glucose absorption,but when the same dose was 
given subcutaneously a slight, temporary decrease in absorption was 
observed. The authors suggested that gastric emptying, rather than 
intestinal absorption was affected by buformin. Similar findings were 
reported by Fflrster eit al_. (1965).
The effects of phenformin have been studied in man, using a segmental 
perfusion technique. The absorption of glucose v/as reduced by almost 
50% two hours after ingestion of 100 mg phenformin, and this was associated 
with a depressed absorption of sodium and water and alterations in the 
structure of the mitochondria in the villus absorptive cells of the 
jejunum (Arvanitakis ejt aT_., 1973). Similar findings have been found
in rat intestinal preparations after phenformin administration, along 
with reduced ATP concentrations (Riecken et al_., 1971).
These effects on intestinal absorption of glucose may explain the 
observations that phenformin increases the tolerance to orally admin­
istered glucose but has no effect on intravenous glucose tolerance in 
normal (Hollobaugh et al_.,1970) and diabetic humans (Czyzyk et a l .,1968; 
Riecken et a]_., 1971).
The extent to which this action of the biguanides may contribute 
to their therapeutic activ ity  in diabetes is uncertain. Although 
phenformin may decrease the rate of glucose absorption in man, thereby 
contributing to an alteration in glucose tolerance curves, i t  does not 
alter total carbohydrate absorption (Olsen and Rasmussen, 1974). In 
addition, phenformin antagonises the hyperglycaemic effect of an 
intravenous infusion of adrenaline in normal anaesthetised rats 
(Polacek and Ouart, 1974) showing that the hypoglycaemic action of the 
drug is not to ta lly  related to intestinal absorption of glucose.
In view of the essential role of ATP present in the intestinal 
cell in the absorption of glucose i t  seems like ly  that the reduction 
in glucose transport caused by biguanides is a consequence of an 
inhibitory effect on oxidative phosphorylation and hence ATP generation 
in these cells . This may arise from the particularly high concentrations 
of the biguanides which are found in the intestines of animals (especially 
after oral doses) (Wick et ajL , 1960; Cohen and Costerousse, 1961; Hall 
et_al_., 1968) due to the basicity of the biguanide moiety.
Thus, there is evidence that biguanides can substantially reduce 
the rate of intestinal glucose absorption, but do not a lte r the total
carbohydrate absorption. A significant reduction of total absorption 
of carbohydrate would result in symptoms of starvation ketosis (Sterne, 
1969) and osmotic diarrhoea (Arvanitakis'et al_., 1973) which do not 
occur c lin ic a lly . The effect probably results from the ‘inhibition  
of ATP generation in intestinal epithelial cells by high concentrations 
of the drugs which are found in the gut, and is unlikely to contribute 
to the specific antidiabetic activ ity  of the biguanides.
(d) E ffe c ts  on l i p id  metabolism
I t  is generally agreed that the biguanides do not share the 
a b ility  of insulin to suppress lipolysis in diabetic patients (Mehnert 
and Sadow, 1969). This is evident from the in a b ility  of the drugs to 
control diabetes in truly insulin-deficient patients, where in spite of 
the hypoglycaemic action of the biguanides, ketosis can arise from the 
continual mobilisation of fa tty  acids in the absence of insulin. Phenformin 
(1,7 x 10 ^M) reduced the release of both glycerol and free fa tty  acids
in isolated fa t cells of rat, and decreased the lipolysis stimulated by
glucagon, growth hormone and adrenocorticotropic hormone. This effect 
did not appear to involve insulin and occurred in the absence of glucose, 
suggesting that i t  is independent of the action of phenformin on glucose
metabolism (Stone and Brown, 1968). In view of the high concentration
of phenformin used to produce this an tilipo ly tic  action, and the clin ical 
observations mentioned earlie r, i t  seems doubtful that this effect is 
produced by therapeutic doses in man.
Lower concentrations of the biguanides have been shown to possess 
antilipogenic ac tiv ity . Phenformin inhibited a number of steps in the 
biosynthesis of cholesterol and other lipids in vitro (McDonald and
Dalidowicz, 1962; Dalidowicz and McDonald, 1965; Dempsey, 1968). In
c
isolated fa t cells lipogenesis was inhibited by 5 x 10 M buformin 
(Ditschuneit et al_., 1967) which is similar to the concentrations 
measured in human serum after single therapeutic doses (Beckmann and 
Hflbner, 1965; L in tz e t a l . ,  1974).
After a single dose of phenformin (50 mg/kg, intraperitoneally) 
blood free fa tty  acid levels in the non-fasted ra t showed a s ligh t, 
temporary increase followed by a slight decrease to lower than resting 
levels (Muntoni et aV., 1970). In the rat with free fa tty  acid levels 
elevated by hypothermia or noradrenaline phenformin caused a further 
increase in the levels or caused high concentrations to last longer.
As phenformin has no known lipo lytic  action, Muntoni et a l .(1970) 
proposed that the drug caused an inhibition of fa tty  acid oxidation 
in addition to its  anti lip o ly tic  ac tiv ity .
Phenformin provides an effective means of lowering the elevated 
serum lipids in maturity-onset diabetics (Schaefer, 1968) and has a 
beneficial effect in human obesity (Roginsky and Sandler, 1968), which
(
is common in diabetic patients of middle age~(Meinert and Schwartz, 1968). 
Obese diabetic patients and experimentally obese mice treated with 
phenformin showed a slow persistant loss of weight which could not be 
attributed to anorexia (Grodsky et al_., 1963; Waxier and Leef, 1968).
This loss of body weight in diabetic patients who were well controlled 
by phenformin therapy was associated with a decrease in serum cholesterol 
and triglycerides (Alterman and Lopez-Gomez, 1968; Mirsky, 1968; Schaefer, 
1968). Lowering of circulating cholesterol v/as greatest in those patients 
with levels varying most from the normal range (Alterman and Lopez-Gomez,
1968). Total serum lipids were also significantly reduced in diabetic
patients with elevated levels, but not in normolipidaemic diabetics or 
non-diabetic subjects with high lip id  levels (Schaefer, 1968).
The mechanism by which the biguanides exert an influence on 
lip id  metabolism is not known. Muntoni (1974) has suggested that the 
biguanides may act on lipogenesis through an interaction with carnitine.
The rate of long-chain fa tty  acid oxidation is controlled by their 
transport through the mitochondrial membrane, which is mediated by the 
formation of acyl-carnitine derivatives (F ritz , 1967). Carnitine also 
influences fa tty  acid synthesis. Carnitine and its  long-chain acyl 
derivatives release the inhibition of acetyl-CoA carboxylase which is 
inhibited by high levels of acyl-CoA (F ritz , 1967). Thus carnitine 
has an important regulatory function in both synthesis and oxidation 
of long-chain fatty  acids. Muntoni (1974) suggested that a block in the 
carnitine system would cause feedback inhibition of acetyl-CoA carboxylase 
by long-chain acyl-CoA derivatives thus reducing lipogenesis. This in 
turn would give rise to an increase in the NADPH/NADP* ratio which would 
inh ib it the pentose phosphate pathway, effects which are known to occur 
with the biguanides (Wick et al_., 1958, Ditschuneit and Hoff, 1964; Sdling 
et a l . ,  1967). In addition, by reducing the effectiveness of the carnitine 
system for transporting fatty  acids into the mitochondria the biguanides 
could inh ib it fa tty  acid oxidation.
This indirect inhibition of acetyl-CoA carboxylase has not been 
demonstrated experimentally, but does account for both of the metabolic 
effects of the biguanides on lip id  metabolism. Although this mechanism 
may explain, at least in part, the weight-reducing effect of phenformin 
in obese diabetic subjects the reason for the lack of influence in normo­
lipidaemic diabetics and hyperlipidaemic non-diabetics reported by Schaefer
(1968) is not clear. The relationship between these effects on lip id  
metabolism and the anti diabetic therapeutic actions of the biguanides 
remains to be investigated.
(e) Biguanides and, in s u l in
In whatever way the biguanides may lower blood sugar i t  is generally 
agreed that this effect is not primarily mediated by insulin. However, 
some degree of interaction between the two hypoglycaemic agents is 
indicated by a number of experimental results.
Biguanides do not increase the quantity of insulin released, or its  
rate of release from the pancreas (Boshell et  a K , 1968; Mehnert and 
Sadow, 1969). The compounds do have a beneficial secondary influence on 
the patterns of the late and excessive insulinogenic response of the 
pancreas to hyperglycaemia in many over weight, stable adult diabetics 
(Grodsky et al_., 1963;Mehnert and Sadow, 1969). Phenformin therapy 
produces an improvement in carbohydrate tolerance and a concomitant 
decrease in circulating serum insulin levels (Boshell et a l .,1968; 
Butterfield, 1968).
According to some authors (Butterfield , 1968; Sterne, 1969;
Muntoni, 1974) the presence of insulin is necessary for at least some 
effects of biguanides, such as the increased peripheral uptake of 
glucose. The experiments of Butterfield (1968) on the effects of 
phenformin on peripheral glucose u tilisation  and insulin action in 
human obese and diabetic patients suggested that phenformin causes a 
clearance of insulin from the blood towards the insulin-responsive 
muscles enabling glucose to be used more e ffic ie n tly . A number of 
in vitro experiments with isolated muscle preparations have demonstrated
this increase in glucose uptake in the presence of phenformin without
addition of insulin (Tyberghein and Williams, 1957; Steiner and Williams,
1958). According to Muntoni (1974) this does not necessarily indicate
an action independent of the hormone as insulin may be fixed to the
%
muscle.
Sim ilarly, the experiments in surgically pancreatectomised animals 
are not unequivocal, bearing in mind the extent of surgery and the 
possible influence of insulin bound to tissues and blood proteins.
However, the work of Butterfield (1968) does not explain the 
selective action of phenformin on serum unsulin levels. According to Roddam 
and Boshell (1966) and Boshell et al^ . (1968) the effect of phenformin 
on serum insulin only occurs significantly in patients with hyper- 
insulinaemia.
The relationship between the biguanides and insulin are far from 
well understood. This complex picture is to be expected in view of 
the multiple metabolic effects of both insulin and the drugs and 
although there is evidence for a beneficial interaction in the over­
weight diabetic, the significance in other groups of diabetics are not 
clear.
1.5 BIGUANIDES AND LACTIC ACIDOSIS
There is no doubt, from clinical and experimental evidence, that
lactate metabolism is influenced by the biguanides. In ordinary
%
therapeutic use the drugs are non-toxic substances (Mehnert and Sadow,
1969) but in special circumstances when lactate metabolism is disturbed, 
lactic  acidosis can arise. The association between biguanide therapy 
(particularly with phenformin) and lactic acidosis has received a great 
deal of attention since the f ir s t  report by Tranquada et al_. (1963).
There has been considerable disagreement over the definition and 
classification of lactic  acidosis. Many authors have defined the 
condition in terms of blood lactate exceeding certain stated lim its  
such as l,3mM (Peretz et al_., 1964), 2mM (Oliva, 1970) and 7mM (Tranquada, 
1964). These definitions are necessarily arbitrary, and a .more reliable  
course in the diagnosis of the condition may be to employ a definition  
which is based on the clinical state of the patient such as ‘a state of 
metabolic acidosis associated with a high blood concentration of lactate ' 
(Cohen and Woods, 1976) or 'an i l l  patient with clinical signs of an 
acidosis together with a blood lactate concentration persistently above 
5mM and an arteria l pH of 7.25 or less' (Alberti and Nattrass, 1977).
In this type of lactic  acidosis there tends to be no clear evidence 
of tissue anoxia, and diagnosis is often d if f ic u lt  (Alberti and Nattrass, 
1977). Clinical features may include hyperventilation, vomiting, diarrhoea, 
abdominal pain and various degrees of reduced consciousness from drowsiness 
to coma,, and may be accompanied by hyperketonaemia ana arteria l pH values 
as low as 6.62 (Ball et al_., 1974; Dembo et al_., 1975; Heuclin et a l . ,
1975; Cohen and Woods, 1976; Fulop and Hoberman, 1976;Thimme et cH^ ., 1976;
Williamson, M., 1976). Similar features have been recorded in cases 
of metformin- and .buformin- associated lactic acidosis (Clava- 
detscher et aj_., 1976; Thimme et al_., 1976; Assan e_t al_., 1977).
The available evidence clearly indicates that lactic  acidosis 
does not usually occur in ' f i t '  patients (Cohen and Woods, 1976), but 
that diabetics on biguanide therapy may develop the condition when 
seriously i l l  from other causes (Oliva, 1970; Fulop and h'oberman, 1976; 
Alberti and Nattrass, 1977). The nature of these complicating illnesses 
and their involvement in the development of lactic  acidosis in biguanide 
therapy w ill be discussed in a la ter section.
Incidence of biguanide-associated lactic  acidosis
From the frequency of case reports in medical journals i t  appears 
that lactic  acidosis occurs with phenformin therapy far more frequently 
than with metformin or buformin. Phenformin (Dibotin) was introduced 
into the U.K. in 1959 and since then i t  has been estimated that about
340,000 patient-years of treatment have been given. From the time of its  
introduction until February 1977, there have been 24 published cases in 
the U.K. of lactic  acidosis associated with Dibotin (Sterling Winthrop 
Research Laboratories, personal communication, 1977). Comparison with 
the other biguanides is d iff ic u lt  as metformin and buformin are not 
widely used in the U.K. Metformin is prescribed predominantly in France, 
and buformin in Germany, and accurate assessment of the occurrence of the 
illness may be hampered by the different philosophies regarding reporting 
of adverse cases.
Although a number of cases of metformin associated (Lebacq and 
Tirzmalis, 1972; Hayat, 1973; Robert et a l ,  1973; Bismuth et a \ ,  1976;
Assan £ t  a/L, 1977) and buformin associated (Clavadetscher, 1976;
Thimme et al_., 1976) lactic  acidosis have been reported, there can be 
no doubt that such cases are less frequent. The collection of data 
from cases of biguanide-induced lactic  acidosis reported worldwide, 
shows that those associated with phenformin now number some 281, as compared 
with metformin-and buformin-associated cases which number 16 and 10 
respectively (Sterling Winthrop Research Laboratories, personal 
communication, May 1977).
At present there is no widely accepted explanation for the higher 
incidence of lactic  acidosis in phenformin treated diabetics. The 
possible explanation that the differences may lie  in the relative usage 
of the three drugs is unlikely to provide the whole answer. In France, 
where 3 times as many patients receive metformin as phenformin, there 
is a higher incidence of lactic  acidosis reported with phenformin 
(Tsnard and Lavieuville, 1977). While less is known of buformin, the 
study by Thimme et aj, (1976) in Berlin showed that lac tic  acidosis is 
more frequent with phenformin, although buformin is the more frequently 
prescribed drug.
As there is l i t t le  evidence to suggest that the biguanides do not 
share a common mechanism of action, i t  is possible that the differences 
which exist regarding the frequency of adverse reactions, may be related 
to differences in pharmacokinetics (Bismuth et a K , 1976; Assan et a l . ,
1977). The existence of various contributory clinical conditions in 
cases of biguanide-induced lactic  acidosis has received much attention 
in recent years (Assan et aJL, 1975;Heuclin et efL, 1975; Romankiewicz.
1975; Cohen and Woods, 1976; Mehnert, 1976; Thimme et  al_., 1976; Wise 
et al_.»1976; Alberti and Nattrass, 1977; Assan £ t a K , 1977). The effects
of these complaints such as renal failure,hepatic and myocardial 
diseases, circulatory disorders, acute infections and alcoholosis on 
the normal pharmacokinetics of the biguanides, particularly in 
relation to the aetiology of lactic acidosis, w ill be discussed 
further in a la ter section.
Control of lactate metabolism
Lactic acid is formed as an end-product in glycolysis under 
anaerobic conditions. The reaction (1) occurs in the cytosol and 
is catalysed by the enzyme lactate dehydrogenase requiring NADH.
The equilibrium normally lies in favour of lactic  acid with a 7-15 
to 1 ratio on a molar basis. This is reflected by blood concentration 
in resting man of 0.44 - 1.8 mM lactate and 0.07 - 1.2 mM pyruvate 
(Harper, 1965). Lactate u tilisation  in anaerobic conditions depends 
upon reversal of the reaction either in the tissues where lactate is 
formed (predominantly muscle) or in other tissues (liv e r and kidneys).
lactate (1)
pyruvate + NADH + H+^ —^  ------- s*- lactate + NAD+
CH3-CH-C-0“
I li 
OH 0
Rearrangement of (1) shows that the reaction can be pushed in the 
direction of lactate by an increase in the NADH concentration or a • 
decrease in pH (Huckabee, 1961; Cohen and Woods, 1976). This is shown 
in equation (2).
CHo-C-C-0 
3 II I!
0 0
[lactate] .. [NADHl [H+]
[pyruvate] 8 [MD+]
( 2 )
The NADH/NAD+ ratio is linked to the state of phosphorylation of 
the cell through the substrate-level phosphorylation reactions involved 
in the interconversion of glyceraldehyde 3-phosphate and 3-phospho~ 
glycerate.
glyceraldehyde 3-phosphate + NAD+ + Pi ^
1,3-diphosphoglycerate + NADH + H+
1,3-diphosphoglycerate + ADP 3-phosphoglycerate + ATP (4)
The implications of this relationship have been discussed in detail 
by Stubbs et al_.(1972) and by Cohen and Woods (1976). B riefly , impaired 
phosphorylation of ADP and an increased NADH/NAD ratio can result from 
a block in the electron-transport chain, both producing an elevation of 
the lactate/pyruvate ratio .
However, the value of the lactate/pyruvate ratio in characterising 
lactic acidosis is questionable [Olsen, T963; Alpert, 1965; Cohen and 
Woods, 1976) particularly as the ratio is determined in the blood rather 
than the various tissues. Since there are separate pools of NADH and NAD 
in the cytoplasm and mitochondria of the cell (Boxer and Devlin, 1961), 
the blood lactate/pyruvate ratio , which depends upon the cytoplasmic
+ -j.
NADH-NAD system, may not reflect the NADH/NAD ratio within mitochondria 
which is the ultimate determinant of oxidative metabolism (Alpert, 1965) 
In addition, i t  is unlikely that a ll tissues w ill have similar lactate / 
Pyruvate ratios. In blood its e lf ,  due to a difference in erythrocyte 
permeability to lactate and pyruvate, the intracellu lar lactate/pyruvate 
ratio is greater than the extracellular ratio (Huckabee, 1956) so that 
the presence of red cells may distort the lactate/pyruvate ratio relative  
to the tissues.
Lactate elimination may proceed either by direct oxidation of 
pyruvate by the c itr ic  acid cycle, or by conversion to glucose (gluconeo- 
genesis) in the live r and kidneys.
The rate at which lactate is eliminated in the c itr ic  acid cycle 
depends upon the rate of metabolism of pyruvate to acetyl-CoA by the 
enzyme pyruvate dehydrogenase, which exists in an active (dephosphorylated) 
and an inactive (phosphorylated) form. The interconversion of these forms 
is catalysed by an ATP-requiring kinase and a phosphatase (Linn et a l . ,  
1969;Wieland et  al_., 1971). The reaction is inhibited by the products, 
acetyl-CoA and NADH and therefore the enzyme is maintained in an inactive 
state when the concentration of ATP and acetyl-CoA are kept high by 
oxidation of fuels such as fatty  acids. Thus pyruvate dehydrogenase has 
an important regulatory function in lactate metabolism because its  activ ity  
decides whether lactate is converted to acetyl-CoA or whether i t  is used 
to resynthesise glucose in the liv e r and kidneys.
For gluconeogenesis to proceed several special reactions are required 
to overcome the unfavourable energy transitions which prevent the total 
reversal of glycolysis. The irreversible stages of glycolysis are those 
controlled by pyruvate kinase, phosphofructokinase and hexokinase or 
glucokinase.
The interconversion of pyruvate and phosphoenolpyruvate through the 
combined actions of pyruvate carboxylase and phosphoenolpyruvate carboxy- 
kinase is presently believed to be the principal site of control of hepatic 
gluconeogenesis, as this stage controls the generation of hexose derivatives 
from lactate and amino acids. The stages involving fructose 1,6-diphos­
phatase and glucose 6-phosphatase control the conversion of hexose
derivatives to glucose and the regulation of blood glucose levels 
(Nordlie, 1976).
The control systems for pyruvate carboxylase and phosphoenol- 
pyruvate carboxykinase in mammalian species are complicated and w ill 
only briefly  be discussed. More detailed descriptions have recently 
been published (Cohen and Woods, 1976; Hanson and Mehlman, 1976).
While pyruvate carboxylase is generally believed to be located 
in mitochondria (B arritt et al_., 1976) phosphoenol pyruvate carboxykinase 
exhibits a species dependent intracellu lar distribution (Nordlie and 
Lardy, 1963). In rat liver phosphoenolpyruvate carboxykinase is mainly 
cytosolic,while in guinea-pig, rabbit and human live r the enzyme is 
distributed to differing degrees between the cytosol and mitochondria. 
According to Lardy et al_. (1965) the synthesis of phosphoenol pyruvate 
by the cytosolic enzyme requires the transport of four-carbon units 
from the mitochondria, as the mitochondrial membrane is relatively  
impermeable to oxaloacetate. Thus mitochondrial oxaloacetate is either 
converted to aspartate by glutamate-oxaloacetate transaminase, or reduced 
to malate by malate dehydrogenase and NADH; both of these four-carbon 
units are relatively easily transported into the cytosol and reconverted 
to phosphoenolpyruvate. The balance between malate and aspartate transport 
from the mitochondria in rat liv e r depends upon whether suffic ient NADH 
is generated in the cytosol to meet the needs of glyceraldehyde 3-phosphate 
dehydrogenase (Williams, J ., 1976). Thus with lactate as substrate, NADH 
is formed in the cytosol and transport of aspartate provides the four- 
carbon moiety for glucose synthesis (see FIG.1.4a) whereas when pyruvate 
is the substrate malate transport provides both the carbon units and a 
mitochondrial reducing equivalent for gluconeogenesis (see FIG. 1.4b).
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FIG. 1.4 Metabolic schemes for the transport of four-carbon units 
from mitochondria to the cytosol during gluconeogenesis in 
rat liv e r from (a) lactate and (b) pyruvate according to 
Williamson, 0 . (1976). For explanation of schemes see text.
Enzymes:- (1) pyruvate carboxylase; (2) phosphoenol pyruvate 
carboxykinase; (3) glutamate-oxaloacetate transaminase;
(4) malate dehydrogenase; (5) glyceraldehyde 3-phosphate 
dehydrogenase; (6 ) lactate dehydrogenase.
Thus aminooxyacetate, a transaminase inhibitor, causes almost 
complete inhibition of gluconeogenesis from lactate in rat liv e r , but 
very l i t t l e  inhibition from pyruvate (Anderson et aK* 1971). In guinea- 
pig live r aminooxyacetate causes a 50-60% inhibition of gluconeogenesis 
from lactate and a significant inhibition from pyruvate, indicating the 
involvement of the mitochondrial as well as the cytosolic phosphoenol- 
pyruvate carboxykinase in gluconeogenesis in this species (Arinze et a l . ,  
1973). In man the carboxykinase enzyme is located in both the cytosol 
and the mitochondria which suggests that, as in the guinea-pig, lactate 
metabolism could be significantly impaired by inhibition of transamination.
Phosphoenolpyruvate carboxykinase in the cytosol is responsive to 
dietary and hormonal stimuli (Shrago et a^.,1963; Nordlie et al_., 1965; 
Hanson and Garber, 1972; Sdling and Kleineke, 1976). A recent report 
(E llio tt  and Pogson, 1977) suggests that the mitochondrial enzyme in the 
guinea-pig is also increased during starvation. The enzyme activ ity  is 
affected by a number of hormones and the response varies with different 
tissues; thus insulin has no effect on the renal enzyme, but decreases 
the activ ity  in liver and adipose tissue (Shrago et al_., 1963). When 
rats are made insulin-deficient by alloxan administration the activ ity  of 
phosphoenolpyruvate carboxykinase rises sharply and insulin injection 
returns the activity to normal (Shrago et a l . ,  1963; Foster ejt al_., 1966). 
There is also evidence for a role of insulin as a mediator of the fasting 
response, perhaps by lowering intracellu lar cyclic AMP levels (Tilghman 
et sil_., 1976) but whether this occurs by a direct action on the liv e r  or 
by blocking the release of another hormone such as glucagon is s t i l l  not 
clear.
Glucagon and the catecholamines produce increases in phosphoenol- 
pyruvate carboxykinase activity in the liv e r , effects which are mediated 
by cyclic AMP (Shrago et al_., 1963; Reshef and Hanson, 1972) and involve 
de novo synthesis of the enzyme (Wicks et al_., 1972). The renal enzyme 
activity increases during metabolic acidosis within a few hours (Flores 
and Alleyne, 1971), an effect which probably involves hormonal regulation 
(Iynedjian et a l .,  1975).
The activation of pyruvate carboxylase by acetyl-CoA is strongly 
pH dependent in vitro (Kleineke and S51ing, 1971) and could have the 
greatest significance in the metabolic changes leading to lactic  acidosis 
(Cohen and Woods, 1976). The concentration of acetyl-CoA required to 
activate the enzyme is much greater at acid pH (Scrutton and Utter, 1967; 
Kleineke and Sttling, 1971; Scrutton and White, 1974), and in chicken liver 
the enzyme is v irtually  inactive below pH 7.0 (Scrutton and Utter, 1968). 
The intracellu lar pH in liv e r may , therefore, be an important regulating 
factor in the rate of gluconeogenesis from lactate, pyruvate and some 
amino acids.
Lloyd £ t l i *  (1973) have shown that lactate uptake in the perfused
rat liv e r decreases when the intracellu lar pH fa lls  below 7.1. The
decrease in lactate consumption and glucose output observed in the
-5 -4presence of phenformin (5 x 10 M - 5 x 10 M) is associated with a fa ll 
in in tracellu lar pH (Lloyd et al_., 1975) and the rate of lactate uptake 
appeared to be a controlling factor in the maintenance of hepatic cell 
pH.
The live r cell pH during lactic  acidosis has not been determined. 
Cohen and Woods (1976) have suggested that decreases of 0.2 - 0.3 units
may accompany such changes in extracellular pH as could be expected 
to occur in this condition, but point out that these values are 
derived from experiments in the normal cell and that larger decreases 
may occur in some conditions. Such a pH change would be equivalent to 
a doubling of the lactate/pyruvate ratio (see equation 2 ) but in cases 
of phenformin-associated lactic  acidosis blood lactate/pyruvate ratios 
tend to be greater than this (see FIG. 1.6) and the arterial pH is 
usually lower than in non-phenformin-associated cases (Cohen and Woods,
1976). Thus i t  remains a possibility that hepatic cell pH is considerably 
decreased in phenformin-associated lactic  acidosis.
When the intracellu lar pH in rat liv e r fa lls  below 7.0 - 7.07 lactate 
uptake ceases and production of lactate may occur (Lloyd et al_., 1973,1975). 
Coheri et al_. (1967. 1971 ) suggested that the metabolism of lactate may be 
accompanied by intracellu lar production of hydroxyl ions which results in 
the consumption of intracellu lar protons. Thus interference with lactate 
consumption may lower cell pH, and by bringing the value below 7.1 further 
inh ib it uptake. Cohen and Woods (1976) have suggested that a ‘vicious 
circ le ' could arise where an inhibition of gluconeogenesis from lactate 
(e.g. by high levels of phenformin) causes a fa ll in the in tracellu lar  
pH which in turn (perhaps by inhibiting the activation of pyruvate carboxylase 
by acetyl-CoA) further inhibits lactate uptake and metabolism. Such a 
> mechanism could explain the rapid development of lactic  acidosis once 
the process has started. The possible involvement of such a sequence 
in phenformin-treated diabetics suffering from lactic  acidosis is 
discussed la ter.
Biguanides and lactate metabolism
(a) Blood la c ta te  co ncen tra tion
Biguanide administration can increase the blood lactate concentration 
in normal and diabetic animals and man, but as with the h y p o g ly c a e m ic effect of 
the drugs (see SECTION 1.4) there is a considerable variation in response 
between different species and between diabetic and non-diabetic subjects.
The results of studies on the effects of the biguanides on the blood lactate
concentrations in animals and man are shown in TABLE 1.3.
These investigations have shown that hyperlactataemia is produced
in the guinea-pig with lower doses of phenformin than in the ra t, and 
that the diabetic rat is more susceptible to this effect than the normal 
ra t. Fasted animals show a greater increase in blood lactate concentration 
after biguanide therapy than do non-fasted animals. The hyperlactataemic 
response appears to be dose dependent (Bramanti ,1971a; Losert et a l . ,
1972b).
Experiments in guinea-pig (Tyberghein and Williams, 1957) and rat 
(Heuclin £ t  al_., 1975) have demonstrated that phenformin causes a much 
greater increase in blood lactate levels in nephrectomised animals than 
in normal animals. This finding is significant when considering the 
aetiology of phenformin-associated lactic acidosis, and w ill be discussed 
in a la ter section.
In non-diabetic human subjects only very small increases in blood 
lactate concentrations are seen with normal therapeutic doses of phenformin, 
even after fasting (Fajans et_al_., 1960; Lyngsoe e_t al_., 1972). The 
changes in blood lactate levels in man after phenformin administration
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are greatly increased by ethanol ingestion (Johnson and Waterhouse, 1968), 
a fact which w ill be discussed further in a la ter section.
In lactic  acidosis associated with phenformin therapy blood lactate 
concentrations reach much higher levels, often 15 - 20 times higher than 
those of untreated diabetics. The distribution of blood lactate concentration 
in two hundred published cases of phenformin-associated lac tic  acidosis 
is shown in FIG. 1 .5 . Over 70% of the patients had blood lactate levels 
between 50 and 200 mg/100 ml (5.5 - 22.2 mM), while Ball et aJL (1974) 
have shown that the normal value (taken from 308 diabetic patients) is 
9.0 3.6 mg/100 ml (1.0 + 0.4 mM). In a study of eighty-two'recorded
cases of lactic  acidosis, Cohen and Woods (1976) reported that blood 
lactate concentrations in patients treated with phenformin were s lightly  
but significantly (P < 0.02) higher than those in cases not associated with 
biguanide therapy.
Similar blood lactate concentrations occur in metformin- and bufcrmin- 
associated lactic  acidosis. In the twelve of thirteen published cases of 
metformin-associated lactic acidosis in which blood lactate levels were 
determined, concentrations of 60-180 mg/100 ml (6.5 - 20.0 mM) were recorded, 
while in the ten published cases of buformin-associated lactic  acidosis 
blood lactate levels ranged from 60 - 270 mg/100 ml (6.5-30 mM).
(b) Blood la o ta te /p y ru va te  r a t io
The fact that the blood lactate/pyruvate ratio may not be an accurate 
indicator of the state of tissue oxidation has been discussed earlie r. 
Nevertheless, the ratio is considered by some to be a useful clinical 
parameter related to tissue perfusion (Oliva, 1970; Harken, 1976).
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FIG.1.6 Distribution of blood lactate/pyruvate ratio in 
forty-eight published cases of lactic acidosis 
associated with phenformin therapy.
The distribution of values of blood lactate/pyruvate ratios in 
forty-eight published cases of lactic  acidosis associated with phenformin 
therapy is shown in FIG. 1.6. Some 80% of the patients had ratios 
higher than the normal range (7 -15),and two-thirds were greater than 30. 
This is in agreement with the report of Cohen and Woods (1976) who found 
that the blood lactate/pyruvate ratios in patients treated with phenformin 
were significantly (P < 0.001) higher than in cases not associated with 
biguanide therapy; most of the values in the non-phenformin group were 
below 30.
The presence of contributory illnesses
Biguanide-associated lactic  acidosis does not usually occur in 
diabetics who are otherwise heal thy,and is almost invariably a complication 
of serious illnesses. Of the 281 published cases of lactic  acidosis in  
patients receiving phenformin, less than 40 had no concomitant condition 
at the time of treatment (data extracted from literature survey provided, 
by Sterling Winthrop Research Laboratories, 1977). Of the remaining 
patients most suffered from renal, cardiovascular, hepatic or infectious 
diseases. Similar conditions have been identified in cases of metformin- 
associated (Lebacq and Tirzmalis, 1972; Hayat, 1974; Heuclin et al_., 1975; 
Bismuth et al_., 1976; Assan et afh, 1977) and buformin-associated lac tic  
acidosis (Clavadetscner £ t  aT_., 1976; Thimme £ t al_., 1976).
Renal fa ilure appears to be the most frequent aetiological factor 
in precipitating biguanide-associated lactic  acidosis. Metformin and 
buformin are normally excreted rapidly by the kidneys, and are not 
metabolised in man (Cohen and Costerousse, 1961; Pignard, 1962; Beckmann, 
1968). Phenformin is partly metabolised to 4-hydroxyphenformin which may
be less pharmacologically active (although there is no published information 
on the effects of this compound in man). Thus both renal and hepatic 
insufficiency promote accumulation of phenformin. Increased circulating 
phenformin concentrations of 3-15 times normal have been measured in diabetic 
patients with lactic  acidosis due to the presence of renal and liv e r  
diseases (Assan et al_., 1975).
In subtotally nephrectomised rats administration of phenformin (16 mg/ 
day) for 5-7 days produced a 7-10-fold increase in blood lactate concentration 
compared to untreated nephrectomised rats and phenformin-treated control 
rats, and reduced the rate of glucose production from lactate by some 60% 
(Heuclin et al_.. 1975). This blockage of gluconeogenesis is reversible; i t  
disappears from perfused rat liver when the biguanide is removed from the 
circulating flu id (Cook et_ al_., 1973b). In rats with chronic renal 
insufficiency phenformin excretion is reduced to 10% of the normal rate 
and the drug is s t i l l  present in the plasma 24h after administration, whereas 
i t  is no longer detectable in the plasma of control animals after !h (Heuclin 
et al_., 1975).
I t  therefore appears that, while at therapeutic levels of biguanides
lactate removal is unaffected or even stimulated (see SECTION 1 .4 ), at
higher concentrations, such as those achieved by suicidal self-poisoning 
-5(1 x 10 M, Karam et , 1974) or in cases of renal insufficiency removal 
of lactate is impaired. Thus over-production and under-utilisation of 
lactic  acid may produce the self-perpetuating series of events described 
earlier (SECTION 1.4) and lead to lactic acidosis.
Apart from an obvious association with impaired renal function, patients 
with cardiovascular complaints are predisposed to lactic acidosis because of
the poor tissue perfusion which favours the over-production of lactate 
(Assan ej: al_., 1976).
Lactic acidosis can occur despite normal circulatory conditions in
i
patients with dangerous infections, and such patients are particularly  
at risk in biguanide therapy (Thimme et al_., 1976).
Ethanol ingestion causes a sharp rise in the hepatic NADH/NAD4" 
ratio which in turn inhibits gluconeogenesis from lactate. In normal man 
there is a small increase in lactate, but in the presence of phenformin 
ethanol can lead to lactic acidosis (Johnson and Waterhouse, 1968; Cohen 
and Woods, 1976; Alberti and Nattrass, 1977).
These contraindications have led to the publication of lis ts  of 
restrictions for the use of biguanides (Mehnert, 1976). Unfortunately, 
diabetic patients treated with the drugs tend to be in the older age- 
groups and may acquire some of these complaints during therapy, and 
constant monitoring is essential (Cohen et al_., 1973; Assan £ ta l_ .,  1975, 
1976, 1977; Cohen and Woods, 1976; Thimme et al_., 1976; Alberti and 
Nattrass, 1977).
Dichloroacetate and lactic acidosis
The clinical treatment of lactic  acidosis by methods such as dialysis, 
insulin therapy and alkalinisation is not always successful and the mortality 
rate in phenformin-associated lactic acidosis is 45-50% (compared with 80% 
mortality in other forms of lactic acidosis, Alberti and Nattrass, 1977).
For this reason there is considerable interest in developing other forms of 
treatment such as dichloroacetic acid.
(a) M etabo lic  e ffe c ts  o f  d ich lo ro a ce ta te
Acetate and its  halogenated derivatives are known’ to affect several
aspects of metabolism. Acetate its e lf  exerts an anti lip o ly tic  effect on
%
adipose tissue but has no significant effect on blood sugar levels 
(Abramson and Arky, 1968)or may lead to hyperglycaemia by increasing citrate  
levels and inhibiting phosphofructokinase (Williamson, J ., 1967). Hoffman 
and Paulshock have reported a number of acetate derivatives to be effective 
in lowering blood glucose in diabetic animals, including dichioroacetic 
acid (Hoffman and Paulshock, 1961).
Lorini and Ciman (1961) f ir s t  showed that diisopropyl ammonium 
dichloroacetate, a mild vasodilator, reduced the hyperglycaemia of alloxan- 
induced diabetic rats without affecting normal rats. The active component 
of this compound is the acid moiety, dichloroacetic acid (Stacpoole and 
Felts, 1970;Eichner et al_., 1974).
A reduction in blood glucose levels is seen in the diabetic rat after 
enteral (Eichner et al_., 1974) and parenteral (Lorini and Ciman, 1961; 
Stacpoole and Felts, 1970, 1971; Blackshear £ t a K , 1975) administration 
of dichloroacetate as the sodium or diisopropylammonium sa lt. Hypoglycaemia 
is produced by the compound in 24h-fasted rats (Blackshear e t a l . , 1974) 
but not normal fed animals (Lorini and Ciman, 1961; Stacpoole and Felts, 
1970; Eichner et al_., 1974).
Experiments with rat diaphragm and heart muscle preparations show that 
dichloroacetate stimulates glucose oxidation which has been inhibited by 
alloxan-induced diabetes or by 3-hydroxybutyrate, acetate and palmitate 
(Stacpoole and Felts, 1970, 1971; McAllister et a l . ,  1973) and inhibits the
oxidation of acetate,3-hydroxybutyrate, palmitate and oleate (Stacpoole 
and Felts, 1970; McAllister et 1973; Whitehouse and Randle, 1973). 
Stacpoole and Felts (1970, 1971) have demonstrated that dichloroacetate 
returns to normal the elevated citrate and reduced glycerol 3-phosphate 
levels in heart and diaphragm muscle of diabetic rats, but has no effect 
in tissues from normal rats. In hearts from normal rats perfused with 
glucose and insulin dichloroacetate increases the concentrations of 
acetyl-CoA and acetyl carnitine and the conversion of pyruvate to acetyl-CoA 
(McAllister et al_., 1973). I t  has therefore been suggested that dichloro­
acetate may directly activate pyruvate dehydrogenase which exists in an 
active (dephosphorylated) and an inactive (phosphorylated) form. In te r­
conversion is catalysed by a specific ATP-requiring kinase and a phosphatase 
(Linn et al_., 1969; Wieland et al_., 1971). Dichloroacetate increases the 
activity of pyruvate dehydrogenase in rat hearts perfused with glucose or 
glucose and acetate, and inhibits the incorporation of 32P from [y-32P]ATP 
into the enzyme probably by inhibition of pyruvate dehydrogenase kinase 
(Whitehouse and Randle, 1973; Whitehouse et al_., 1974).
Blackshear et a l. (1974, 1975) have shown that the effects of dichloro­
acetate on glucose metabolism are similar in severely diabetic and fasted 
normal ra t. Blood glucose, lactate and pyruvate levels are decreased, as 
are the hepatic concentrations of most gluconeogenic intermediates. Dichloro­
acetate also causes a decrease in the accumulation of lactate, pyruvate and 
alanine in the blood of functionally-hepatectomised diabetic animals and 
abolishes the rise in blood lactate levels caused by insulin administration. 
These effects could arise from an activation of extra-hepatic pyruvate 
dehydrogenase (Whitehouse et al_., 1974) and suggest that dichloroacetate 
causes hypoglycaemia by decreasing the net release of gluconeogenic precursors 
from peripheral tissues (Blackshear et a l . ,1974,1975; Whitehouse et a K , 1974).
In the non-diabetic fasted rat dichloroacetate causes an increase 
in the blood concentration of acetoacetate and 3-hydroxybutyrate which 
is associated with a marked reduction of ketone-body uptake (Blackshear 
et a l . ,  1974). However, in the diabetic rat dichloroacetate infusion 
decreases the blood concentration and peripheral uptake of the ketones, 
but no anti lipo ly tic  effect was demonstrated (blood glycerol levels 
remained constant). The impaired ketone-body metabolism may arise from 
competition for coenzyme A between activated pyruvate dehydrogenase and 
the enzymes of ketone-body oxidation (McAllister et al_., 1973) or from 
the elevated tissue concentration of acetyl-CoA which would inh ib it the 
formation of acetyl-CoA from ketones and thus ketone-body uptake 
(Blackshear et a l. ,  1975). The decrease in blood levels of ketones in 
spite of the impaired peripheral uptake in the diabetic rat probably 
results from a fa ll in hepatic production (Blackshear et a1_., 1975).
In the non-ketotic, adult-onset diabetic sodium dichloroacetate 
given orally (0 .8-4.0 g/day for 6 - 7  days) reduced plasma glucose levels 
by an average of some 10%, plasma triglycerides by 50% and plasma 
cholesterol concentrations by approximately 15% (Stacpoole et ajL, 1976). 
Lactate, alanine and free fatty  acid concentrations were also decreased in 
a ll 5 patients studied, but insulin levels were unchanged. These findings 
are similar to those observed in the rat (Blackshear et al_., 1974, 1975) 
and suggest that peripheral release of gluconeogenic precursors and fa tty  
acids is inhibited by dichloroacetate, in the absence of an effect on 
insulin.
(b) D ich lo roace ta te  and phenform in-associa ted la c t ic  a c id o s is
In view of the a b ility  of dichloroacetate to decrease blood lactate 
and glucose concentrations, the effects of the compound on phenformin- 
associated hyperlactataemia and hypoglycaemia have been studied. Man and
Alberti (1976) have shown that dichloroacetate given to.rats 
simultaneously with phenformin (75 mg/kg, i .p . )  every 12h over a 
period of 28 days can prevent the development of lactic  acidosis.
The reduced blood glucose levels seen after combined treatment with 
phenformin and dichloroacetate are not significantly different from 
those seen after administration of either compound alone. Phenformin 
administration considerably elevates blood lactate concentrations, 
while the levels in rats given phenformin and dichloroacetate together 
are as low as, or lower than those in saline-treated control animals.
The increased hepatic concentrations of gluconeogenic precursors 
produced by phenformin are reversed by combined administration with 
dichloroacetate, but ketone-body levels are elevated.
As well as preventing the development of lactic  acidosis, bolus 
injections of dichloroacetate ( i .v . )  reverse a moderate phenformin- 
induced lactic  acidosis in the fasted, non-diabetic and non-ketotic, 
diabetic ra t, but hyperketonaemia may result (Alberti and Holloway,
1977),
In the dog dichloroacetate given as an infusion commencing before 
administration of phenformin prevents hyperlactataemia without affecting 
the hypoglycaemic action, but is less effective when infusion is started 
3h after the phenformin injection (Loubatieres et al_., 1976).
There is considerable interest in the potential of dichloroacetate 
in combination with phenformin for use in the treatment of diabetes, but 
whether i t  w ill have a beneficial effect on lactic  acidosis in man remains 
to be investigated.
1.6 THE METABOLIC FATE OF THE BIGUANIDES
Although there has been a great deal of research to determine the 
mechanism of action of biguanides, their metabolism and disposition has
i
received relatively l i t t l e  study.
The concentrations of phenformin and its metabolites in blood and 
tissues have been estimated by fluorimetric (Hall jet , 1968) and 
colorimetric methods (Freedman _et aj_., 1961; Tranquada, 1961; Assan 
et aT_., 1975) but the valid ity  of these methods is not generally accepted 
(Mehnert,1969a; Beckmann, 1971; Cohen and Woods, 1976). More recently 
a specific and sensitive g .l.c . method for the determination of phenformin 
in biological fluids has been developed (Sterling Winthrop Research 
Laboratories, personal communication, 1974; Alkalay et aJL, 1975; Matin 
et a]_., 1975) but i t  is not possible to determine the concentration of 
metabolites by this technique.
Because of these d ifficu lties  a number of metabolic studies have 
used radioactively-labelled phenformin (Wick et al_.5 1960, 1961 ; Beckman, 
1967, 1968). However, in view of the ab ility  of the biguanide moiety 
to alternate between several resonant and tautomeric structures (Shapiro, 
1959; Elpern, 1968; see FIG. 1.2) the randomly-labelled[3H]phenformin used 
by Beckmann (1967, 1968) may be susceptible to exchange of label between 
the compound and water, particularly in acid solution.
Absorption and excretion of the biguanides
Determination of the unchanged phenformin in plasma of human patients 
by g .l.c . has shown that the concentration of the drug after oral adminis­
tration of 50-150 mg/day-reached peak levels of 100-200 ng/ml (0 .5-1 .0  x 
~610 M), 2-4h after ingestion (Sterling Winthrop Research Laboratories, 
personal communication, 1974; Karam et a l . ,  1974;A1kalay et a l . ,  1975;
Mati n et jfj_., 1975). The composite level of phenformin and its metabolites 
[measured as plasma radioactivity) 2h after oral administration of 100 mg 
[3H]phenformin was of the order9 220 ng/ml, 1.1 x 10” M (Beckmann, 1967,
1968).
The pharmacokinetics of buformin and metformin have been the subject
of l i t t l e  attention. After oral ingestion of TOO mg [ lt+C]buformin the peak
plasma level of radioactivity at l-2 |h  was equivalent to 2.0-6.4 x 10” M
(Beckmann and Hflbner, 1965; Lintz et al_. ,1974). Pignard (1962) has reported
-5serum concentrations of metformin of 4 x 10 M during oral therapy (lg/day)
-4 -
and the levels may be as high as 3.5-8.5 x 10 M in patients with lactic  
acidosis (Assan et j fL ,  1977) although the specificities of the colorimetric 
assays used for biguanide determinations are not generally accepted.
After intraperitoneal administration of phenformin to the rat (100 mg/kg) 
and guinea-pig (15 mg/kg) the livers of both species contained 18-35% of the 
radioactivity in the f ir s t  2-3h but this rapidly declined to 2-3% at 12h 
and less than 1% at 24h (Wick et'al_., 1960, 1961 ; Hall £ t  a K 5 1968). This 
does not indicate a selective concentration of the active parent drug as 
almost a ll of the radioactivity in rat live r and nore than half in guinea-pig 
live r was attributable to metabolic products (Hall et al_., 1968). The 
stomach and intestines also contained large amounts of radioactivity after 
parenteral administration of phenformin, suggesting that the drug and/or 
its  metabolites were secreted into the stomach and the gut, perhaps due to 
the extremely basic nature of the biguanide moiety. Bases such as aniline 
(Shore et _ah, 1957) and nicotine (Andersson et j f h , 1965) were secreted 
from the plasma into the stomach of rats. B iliary excretion of radio­
activ ity  into the lumen of the gut may also occur (Hall et a l . ,  1968).
After oral administration of phenformin to rats most of the radio­
activ ity  was associated with the gastrointestinal tract and appeared to 
be trapped by the acidic stomach juices rather than associated with the 
tissue (Wick et al_., 1960). *
The excretion of radioactivity in urine and faeces after oral and 
intraperitoneal administration of phenformin is shown in TABLE 1.4. I t
can be seen that the data is inconclusive as there is considerable 
disagreement. The values reported by Wick et a_l_. (1960) were obtained 
from one animal each and must be viewed with reservations. Although the 
major portion of the dose was rapidly eliminated within 24h the excretion 
in subsequent days was also significant. Beckmann (1967) found small 
amounts of radioactivity in the 48-72h urine and faeces after intraperitoneal 
administration of phenformin to ’rats, and the drug could s t i l l  be detected 
by g .l.c . in the urine of human patients 60-1OOh after ingestion of 100 mg
phenformin (Alkalay et a l . ,  1975; Matin et al_., 1975).
Beckmann (1967, 1968) reported that the rat completely metabolised 
phenformin, mainly to 4-hydroxyphenformin glucuronide, after an oral dose 
of 50 mg/kg [3H]phenformin (see FIG. 1 .7). A small amount of the free phenol 
was also detected, Murphy and Wick (1968) also found only 4 -hydroxyphenformin 
and its glucuronic acid conjugate in rat urine after oral administration of 
100 mg/kg [1I+C-biguanide]phenformin but reported that these metabolites existed 
in equal quantities. Rat faeces contained mainly phenformin with small 
quantities of 4-hydroxyphenformin and its glucuronic acid conjugate (Beckmann, 
1967). B iliary excretion in the rat accounted for some 5-12% of a 50 mg/kg 
of [3H]phenformin in 24h and the bile  contained mainly phenformin. The metabolites 
4-hydroxyphenformin and its glucuronide accounted for some 10-30% of the b ilia ry  
radioactivity (Beckmann, 1967).
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The mouse, rabbit and guinea-pig excreted the same metabolites in urine 
as the rat after oral administration of [3H]phenformin but also eliminated 
some unchanged drug (Beckmann, 1967). The degree of metabolism varied with 
species and only traces of metabolic products were detected in guinea-pig 
urine.
Human urine contained phenformin and 4-hydroxyphenformin in a 2:1 ratio  
but no glucuronic acid conjugate was detected (Beckmann, 1967, 1968). ;
Bufonriin in rat and man after oral administration was excreted 
predominantly by the kidney, some 60-80% of the dose being eliminated in 
the urine in 24h (Beckmann, 1965;Losert et al_., 1972a; Lintz £ t aK , 1974). 
After intravenous administration only 60-90% of the dose in man was excreted 
in the urine and 10-40% in the faeces. The presence of the drug in the lumen 
of the gut may be associated with b ilia ry  excretion or secretion from the 
blood into the intestinal lumen (Lintz £ t al_., 1974).
Rat and mouse metabolised buformin more or less quantitatively by 
introduction of a hydroxyl group to give l-(3-hydroxybutyl) biguanide (see 
FIG. 1.7); man appeared to excrete only unchanged buformin (Beckmann, 1965,1966, 
1967, 1968).
In the rat and guinea-pig after oral administration of 10 mg/kg buformin 
a ll of the tissues examined contained levels of radioactivity significantly  
higher than that of the blood at 24h after dosing (Losert et al_., 1972a).
There was no evidence of selective concentration of radioactivity in the 
liv e r. Higher concentrations than those in live r were found in the gastro­
intestinal tract and skeletal muscle in rat and in the urinary bladder, gut 
and kidneys in the guinea-pig. The very high level of radioactivity in the 
bladder and kidneys of the guinea-pig may have reflected the slower rate of
elimination in this species. At 24h the rat had excreted some 85% of 
the dose compared with 69% in the guinea-pig (Losert et al_. , 1972a).
A study of the tissue distribution of radioactivity after oral, 
subcutaneous and intravenous administration of [14C-biguanide]metformin 
in the mouse showed that the radioactive label was rapidly associated 
with the stomach and gastrointestinal tract and was eliminated primarily 
in the urine (Cohen and Costerousse, 1961). After oral administration 
the liver did not show a significant accumulation of radioactivity and 
after the parenteral doses the accumulation was only transitory. The 
rapid appearance of 1I+C in the gut after parenteral administration did 
not appear to involve b iliary  excretion. The radioactivity in the urine 
was associated with unchanged metformin.
The metabolism of metformin has been studied in the ra t (Beckmann,
1969) and in man (Pignard, 1962; Debry and Cherrier, 1965). Only unchanged 
metformin has been found in the urine, but when metformin was administered 
to diabetic patients only a small part of the dose was recovered in the 
urine and faeces. Debry and Cherrier (1965) suggested that this might 
indicate that metformin was partly metabolised in man, but in view of the 
relatively non-specific colorimetric technique used these findings are not 
generally accepted (Beckmann, 1967, 1968; Mehnert, 1969a).
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1.7 THE OBJECTIVE OF THIS THESIS
A survey of the literature to date shows that the metabolic fate 
of phenformin has not been adequately studied (see SECTION 1.6). The 
most comprehensive study has been that of Beckmann (1968)twho, perhaps 
unwisely, used [3H]phenformin and whose results did not agree with those 
obtained using [14C]phenformin [Hall et al_., 1968; Murphy and Wick, 1968); 
see TABLE 1.4. In view of the current concern regarding the occurrence 
of lactic  acidosis associated with the biguanides a more detailed knowledge 
of the absorption, excretion and metabolism of phenformin is desirable.
Although there has been a great deal of research into the problem 
of lactic  acidosis i t  has been largely concerned with the clinical 
treatment of diabetic patients. Only recently have studies on the 
mechanism of biguanide-associated lactic acidosis been published 
(Heuclin et_ a]_., 1975; Lloyd et a]_., 1975; Assan et a h , 1976; Man and 
Alberti, 1976; Alberti and Holloway, 1977). Although i t  is generally 
believed that the pharmacologically active molecule is the parent compound 
this has not been demonstrated experimentally. Conflicting reports have 
been published regarding the hypoglycaemic activ ity  of 4-hydroxyphenformin; 
according to Wick et al_. Cl970) the phenol is half as effective as phenformin 
in the rat while Beckmann (1968) found the metabolite to be ineffective  
in the mouse. Cook slI^-0973a) have reported that the metabolism of 
phenformin to 4-hydroxyphenformin is the controlling factor in the 
differential hypoglycaemic response of rats and guinea-pigs to phenformin, 
but no attempt was made to ju s tify  the assumption that the metabolic 
products were 4-hydroxyphenformin and its  glucuronic acid conjugate.
The relationship between the metabolism of phenformin and its  
pharmacological activity remains to be investigated, particularly with
a view to understanding the species difference in hypoglycaemic and 
hyperlactataemic response to the drug.
In these studies the absorption, excretion and metabolism of 
[2‘ -^C]phenformin were studied in the rat and guinea-pig‘with particular 
regard to the possible existence of pharmacologically active metabolites. 
The hypoglycaemic and hyperlactataemic activities of phenformin and 
4-hydroxyphenformin were investigated in both species and the potential 
of dichloroacetic acid (and other compounds of interest) as a means of 
controlling phenforrnin-associated lactic acidosis was studied.
-7 1 -
CHAPTER 2
METABOLISM OF PHENFORMIN IN RAT AND GUINEA-PIG
2.1 MATERIALS AND METHODS
Chemicals
1 ^Sodium [ *C]cyanide (specific radioactivity 50mCi/m mole) was 
obtained from the Radiochemical Centre, Amersham, Bucks. and tyramine 
hydrochloride from Sigma Chemical Co. Ltd., London.
Chemicals used in scintillation  counting were 2 ,5-diphenyloxazole, 
Instagel and Cab-O-Sil thixotropic gel-powder (Packard Instruments Ltd., 
Reading, Berks.) and 1,4-di(2-methylstyryl)benzene (Koch Light 
Laboratories, Colnbrook, Bucks.). Toluene of low sulphur content used 
for sc intillation  counting was obtained from Fisons, Loughborough,
Leics.
Saccharic acid 1,4-lactone was purchased from Sigma (London) and 
Ketodase, ox-liver 3-glucuronidase from Warner-Chilcott Ltd.,
Eastleigh, Hants.
Except where otherwise specified, a ll other solvents and chemicals 
used were from common laboratory suppliers and were of reagent grade.
. Phenformin hydrochloride was kindly donated by Sterling Winthrop 
Research Laboratories (Fawdon, Newcastle-upon-Tyne). Visualisation 
under u.v. light (254nm) after t . l . c .  on s ilica gel ^ 5 4  and 
alumina 6OF254 in solvent systems A and G respectively revealed a 
single component which gave a positive colour reaction with a 
nitroprusside-ferricyanide spray reagent [see Chromatography).
Sodium pentobarbitone anaesthetic was obtained from Abbot Laboratories, 
Queenborough, Kent (Nembutal) or May and Baker Ltd., Dagenham, Essex
(Sagattal). Urethane anaesthetic solution was prepared from the 
reagent grade material supplied by British Drug Houses Ltd., Poole, 
Dorset.
Materials
Polypropylene mini-vials (5ml) used in scintillation  counting were 
obtained from G. D. Searle and Co. Ltd., High Wycombe, Bucks. All 
cannula tubing was supplied by Portex Ltd., Hythe, Kent. Neutral glass 
collection tubes (2ml) were obtained from Glass Wholesale Supplies Ltd., 
London and plastic cups with concave base (1ml auto-analyser cups) from 
Scientific Supplies Co. Ltd., London.
i
14Synthesis of [2*- C]phenformin hydrochloride
RadioactiveTy labelled phenformin was synthesised essentially
according to the procedure described by Sterling Winthrop Research
Laboratories (personal communication, 1974). Carbon-14 is introduced 
14as sodium [ C]cyanide as shown in FIG. 2.1.
•CH0C1 Na1I+CN
NH NH 
iu 11 HCH “ CH NH-C-NH-C-NH .HC1 -* ■CH lllCH2NH2.HCl
Scheme for the synthesis o f . T2'-^Cl phenformin
-7 4 -
(a) B e n zy l^C Jcya n id e
_2
Benzyl chloride (1.27g, 1 x 10 mole) in ethanol (2ml) was added
slowly to an aqueous solution ( 1 . 0- 1 . 5ml) of sodium [^C]cyanide 
_o
(0.49g, 1 x 10 mole, 500pCi) and the mixture refluxed for 4h. After 
filte rin g  and washing the precipitate of NaCl with ether, the organic 
layer was washed successively with 55% (w/v) sulphuric acid (1ml), 
saturated sodium bicarbonate solution ( 1ml) and saturated sodium 
chloride solution (1ml). The organic phase was separated, dried 
(anhydrous sodium sulphate) and evaporated under reduced pressure to 
yield a pale yellow o il,  benzyl [^C] cyanide (0.97g, 83.0%).
14 1(b) [ 2 r-  C] Phene thy lourrtne hydroch lo ride
_2
Lithium aluminium hydride (0.4g, 1.05 x 10 mole) in sodium-dried
ether (20ml) was stirred under nitrogen while anhydrous aluminium
-2chloride (1.40g, 1.05 x 10 mole) in sodium-dried ether was added over 
a period of 10 min. Benzyl [^C]cyanide (0.97g, 0.83 x 10”^mole) in 
sodium-dried ether ( 20ml) was added slowly over a period of 20 min and 
stirred for 2h. Excess hydride was destroyed by successive addition 
of water (0 .8ml), 2N-sodium hydroxide (0 .6ml) and water ( 2 .0ml) and 
the pH fin a lly  adjusted to 11.0 with 30% (w/v) sodium hydroxide. The 
solid was filte red  off and washed with water and ether and the f i l t r a te  
extracted with ether. The combined ether extracts were dried over 
sodium sulphate and evaporated under reduced pressure to give an o il .  
This was dissolved in sodium-dried ether (2ml), cooled to 4°C and 
bubbled with dry hydrogen chloride gas for 5-10 min. The white solid 
was filtered  o ff and dried in vacuo (0.80g, 61.3%).
-7 5 -
(o) [ 2 Phene thy Ib iguan ide  (phenform in)
14[2‘- C]Phenethylamine hydrochloride (0.80g, 5.1 x 10 mole)
_3
was stirred in xylene (2ml) with dicyandiamide (0.43g, 5.1 x 10 mole) 
and heated under reflux for 4h with the temperature of the o il bath 
being maintained above 140°C to ensure the best yield. The xylene was 
removed under reduced pressure and the solid crystallised once from 
propan-2-ol-water (95:5, by vol.) and once from butan-l-ol. The solid 
was filte red  o ff and dried at 60°C in vacuo (0.480g, 39.1%), m.p. 169- 
174°C and radiochemical purity 92.2%.
Radiochemical purity was determined by t . l . c .  on silica-gel GF254 
in system B using 50-100yg loadings of radioactive phenformin 
co-chromatographed with authentic non-radioactive phenformin. After 
removal of the zones corresponding to the biguanide the remaining area 
in each run was divided into 1cm bands and taken for scin tillation  
counting. The radiochemical purity was expressed as the percentage of 
the total radioactivity attributable to phenformin.
Further recrystallisation from propan-2-ol-water (95:5, by vo l.) 
gave 0.155g of phenformin hydrochloride; radiochemical purity>98%, 
m.p. 177-179°C. Similar treatment of the mother liquor yielded an 
additional 0.075g of the compound; radiochemical purity>98%, m.p. 176- 
179°C.
14The specific radioactivity of the [2 '- C]phenformin hydrochloride 
was 223.2yCi/g (53.9mCi/mole) and the total yield 51.3yCi (0.230g).
Synthesis of 4-hydroxyphenformin hydrochloride
4-Hydroxyphenformin hydrochloride was prepared from tyramine 
hydrochloride and dicyandiamide analogously to the preparation of 
phenformin hydrochloride from phenethylamine and essentially as 
described by Beckmann (1967) and Murphy and Wick (1968).
The product of the reaction was crystallised from methanol, 
but contained considerable amounts of starting materials. Recrystallisati 
twice from butan-l-ol and twice from propan-2-ol-water (95:5, by vol.) 
gave a sample of 4-hydroxyphenformin which produced a single zone when 
v i s u a l t s e d under u.v. light (254nm) after t . l . c .  on s ilica  gel GF254 
in systems B and D and gave a positive reaction with the nitroprusside- 
ferricyanide reagent for guanidines and biguanides.
The m.p. (179-181°C) agreed well with the value (180-183°C) 
reported by Murphy and Wick (1968).
Further samples of 4-hydroxyphenformin hydrochloride (and 
dihydrochloride) were kindly supplied by Sterling Winthrop Research 
Laboratories, Fawdon, Newcastle-upon-Tyne.
Determination of radioactivity
Several different scintillation  fluids were used to accommodate 
the variety of samples counted. These are listed below.
1. Toluene, containing 2 ,5-diphenyloxaxole (4g71) and
1.4-di(2-methylstyryljbenzene (0 .08g /l) .
2. Toluene-Synperonic NXP (2:1, by vol.) (Wood et a l . ,  1975)
2.5-diphenyloxazole (5 .5 g /l).
3. Cab-O-Sil sc in tillan t
Cab-O-Sil thixotropic gel-powder 4-5% ( /v) in sc in tillan t
system 1 .
4. Instagel, commercially prepared sc in tillan t.
> 7 7 -
Aqueaus and organic samples (0.5ml; or adjusted to 0.5ml with 
toater) were generally counted in sc in tillan t system 1 (10ml) after 
addition of 2-ethoxyethanol (5ml) or system 2 (4ml). Highly quenching 
samples (0 .5 -4 .0ml) such as digests of blood, tissues and faecal 
homogenates, or solutions of pi crate salts from reverse isotope 
dilution analysis were counted in sc in tillan t system 4 (4-10ml).
Samples of silica-gel from t . l .c .  plates or paper strips from descending 
paper-chromatography were suspended in sc in tillan t system 3 for 
determination of radioactivity. Samples were stored in the dark and 
counted at 4°C in a Packard Tricarb 3320 or LKB Wallac 1210 
scintillation counter.
Counting efficiencies for most samples were determined using an
automatic, external standard, channels ratio calibration. Quench
14curves were prepared with n -[ l-  C]hexadecane as the standard and 
carbon tetrachloride as the quenching agent. Different curves were 
prepared for different sc in tillan t systems and counting conditions.
The accuracy of the channels ratio correction procedure was checked 
periodically by internal standardisation of randomly selected samples. 
Separate quench curves were prepared for the coloured solutions of 
pi crate salts, using non-radioactive phenformin pi crate as the 
quenching agent.
Counting efficiencies of other highly quenching samples such as 
digests of blood, tissues and faecal homogenates were determined by 
internal standardisation.
Chromatography
Thin-layer chromatography was carried out using commercially 
prepared plates of s ilica  gel GF254 (0.25mm; Schleicher and Schull; 
Anderman and Co. Ltd., London) and alumina (tyPe 0»25mm;
E. Merck, Darmstadt, West Germany), preparative-layer chromatography 
on s ilica  gel 6OF254 (2mm; E. Merck, Darmstadt, West Germany). The 
following solvent systems were used:
A. butan-l-ol-acetic acid-water (4 :1 :1 , by vo1.)
B. butan-l-ol-ammonia (0.88sp. gr.)-water (10:1:1, by vol.)
C. butan-l-ol-chloroform-methanol-25% (w/v)ammonia (45:15:15:15, by vol.)
D. propan-1-ol-ammonia (0.88sp. gr.) (7:3, by vol.)
E. chloroform-methanol (10:3, by vol.)
F. chloroform-methanol-25% (w/v)ammonia (10:2:1, by vol.)
G. ethanol-25% (w/v)ammonia (4:1, by vol.)
For paper chromatography the following solvent system was used:
H. propan-2-ol-ammonia (0.88sp. gr.)-water (80:1:20, by v o l . ) .
All solvents used in the preparation of samples for mass spectrometry 
were of AnalaR quality and t . l .c .  plates were pre-run in the solvent 
system to be used.
Authentic phenformin and 4-hydroxyphenformin were co-chromatographed 
with a ll samples and located by visualisation under u.v. light (254nm).
Two spray reagents were used to detect guanidine and biguanide 
groupings:
1. Sodium nitroprusside-potassium ferricyanide-sodium hydroxide, 
each 10% (W/v) in water (1:1:1, by vol.) diluted with 9 volumes
50% (V/v) aqueous ethanol (Murphy and Wick, 1968);
2 . ct-naphthol, 1% (w/v) in sodium hydroxide (8%, w/v
in water)- 1% (w/v) diacetyl in water (1:1 by vol.) (Smith, 1969).
Glucuronic acid conjugates were detected by spraying plates with 
V! (W/v) naphthoresorcinol in acetone - 10% (v/v ) phosphoric acid 
(4:1, by vol.) followed by heating at 140°C for 15 min (Bridges 
et a ) . ,  1965).
Descending paper chromatography of guinea-pig urine extracts was 
carried out using Whatman 3MM paper in solvent system H. Authentic 
phenformin and 4-hydroxyphenformin were co-chromatographed with 
portions of the extracts and located using spray reagent 2 .
Whole urine and urine extracts were chromatographed on s ilica  gel 
in solvent systems B, C and D, and on alumina in solvent system G.
Faecal extracts were chromatographed on silica gel in solvent systems 
E and F.
Autoradiography
Autoradiographs of t . l . c .  plates were prepared by exposing to 
medical X-ray film (Kodak 'Blue Brand', BB54, 18 x 24cm) for a 
suitable period of time (typically 4-6 weeks) in a lightproof cassette.
The films were developed in Kodak Universal developer for 3-4 min, 
rinsed in di 1. acetic acid and fixed in Kodafix solution for 3-4 min 
before washing in running water for 30 min.
Contact prints of the autoradiographs were made on Agfa Rapidoprint 
paper (grade TP3 semi-matt finish) using an Agfa LD37 Rapidoprinter.
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Where required, permanently fixed copies were made using Kodafix 
solution as described before.
Animals
Adult male Wistar albino rats and Dunkin-Hartley albino 
guinea-pigs were used in a ll experiments. For surgical procedures 
rats were anaesthetised by intraperitoneal injection of Iml/kg sodium 
pentobarbitone solution (60mg/ml) and guinea-pigs received urethane 
(28% w/v aqueous solution, 8-10ml/kg, i .p .)  as described by Schanker 
et al_. (1958). All animals subjected to surgery were .sacrificed 
before recovery from anaesthesia.
Determination of phenformin in blood
Guinea-pigs (350-500g) and rats (300-400g) were anaesthetised 
and the neck area shaved. A 3cm mid-line incision was made commencing 
in the region of the larynx and terminating before the ventral thorax 
wall. The common carotid artery was located and cannulated using 
PP50 (guinea-pig) or PP25 (rat) polypropylene tubing. The cannula was 
kept patent by frequent administration of small volumes of saline 
(0.9%, w/v) containing lithium heparin (lOOOU/ml) and was clamped 
between collections.
Samples (approx. 0.5ml) were collected at intervals into 1ml 
plastic auto-analyser cups which had been rinsed in heparinised saline 
and dried before use.
[2'-^C]Phenformin was adminstered intravenously through the 
cannula at a dose level of 10-12mg/kg or intraperitoneally (15-25mg/kg).
Aliquots of blood (0.1ml in trip lica te ) were digested at 50°C 
in glass scintillation vials with 62% (w/v) perchloric acid ( 0 . 2ml) 
and decolourised with 100 vol. (30%, w/v) hydrogen peroxide (0.2ml) 
before counting in scin tillan t 4.
Excretion balance studies
Rats (250-350g) and guinea-pigs (300-350g) were individually 
housed in all-glass metabolism cages (Metabowls, Jencon Scientific Ltd. 
Hemel Hempstead, Herts.).
14Guiriea-pigs were dosed with aqueous solutions of [21 - C]phenformi
hydrochloride at a level of 25mg/kg orally (1 .5 -1 .8yCi) or 12.5mg/kg
intraperitoneally (1 .0 -1 .2yCi) .  Rats were dosed with aqueous solutions 
14of [2‘ - C]phenformin hydrochloride (7mg/kg, orally) or diluted with 
non-radioactive phenformin hydrochloride at doses equivalent to 
lOOmg/kg (1.6-2.8yCi) either orally or intraperitoneally.
The urine and faeces were collected separately each 24h for 
4 days and the expired a ir  drawn at a rate of approximately 200ml/min 
through a series of carbon-dioxide traps containing ethanol amine and 
2-ethoxyethanol (1:3, by v o l.). After each collection of urine and 
faeces the cages were washed through with d is tilled  water to remove 
any radioactivity adhering to the glass surfaces. Each washing was 
collected and assayed ;for radioactivity by liquid scin tilla tion  
counting and the value obtained (^0.3% of the dose) was added to that 
of the appropriate urine sample. Aliquots (0 .1 -0 .2ml) of each urine 
sample were assayed for radioactivity as described previously, usually 
after dilution in water.
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Faecal samples were homogenised in water to give 5-10% (w/v) 
homogenates and trip licate  aliquots (0.5 ml) were transferred 
into glass scintillation  vials and digested with hyamine hydroxide 
(3 ml) at 50-60° for 6h. On cooling the samples were decolourised 
overnight at room temperature with 100 vol. (30% w/v) hydrogen 
peroxide (0.25 ml), neutralised with concentrated hydrochloric 
acid (0.25 ml) and the radioactivity determined by liquid 
scintillation  counting in sc in tillan t 4 (10 ml).
The solvent from each carbon dioxide trap was diluted with 
2-ethoxyethanol and aliquots (4-5 ml) dispensed into vials and 
counted in scin tillan t 1 (10 ml).
B iliary excretion studies
The b iliary  excretion of radioactivity in rats (300-400g) and
guinea-pigs (500-800g) was determined after a single intraduodenal
14administration o f[2 '- C]phenformin hydrochloride (20 mg/kg) in 
0.25 ml saline (2.0-4.0 yCi per animal).
la ) C o lle c tio n  o f  b i le  in  the r a t
Rats were anaesthetised with sodium pentobarbitone, the 
abdominal region shaved and the limbs restrained. The common 
bile duct was cannulated essentially as described by Abou-el-Makarem 
et a/[. (1967a) except that the animals were anaesthetised throughout 
the experiment.
After a mid-line incision through the skin and peritoneum the 
duodenal region of the small intestine was located. The bile duct
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was cleared of mesenteric fa t and ligated at its entry to the 
duodenum. Two loose ligatures were placed in position around 
the duct and a 2 mm hole made in the side wall of the abdominal 
cavity using a trochar. A suitable length (20 cm) of PP10 or 
PP25 cannula tubing was fed through the hole in the abdominal 
wall and f ille d  with saline. After making a small incision 
in the bile duct with iridectomy scissors the cannula was 
inserted and tied in.
When bile flow was evident a 20 cm length of PP25 tubing 
was tied into a small hole made in the duodenum, below the point 
of entry of the bile duct. The other end of the intraduodenal 
cannula was passed through the ventral mid-line incission which 
was then sutured using surgical thread. A third length of 
cannula (PP25) was inserted through the sutures into the peritoneal 
cavity for subsequent administration of saline and anaesthetic.
The outer skin was closed using suture clips and the exposed 
surface skin covered with cotton wool moistened with saline.
(b) C o lle c tio n  o f  b i le  in  the gu inea-p ig
Guinea-pigs were anaesthetised and prepared in a similar 
fashion to rats. The gall bladder was located and tied o ff at its  
junction with the common bile duct. In cases where the gall 
bladder was highly distended the bile  was withdrawn using a 
hypodermic needle and syringe. This improved access to the bile  
duct which was cannulated as described previously using PP25 
cannula tubing.
Bile from rats and guinea-pigs was collected into preweighed 
2 ml neutral glass tubes and the weight determined. Duplicate 
aliquots (50 y l ) from each collection period were assayed for 
radioactivity in sc in tillan t 2 .
(c) Enterohepatic re c ir c u la t io n  in  the r a t
The significance of enterohepatic recirculation of
b iliary  metabolites in the rat was determined by inserting the
bile duct cannula from one rat (donor) into a tig h t-fittin g
plastic sleeve which had been tied into the duodenum of a
second bile duct-cannulated animal (recipient). The donor
14animal was dosed with [21- C]phenformin hydrochloride in tra - 
duodenally and the radioactive bile  allowed to flow into the 
duodenum of the recipient rat whose bile was collected and 
assayed for radioactivity. Bile flow from the donor rat was 
checked periodically by removing the cannula from the plastic 
sleeve.
In a second experiment freshly collected radioactive bile (2 ml) 
was injected directly into the duodenum of a cannulated rat 
whose bile was collected and assayed for radioactivity.
Extraction of radioactivity from urine
(a) S o lvent e x tra c tio n
Duplicate aliquots (0 .5 -2 .0ml) of the 24h urine from rats and 
guinea-pigs were adjusted to a range of pH values (1-11) and extracted 
two or three times with two volumes of ethyl acetate, diethyl ether 
or chloroform-methanol (85:15, by v o l.) . After incubating for 18h 
at 37° with 3-glucuronidase (Ketodase, 5000 Units/ml in 0.2M-sodium 
acetate buffer, pH 5.0) the extraction procedure was repeated. The 
radioactivity in aliquots of the organic extracts from each sample 
was determined by liquid scintillation  counting. The remaining 
portions of the extracts were evaporated under reduced pressure and 
the residues dissolved in methanol (50-100y1) for examination by t . l . c .
(b) Ion-exchange chromatography
The radioactivity in rat and guinea-pig urine collected 24h after  
14administration of [21- C]phenformin was isolated using cation-exchange 
chromatography. Whole rat urine (10-25ml) and urine after extraction 
with chloroform-methanol (85:15, by vol.) was applied to columns of 
200 mesh Amberlite CG-50 (a weakly acidic carboxylic acid resin) and 
Amberlite CG-1.20 (a strongly acidic sulphonated polystyrene resin) 
and eluted as described by Murphy and Wick (1968).
Guinea-pig urine (15-30ml) was passed through a column (35 x 1.5cm) 
of Zerolit 225 (a strongly acidic sulphonated polystyrene resin) in 
the H+ form. The column was eluted with water (50ml) and fractions 
collected until the eluate was pH 5.0. Weakly basic metabolites were 
eluted with 2N-aqueous ammonia ( 100ml) and strongly basic metabolites
with 50ml 4N-sodium hydroxide-ethanol (1:1, by v o l.) , 5-10ml fractions 
being collected . The fractions containing most of the
radioactivity were pooled for each eluent, the slodium hydroxide solution 
neutralised and both samples concentrated for examination by t . l . c .
Extraction of radioactivity from faeces
(a) Solvent e x tra c tio n
Homogenates (5-10%, w/v) of faeces containing radioactivity from
' 14guinea-pigs after oral dosing with [2 '- C]phenformin were centrifuged
and the aqueous supernatant collected. The residues were extracted
successively with 2 volumes of methanol and ethanol-25% (W/v) ammonia
(9:1, by v o l.). This procedure gave quantitative recovery of the
radioactivity but further purification was necessary before examination
by t . l .c .  This was achieved by adsorption chromatography.
The extraction of radioactivity from rat faecal homogenates for 
reverse isotope dilution determination of phenformin is described la ter.
(b) Adsorption chromatography
A glass column (40 x 2.5cm) was packed with a slurry of s ilica  gel 
(Kieselgel 60, 70-230mesh, E. Merck, Darmstadt, West Germany) in 
chloroform-methanol (10:1, by v o l.). The faecal extract was evaporated 
to dryness, taken up in 1ml chloroform-methanol (1:4, by vol.) and 
applied to the top of the column. The column was eluted successively 
with chloroform-methanol mixtures of the following composition by 
volume; 10:1 (100ml), 5:1 (60ml) and 1:1 (70ml). The final eluent was 
methanol (80ml).
The eluate was collected as fractions of approx. 5ml and aliquots
taken for sc intilla tion  counting. The fractions containing radioactivity 
were pooled and concentrated before examination by t . l . c .
Extraction of radioactivity from bile
(a) Solvent e x tra c tio n
Samples of bile (1 .0 -2 .0ml) from rats after intraduodenal 
14administration of [2‘ - CJphenformin (20mg/kg) were pooled, diluted 
with water (2ml) and adjusted to pH values of 1, 7 or 11. Each sample 
was extracted with 3 x 5ml volumes of chloroform-methanol (85:15, by vol.) 
and the radioactivity in each extract determined by scin tilla tion  counting.
The residues after solvent extraction were subjected to ion-exchange 
chromatography.
(b) Ion-exchange chromatography
Residues of bile after solvent extraction were applied to 10 x 1.3cm 
columns of Amberlite CG-50 and Amberlite CG-120 (H+ form) as described 
for urinary extraction by Murphy and Wick (1968).
Quantitative determination of metabolites
(a) A f te r  th in - la y e r  chromatography
Metabolites in rat and guinea-pig urine after oral and intraperitoneal 
administration of [2'-^C]phenformin were separated by t . l . c .  of whole 
urine on silica gel (solvent systems B, C and D) and alumina (solvent 
system G) and located by autoradiography. The radioactive zones were 
removed and the s ilica suspended in Cab-O-Sil sc in tillan t. The 
remaining areas of each run were divided into 1cm zones and treated in 
the same way. Radioactive metabolites were determined as a percentage
of the total activ ity  recovered from the plates which corresponded 
to the total activityliin the urine sample. Ion-exchange eluates of 
rat and guinea-pig urine after oral dosing and rat bile after 
intraduodenal dosing were examined in the same way.
Eluates from the adsorption chromatography of guinea-pig faecal 
extracts after oral administration of phenformin were examined by t . l .c .  
on s ilica gel in solvent systems E and F. The distribution of 
radioactivity was determined as described above.
(b) By reverse iso tope  d i lu t io n
Phenformin and 4-hydroxyphenformin were estimated as the pi crate 
salts by reverse isotope dilution.
Whole urine samples (5-10ml) were diluted with an equal volume 
of water and aliquots taken to determine the total radioactivity 
(0.25-0.4yCi). Phenformin hydrochloride or 4-hydroxyphenformin 
di hydrochloride (0 .4 -0 .5g) was added in aqueous solution (5-10ml) and 
a saturated solution of picric acid was slowly added with mixing, until 
no further yellow precipitate formed. The mixture was allowed to 
stand, with occasional mixing, for 30 min and tested with a further 
small amount of picric acid solution to ensure completion of the 
reaction. After filtra tio n  and drying, trip lica te  amounts (10-15mg) 
were dissolved in dimethylformamide (1ml), diluted with water (4ml) 
and aliquots (0.25ml) counted in sc in tillan t 4 as previously described.
The pi crate salts were recrystallised to constant specific 
radioactivity from water and dilute alcohol and a sample of the final 
product was submitted for elemental analysis.
For the determination of phenformin in rat faeces the biguanide 
(approx. 0.3g) was added to a suitable volume of faecal homogenate and 
freeze-dried. The powder was extracted three times with methanol (100ml), 
the solvent evaporated and the residue redissolved in water ( 20ml).
The solution was adjusted to pH 12 and extracted four times with 100ml 
portions of chloroform-methanol (85:15, by v o l.). The residue after 
evaporation of the solvents was dissolved in water (20ml) and converted 
to the picrate salt.
In the presence of a large excess of picric acid solution phenformin 
and 4-hydroxyphenformin formed dipicrate salts, the structures of which 
were assigned on the basis of elemental analyses for C, H and N.
Examples of the analytical data are given below.
phenformin dipicrate, m.p. (from water) 188-192°
C10H15N5 * 2 C6H3N3°7 (mol*wt* 663.24)
calc. C, 39.80; H, 3.19; N, 23.23;
obs. C, 39.83; H, 3.15; N, 23.24;
4-hydroxyphenformin dipicrate, m.p. (from water) 220-224° 
cinHiRNR° • 2 CfiHqN?°7 (mol.wt. 679.24) 
calc. C, 38.87; H, 3.12; N, 22.68;
obs. C, 38.76; H, 3.15; N, 22.56;
Isolation of metabolites for mass spectrometry
Metabolites in the eluates from the ion-exchange chromatography 
of rat and guinea-pig urine and adsorption chromatography of guinea-pig
faecal extracts were separated by repeated preparative-layer or paper
chromatography and located by autoradiography or strip-counting 
respectively. Final separation was achieved using t . l . c .  and the 
compounds were eluted from the s ilica  with methanol into washed melting 
point tubes. The methanol was evaporated under nitrogen and the tubes
sealed for use as sample probes for direct insertion mass spectrometry. 
In vitro metabolism studies
(a) Metabolism by is o la te d  eaeoal rrrlo ro flo ra
Rats and guinea-pigs were killed by cervical dislocation and
portions of the caecal contents removed rapidly and suspended in
approx. 10 volumes of O.IM-phosphate buffer, pH 7.4 by shaking. The
coarse debris was removed by centrifugation at very low speed for
15-20 sec and the supernatant separated and used to inoculate aliquots
of incubation medium which was prepared as follows. Glucose, yeast
extract and proteose peptone (each 0.5%, w/v) were dissolved in the
phosphate buffer and the solution boiled for 30 min and allowed to cool.
14Portions of the medium (10ml) and [21- C]phenformin hydrochloride 
(2-3mg) in buffer (0.5ml) were transferred to Thunberg tubes. Each 
tube was inoculated with 0.5ml of caecal supernatant (test samples) or 
buffer (control samples). The tubes were evacuated and f ille d  with 
nitrogen and incubated for 3 days at 37°.
After incubation portions (1ml) of medium from each tube were 
diluted with water (1ml), the pH adjusted to pH 2, 7 or 13 and the 
samples extracted with ethyl acetate (3 x 5ml) or chloroform-methanol 
(85:15, by vo l., 3 x 5ml). Extracts containing appreciable quantities 
of radioactivity were concentrated and examined by t . l . c .  on silica-gel 
in solvent systems B, C and E.
The amount of unchanged phenformin in control and test samples 
was determined as the picrate salt by reverse isotope dilution.
(b) Metabolism by is o la te d  hepatooytes
Suspensions of isolated rat and guinea-pig hepatocytes were prepared 
according to Fry et (1976). The cells were suspended in L15 
Leibovitz medium with glutamine (Gibco, Scotland) containing tryptose 
phosphate broth ( 10%, w/v) and foetal calf serum (10%, w/v) and the 
total yield of cells determined by counting in an improved Neubauer 
counting chamber. The v iab ility  of the cells was determined on the 
basis of the ab ility  of the cells to exclude trypan blue dye. The viable
c
cell concentration was adjusted to approximately 2 x 10 cells/m l.
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The choice of substrate concentration (1 x 10 M) was based upon
preliminary studies on the cytotoxicity of phenformin in rat and
-5 -3guinea-pig liv e r cells. These experiments using 5 x 10 - 2 x 10 M
-3phenformin showed that concentrations of the biguanide up to 1 x 10 M 
did not cause a significant decrease in viable cells after 90 min 
compared to control (phenformin-free) incubations. V iab ility  of cells 
was in the order of 80-85% from rat liver and 70-80% from guinea-pig 
liver.
14[2‘ - CjPhenformin hydrochloride (1.2mg, 0.3yCi, in 0.2ml Dulbecco's 
Ca++- and Mg++-free phosphate buffered saline) was incubated with the 
cell suspensions (5ml) in a conical flask in a shaking water bath at 
37°. Aliquots (0.1ml) of the incubates were taken at timed intervals 
and added to cold acetone (0 .02ml) to stop the reaction, centrifuged 
and portions of the supernatants (0.02-0.03ml) examined by t . l . c .  on 
silica and alumina in solvent systems C and E respectively. Radioactive 
zones were located by autoradiography and the radioactivity in each zone 
determined by scintillation counting in Cab-0-Sil.
2.2 RESULTS
Phenformin levels in blood
Determination of the radioactivity in whole blood after a single 
intravenous dose of [2 '- llfC]phenformin hydrochloride (10 mg/kg, 0.8-
1.0 yCi) to the rat and guinea-pig showed that phenformin was very 
rapidly removed from the circulation, fa lling to levels below the lim it 
of detection of the assay (approx. 0 .8  yg - equivalent/ml blood) within 
10 min. Measurement of the plasma concentrations of phenformin in a 
single guinea-pig after a 10 mg/kg intravenous dose of the non-radioactive 
drug using the g .l.c . assay developed by Sterling Winthrop Research 
Laboratories (Fawdon) showed that after an in it ia lly  rapid decline in 
the f ir s t  10 min, phenformin levels remained fa ir ly  constant over the 
next 30 min (see TABLE 2.1 and FIG. 2 .1 ). The fa ll in blood and plasma 
levels of the drug showed two phases, the second of which was linear on 
semilogarithmic coordinates; see FIG. 2.2(b). The in it ia l concentration 
(CQ) ,  elimination rate constant (Kg) , h a lf- life  ( t | )  and apparent volume 
of distribution (V^) for the linear portion of the graph are shown in 
FIG. 2.2(b).
After intraperitoneal administration of 15 mg/kg phenformin hydro­
chloride (1.2-1.5 yCi) to rats and guinea-pigs the blood concentration 
of radioactivity did not rise above the lim it of detection (0 .8  yg- 
equivalents/ml) during the course of the experiment (90 min).
Excretion of radioactivity
After oral administration of [2L l4C]phenformin hydrochloride to 
rats (100 mg/kg) and guinea-pigs (25 mg/kg) only 50-60% of the radio­
activity was excreted in the f ir s t  24h. Large amounts of radioactivity  
were found in the 48h urine and faeces in both species and small quantities 
in the excreta up to 96h in the rat and 144h in the guinea-pig (see 
TABLE 2.2 and FIGS. 2.3 and 2 .5 ).
TABLE 2.1 Blood concentrations of radioactivity or plasma 
phenformin concentrations after intravenous 
administration
radioactive assay^  ^
(yg-equivalents/ml blood)
g.l .c. assay^2)
(yg phenformin/ml plasma)
Time
(min) rat guinea-pig guinea-pig^
1.0 4.93 7.63 n.d.
1.5 4.04 4.80 3.00
2.0 3.49 4.00 n.d.
.2.5 2.88 2.36 n.d.
3.5 2.29 2.08 n.d.
5.0 1.78 1.70 1.63
7.5 1.05 1.10 n.d.
10.0 0.85 <0.80 0.81
15.0 <0.80 <0.80 0.79
30.0 <0.80 <0.80 0.73
45.0 <0.80 <0.80 0.69
(1 ) two individual experiments
(2 ) only one experiment
(3) n.d, = not determined
Phenformin hydrochloride (10 mg/kg) was administered;in 0.25 ml saline.
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FIG.2.2 Blood concentrations of radioactivity in the rat 
and guinea-pig and plasma phenformin levels in the 
guinea-pig after an intravenous dose (10 mg/kg)
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In the rat urinary excretion accounted for 55-57% and faecal 
excretion the remaining 40-42% of the radioactivity after doses of 
7 and 100 mg/kg, but the rate of elimination differed. After a dose 
of 7 mg/kg almost 90% of the dose was excreted in the f ir s t  24h while 
after 100 mg/kg only about 63% of the radioactivity was eliminated in 
this period, the difference being due to the more rapid faecal 
excretion at the lower dose (see FIG. 2 .4 ). At the higher dose the 
48h faeces contained as much radioactivity as the 24h faeces (15-16%) 
while at the lower dose almost a ll of the faecal excretion occurred in 
the f ir s t  24h; see TABLE 2.2a
In the guinea-pig after oral administration of phenformin 
hydrochloride (25 mg/kg) 37% of the dose was excreted in the urine and 
20% in the faeces in the f ir s t  24h. Excretion in the urine and faeces 
in the second day was 6% and 14% respectively, but at 96h only some 
80-90% of the dose was recovered which was significantly different from 
the recoveries achieved in the rat at 7 mg/kg and 100 mg/kg (p < 0.01 
in both cases). The liver taken from one guinea-pig 96h after a single 
oral dose of phenformin contained a small amount of radioactivity 
(approx, 0.3% of the dose).
After intraperitoneal administration of the drug to rat and guinea- 
pig 81-87% of the dose was recovered in 24h, most of which appeared in 
the urine (see TABLE 2.2 and FIGS. 2.3 and 2 .5). After 48h approximately 
95-97% of the administered radioactivity had been eliminated in the 
urine and faeces. Faecal excretion in the f ir s t  24h was significantly  
greater (p < 0.001) in the guinea-pig (13-18%) than in the rat (7-10%) 
but elimination in the 24-48h period was significantly greater CP < 0 . 001) 
in the rat (9.5-13.5%) than in the guinea-pig (4-7%). The presence of
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FIG,2.3 Cumulative excretion of radioactivity in urine 
and faeces following a single dose (100 mg/kg) 
of [2,- I 4C]phenformin orally or intraperitoneally 
to rats.
100
% of dose 
excreted
2 3 4
days following drug administration
Phenformin hydrochloride (100 mg/kg, 1.6-2.8yCi) 
administered in water (0.5 ml approx.). Results 
expressed as means of 5-7 experiments + S.E.M. 
represented by vertical bars. • ,  urine - oral dose; 
■ , faeces - oral dose;o, urine - intraperitoneal 
dose; □, faeces - intraperitoneal dose.
FIG.2.4 Cumulative excretion of radioactivity in urine and 
faeces following a single oral dose of 7 mg/kg or 
100 mg/kg [2 ' - ll+C]phenfomiin to rats.
100
% of dose 
excreted
2 3 4
days following drug administration
Phenformin hydrochloride, 7 mg/kg (0.5-0.6yCi) or 
lOQ mg/kg (1 .6 -2 .8yCi) administered in water (0.5 ml 
approx.). Results expressed as means of 4-7 experiments 
+ S.E.M. represented by vertical bars.
•  , urine - 100 mg/kg; y , urine - 7 mg/kg; 
o , faeces -100 mg/kg; v , faeces - 7 mg/kg.
FIG.2.5 Cumulative excretion of radioactivity in urine and 
faeces following a single oral (25 mg/kg) or intra- 
peritoneal (12.5 mg/kg) dose of [2 '-^CJphenformin 
to guinea-pigs.
100
% of dose 
excreted
42 3
days following drug administration
Phenformin hydrochloride administered orally ( 25 mg/kg, 1 .5-1 .8 Ci) 
or intraperitoneally (12.5 mg/kg, 1 .0 -1 .2yCi) in water (0.3-0.5 ml). 
Results expressed as means of 4-6 experiments +_ S.E.M. represented 
by vertical bars.
•  , urine - oral dose; ■ , faeces - oral dose;
o, urine - intraperi toneal dose*,D, faeces - intraperitoneal dose.
-100-
FIG.2.6 Cumulative excretion of radioactivity in the bile 
following a single intraduodenal administration 
(20 mg/kg) of [2 '-1I+C]phenformin to rats and 
guinea-pigs.
30 r-
% of dose 
excreted
25
20
15
10  -
I
¥
/
/1
. /
v O ‘
O"
.9^ o - o - o - o - o - • 0— 0—0
0" * - ± JL
1 2 3 4 5
time after administration (h)
Phenformin hydrochloride (20 mg/kg, 2.0-3.0yCi) administered 
intraduodenally in water (0.5 ml). Results expressed as means 
of 4 experiments + S.E.M. represented by vertical bars.
•  , rat (mean bile flow rate 1.2  ml/h); 
o , guinea-pig (mean bile flow rate 2.1 ml/h).
a substantial proportion of the dose in the faeces of both species after 
parenteral administration suggests that b ilia ry  excretion of radioactivity 
into the lumen of the gut or secretion from the plasma into the stomach 
or gut may occur.
The cumulative excretion of radioactivity in the b ile  after intra- 
duodenal administration of [2* - 1kC]phenformin (20 mg/kg) in the rat and 
guinea-pig is shown in FIG. 2.6. The rat excreted some 27% of the dose 
in 6h while the guinea-pig eliminated only 6% in the same period. The 
gradients of the respective rate curves imply that b ilia ry  excretion may 
play an important role in the elimination of radioactivity in the rat 
but that in the guinea-pig this route is of minor significance.
Experiments to determine the significance of enterohepatic 
recirculation of b ilia ry  radioactivity in the rat showed that when b ile  
from a [2‘ - llfC]phenformin dosed rat was directed continuously into the 
duodenum of a second rat, < 0 . 1% of the original dose was re-excreted 
in the b ile  in 7h. I f  a portion of radioactive b ile  was administered 
as a single intraduodenal injection to the rat no radioactivity ( < 1.5%) 
was detected in the bile  in 8h.
Metabolism of [2* - llfC]phenformin in vivo
(a) U rinary m etabo lites
Metabolites in rat and guinea-pig urine were identified by t 0l . c 0 
of whole urine in at least 3 different solvent systems and where possible 
by reverse isotope dilution and mass spectrometry. The compounds were 
estimated by scintillation counting of the radioactive areas after t . l . c .  
and where possible by reverse isotope dilution.
Whole urine from rat and guinea-pig after oral and intraperitoneal 
administration of [2'-^Cjphenformin contained a total of 5 different 
radioactive metabolites; see FIGS0 2„7 - 2.12. Metabolites 1 and 2 gave 
positive reactions with spray reagents 1 and 2 for biguanide and guanidine 
functions, and co-chromatographed with authentic phenformin and 4-hydroxy- 
phenformin respectively. Metabolite 3 gave a blue colour with the 
naphthoresorcinol spray reagent for glucuronides and hydrolysed on 
incubation with 3-glucuronidase to metabolite 2. The hydrolysis was 
inhibited by saccharic acid 1,4-lactone (25mM), see FIGS. 2.11 and 2.12, 
suggesting that metabolite 3 is the glucuronic acid conjugate of 4-hydroxy- 
phenforminc Confirmation of the presence of phenformin and 4-hydroxy- 
phenformin was obtained by reverse isotope dilution via formation of the 
dipicrate salts.
Mass spectrometric analysis of metabolites 1 and 2 isolated from 
urine by ion-exchange chromatography, solvent extraction and t . l . c .  
produced electron impact spectra which were comparable with those obtained 
from samples of authentic phenformin and 4-hydroxyphenformin respectively. 
Examples of positive ion fragmentation patterns obtained from samples of 
phenformin and 4-hydroxyphenformin isolated from urine are compared with 
spectra from samples of the authentic materials in FIGS. 2.13 - 2.16. A 
more detailed discussion of these spectra is presented in the APPENDIX.
Metabolites 4 and 5 were found in guinea-pig urine and have not been 
identified. Metabolite 5 gave a blue colour with the naphthoresorcinol 
spray reagent for glucuronide conjugates and hydrolysed on incubation 
with 3-glucuronidase to metabolite 4. The hydrolysis was inhibited by 
saccharic acid 1 ,4-lactone (25 mM) (see FIG. 2.9) indicating that metabolite
5 is probably the glucuronic acid conjugate of metabolite 4. Metabolite 
4 did not co-chromatograph with authentic 4-hydroxyphenformin on silica  
in solvent systems B, C, D and G or on paper in solvent system H but 
showed a slightly higher Rp value in each case; see FIGS. 2.19-2.21.
Attempts to determine the structure of this compound by mass spectro­
metry have proved unsuccessful but the spectra have demonstrated the 
absence of the positive ions characteristic of the phenolic function 
of 4-hydroxyphenformin and the absence of a triazine structure such as 
formed by phenformin and 4-hydroxyphenformin; see APPENDIX.
Solvent extraction of rat and guinea-pig urine was most effective  
at pH 11-12 using chloroform or chloroform-methanol (85:15, by vo l.) 
under which conditions some 30-45% of the radioactivity was removed.
This extract was shown by t . l .c .  to contain almost exclusively phenformin.
The more polar metabolites 2-5 could not be extracted from aqueous 
solution with organic solvents and were isolated from urine by ion-exchange 
chromatography. Ion-exchange chromatography of rat urine did not result 
in quantitative recovery of radioactivity unless phenformin was previously 
extracted from the urine. Ion-exchange chromatography of guinea-pig 
urine as described earlier separated metabolite 5 from phenformin (see 
FIG. 2.17) but the appearance of radioactive compounds not seen in whole 
urine suggests that elution with sodium hydroxide may have caused some 
breakdown of the metabolites; see FIG. 2.17A. These procedures proved 
useful for the isolation of metabolites for mass spectrometry.
Details of the urinary metabolic patterns of rat and guinea-pig 
are summarised in TABLE 2.3 and examples of the distribution of radioactivity  
after t . l . c .  of whole urine are shown in FIGS. 2.19 - 2.21.
Rat urine contained unchanged phenformin as well as 4-hydroxy-
phenformin and its  glucuronic acid conjugate but the relative contribution
of these 3 compounds varied with the dose level and route of administration 
Metabolites 4 and 5 were not detected in rat urine. After oral administration 
of 100 mg/kg almost one-quarter of the 24h urinary radioactivity (12.5% 
of the dose) was excreted as unchanged phenformin and the remaining 
radioactivity as 4-hydroxyphenformin and its glucuronide in a 1:3 ratio , 
see FIG, 2.19(a).
After the lower dose of 7 mg/kg orally metabolism of phenformin to
the phenol was more extensive, the parent compound accounting for an
average of only 5% of the 24h urinary radioactivity (2.5% of the dose);
see FIG. 2.20. Of the 4 rats studied two excreted no phenformin in the
urine while the others excreted only 6-13% of the unchanged drug; see 
FIGS. 2.11 and 2.12. The remaining radioactivity was attributable to 
4-hydroxyphenformin and its  glucuronide in a 1:8  ratio .
After intraperitoneal administration to rats of phenformin (100 mg/kg) 
almost one-half of the 24h urinary radioactivity (32.5% of the dose) was 
excreted as the parent compound, the remainder being eliminated as 4-hydroxy­
phenformin and its  glucuronic acid conjugate in a 1:2 ratio; see FIG.2 .19(b).
Following a 25 mg/kg oral dose to guinea-pigs an average of 50%
of the 24h urinary radioactivity (18.5% of the dose) was eliminated as 
phenformin. The remaining radioactivity was excreted as metabolite 4 
and its  glucuronide (metabolite 5) in approximately a 1:3 ratio; see 
FIG. 2.21(a). No significant amount of 4-hydroxyphenformin was detected 
before or after 3-glucuronidase hydrolysis; see FIG. 2.9.
After intraperitoneal administration (12.5 mg/kg) the guinea-pig
TA
BL
E 
2.3
 
M
et
ab
ol
ic
 
pa
tte
rn
 
in 
ra
t 
and
 
gu
in
ea
-p
ig
 
24h
 
ur
in
e 
af
te
r 
or
al
 
an
d 
in
tr
ap
er
ito
ne
al
ad
m
in
is
tra
tio
n 
of 
[2
'-
llf
C] 
ph
en
fo
rm
in
 
hy
dr
oc
hl
or
id
e
I— C- -Q ■ C c;: r>. cz co
O 3 fd CNJ r—
_n a 4-5 ~—'
cd 3 cu
4-5 p— • E
cu a t ---'
E  I
~a LO
cu - ---
•r* «d- XJ
4- «—* cz
•r- cu co > (0
4-5 4-5 r— 00
£ •r— o • 9 •
1 cu cu r— XJ XJ 1 •a 1• • XJ cu o • o CO • r^ - CU
to •r— S- XJ cz cz cz co 4-5
fd CZ 4- <d r— ^ ' •i—
3 I 4-5 r ---—■* CU O
CO E^ Si °
a) fd to
CO 4-5 -r-
cu cu to
s z E >>
+-> *—^ ■
' c co • ft o
a) c  S-.
S- C\J cu O XJ
fd cu 4-5 •*“  >>
Q- *o •r- '—' '---- '  ■- '—- 4-5 SZ
•r— r— o o r— o 3
£ CZ O co 00 • CNJ CU
•r— o -Q co CO XJ CO CO •r— tO
£ c. fd CO I i • CO I i— 1 xj fd
CU •r- 3 4-5 CZ XJ
cn E o CU o co 00 CO cu T-
cz 5- 3 E^ CNJ f— O. C
fd O r— o -—' o  o
s- 4- CO 4-5 i-
£= 1 O 3
CU ut oi— s : s—* •f- 3
>> Q. CNJ r—-
+j >> cu cn
•r* X cu p—- *---- ■— cn i
> o 4-5 r"- CNJ o '—- s- ca•r— c. •i— CnJ |-j- « CNJ LO cu
4-5 ■a cu i— XJ o . > s-
U >> cu o 00 1 o r • co i i cu cu
fd s z  c. XJ 1— t— cz r— Cm 4-5
O 1 4- fd 1— CO CNJ CO 4-
•I— I 4-5 ,— r— xj fd
-a CU •— J cz
cd E fd £
s- o
cn •<—
>> C 4-5
S- •i— fd
cd 4-5 s_
cz C +5
‘ r— 3  cz
C. o  cu
3 o  o
cz
SZ p—- o
«d- i—. o  u
CNJ •
cz CU '—. *■—. r—N —^- I— cu
4- •i— 4-5 o CO 00 CNJ 00 • cz
O E •r— oo r— LO LO LO 4-5 O
S_ r— o
p o I LO 1 O 1 LO I LO I >> >>4- sz CNJ LO <d- LO S i
CZ cz fd <d- O CNJ o p— cn
<d cu 4-5 «d- LO. xj fdcu sz cu CJ >-—5 cu
E O- E cz cz
•i— *r—
E
c~ cu
cu cn
4-5 fd
cu cu
'—' '—< XJ s-
r-— .. o
fd fd CZ >» £
cu CU •r— r -
CZ ' CZ E C
o o i-  o  cu4-5 4-> o  x:
•i— cn-r- 4- cn+->
a t cn 05 cn s- •NC S- £  £
zs -X zs ZxZ <u \  cu cu t-  cn
cu —^ \  Q_ cn O - x: 4-5 fd
CO cn^— cn'— cn—' cn fd E  <0 Q l.  £
o E r— E  r— E r- E S- C- >> 3 XJ
XJ fd <d fd 4-5 LO 4-5 X o  cu
o  S- r^ . s- LO s- o  cz • CZ O O £
o  o, o CNJ O O T-, CNJ •!-. ^  •rw
r -  <-> * r— r— •— J XJ • E
>> o s_
s z  • cu
( r -  4-5
«d" • cu
4-5 xj
XJ
C >> cu
(tJ XJ XJ
•r-*
f—% '—■ '—- £  XJ £
co, LO CO CO •1— cu o
s__> ----5 N—I E CZ c -
C- *r- 3
a t cn P  E O
'T— •r— 4— S- 3
Q. CL £  q  i—
CO 4- CO 1 1 cu 4-5 cn
CU Or— fd fd s z  cu
•r— fd cu cu CLTJ 3^.
U • E cz c
(U O -r 4-5 4-5 •f— 4-5 •f— 1 1
Q l  cz cz fd fd 3 fd 3
co— * fd C- C. cn s - cn r— CNJ
xj
+>oOJ
4-5
cu
x>
4-5
ocz
I UU"
FIG. 2.7 - oral dose
Urines incubated wi th:
A, 3-glucuronidase and
saccharolactone
B, 3-glucuronidase
Urines incubated wi th :
3-glucuronidase and
saccharolactone
3-glucuronidase
2.8 - intraperi toneal dose
T.l .c.-autoradiography of  whole ra t  24h urine a f te r  administra t ion 
o f  [ 2 1- 1^ C]phenformin (100 mg/kg).
- 1 0 7 -
FIG. 2.9 - oral dose (25 mg/kg)
Urines incubated with :
A, buffer
B, 3-glucuronidase and
saccharolactone
C9 3 -glucuronidase
dose (12.5mg/kg)
Urines incubated wi th :
A5 3 -glucuronidase and
saccharolactone
B, 3 -glucuronidase
T . l . c .  - autoradiography o f  whole guinea-pig 24h urine a f te r  
administrat ion of  [ 2 1- 1^C]phenformin.
FIG. 2.10 - in traperi toneal
-  I uo-
F IG .  2 .11
Urines incubated with:
A, buffer
B, 3 -glucuronidase and
saccharolactone
C9 3 -glucuronidase
FIG. 2.12
Urines incubated wi th:
A, buffer
B, 3 -glucuronidase and
saccharolactone
C, 3 -glucuronidase
T. l .c .-autoradiography of whole ra t  24h urine a f te r  oral 
administrat ion o f  [ 2 ' - l 4 C]phenformin (7 mg/kg).
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FIG. 2.19 Distribution of radioactivity after t . l . c .  of whole 24h
urine of rats following a single oral dose or intraperitoneal 
administration of [2 '- ll*C]phenformin (100 mg/kg)
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FIG. 2.20 Distribution of radioactivity after t . l . c .  of 
whole 24h urine of rats following a single oral 
administration of [2 '-^Clphenformin (7 mg/kg).
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gel in solvent system C.
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conjugate of 2 .
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FIG. 2.21
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Distribution of radioactivity after t . l . c .  of whole 
24h urine of guinea-pigs following a single oral or 
intraperitoneal administration of [2 '-11+C]phenformin
(a) oral administration (25 mg/kg)
4->OrtJO
•r—*o
fCJ
i-
fOc
•I—
S-
=3
4-O
oo -
40 -
20 -
i
0.2
—T
0.4
T—
0.6
Rp values
0.8 1.0
control 
uri ne
incubated urine incubated with 
3-glucuronide
100 i
+->ofOo
• r -~oms-
£?
rdc
•r“
i-Z3
60 -
40
20
(b) intraperitoneal administration (12.5 mg/kg)
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Results expressed as means of 2-3 experiments; t . l . c .  on 
silica gel in solvent system D.
1, phenformin; 2 . 4-hydroxyphenformin; 3, glucuronic acid conjugate 
of 2; 4, unidentified metabolite; 5, glucuronic acid conjugate of 4
eliminated some 55% of the urinary radioactivity (40% of the dose) 
as the parent compound. The urine also contained 4-hydroxyphenformin 
(4%), 4-hydroxyphenformin glucuronide (16%) and some 7% of a further 
compound, probably metabolite 4, and its glucuronide (15%); see FIGS.
2.10  and 2.21 (b).
(b) Faecal m etabo lites
Solvent extraction gave approximately quantitative recovery of 
radioactivity from the 24h faeces of guinea-pigs after an oral dose 
(25 mg/kg). Ion-exchange chromatography using Zerolit-225 cation 
resin as described for the extraction of urinary radioactivity was 
unsatisfactory for separation of the radioactivity in faecal extracts 
as >60% of the radioactivity was retained by the resin, even after 
elution with sodium hydroxide or hydrochloric acid. Column chromato­
graphy of the faecal extract on silica-gel eluted with chloroform- 
methanol mixtures gave > 96% recovery of the radioactivity and subsequent 
t . l .c .  of the radioactive fractions showed the presence of a single radio­
active compound (metabolite 6 ) which did not co-chromatograph with 
phenformin or 4-hydroxyphenformin, see FIG. 2.17D. This metabolite 
accounted for a total of approx. 75% of the 24h faecal radioactivity in 
the guinea-pig and showed similar t . l . c .  characteristics to metabolite 
4 on s ilica  in solvent systems B, E and F. Attempts to determine the 
structure of metabolite 6 by mass spectrometry proved unsuccessful but 
the spectra obtained demonstrated the absence of the positive ions 
characteristic of the phenolic function of 4-hydroxyphenformin and the 
absence of the triazine structure typical of the biguanide moiety and shown 
by phenformin and 4-hydroxyphenformin under these conditions, see APPENDIX.
Phenformin, determined by reverse isotope dilution, accounted for
-1 1 7 -
52 and 71% of the radioactivity in the 24h faeces of two rats dosed at 
100 mg/kg orally.
(c) B i l ia r y  m e tabo lites
Extraction of the 6h bile of 3 rats at pH 11 with chloroform- 
methanol (85:15, by vo l.) removed 59-72% of the radioactivity which 
was shown by t . l . c .  to be almost exclusively phenformin. The metabolites 
remaining in the aqueous phase were isolated by ion-exchange chromatography 
and the combined eluates examined by t . l .c .  in solvent systems C and D.
A typical t . l . c .  - autoradiograph of the b ilia ry  ion-exchange eluates alone 
(A) and co-chromatographed with an appropriate portion of the organic 
extract in order to represent the distribution of radioactivity in whole 
bile (B) is shown in FIG. 2.18.
The combined organic and ion-exchange extracts accounted for 96-98% 
of the b ilia ry  radioactivity and contained largely unchanged phenformin 
(75%), 4-hydroxyphenformin (13%) and 4-hydroxyphenformin glucuronide (8%). 
Small quantities (4-5%) of other radioactive compounds were also detected.
In vitro metabolism of [2 *-ltfC]phenformin
Ca) Metabolism by is o la te d  oaeoal m icro f lo r a
Phenformin was not appreciably metabolised by isolated caecal-microflora 
from rat or guinea-pig. Examination by t . l . c .  of organic extracts of the 
incubation medium after 3 days showed a single radioactive component which 
co-chromatographed with authentic phenformin and accounted for > 98% of the 
radioactivity. Reverse isotope dilution analysis for phenformin accounted 
for > 95% of the radioactivity.
(b) Metabolism by is o la te d  hepatocytes
Phenformin was partia lly  metabolised in vitro by hepatocytes from rat
and guinea-pig; see FIGS. 2.22 and 2.23. After incubation of 1 x 10~^ M 
[2' - llfC]phenformin hydrochloride (0.3pCi) for 90 min some 15% metabolism 
occurred in the guinea-pig cells and 20% in rat cells; see FIG. 2.24 (a).
In rat hepatocytes metabolism of phenformin produced 5 radioactive- 
metabolites in measurable quantities ( >0.5% of total radioactivity). 
Metabolite 2 corresponded chromatographically with 4-hydroxyphenformin 
and metabolite 3 to its glucuronic acid conjugate. The structures of 
metabolites 7, 8 and 9 have not been determined. After t . l . c ,  on s ilica  
gel in solvent system C the three unidentified compounds had higher Rp 
values than phenformin but on alumina in solvent system G they showed Rp 
values lower than the parent compound. This suggests that the metabolites 
may be less basic in nature than phenformin. Such a change may result 
from alteration in or loss of part of the biguanide moiety.
A qualitatively sim iliar metabolic pattern was produced by guinea-pig 
hepatocytes except that 4-hydroxyphenformin glucuronide was not detected 
( < 0.6%) at any of the time intervals studied; see FIG. 2.24(b),
Quantitatively there were a number of differences in the metabolic 
patterns produced by the liver cells of the two species; see FIG. 2.24. 
In it ia lly  metabolism was very rapid with metabolites 7-9 being detectable 
almost immediately on addition of the substrate, accounting for 8- 10% 
of the radioactivity at Omin ( i .e .  the time taken to add the substrate, 
mix, remove an aliquot of the incubation and stop the metabolism with 
acetone). T .l.c . of [ 2 - llfC]phenformin in phosphate buffered saline 
produced a single radioactive zone indicating that the appearance of 
other compounds at Omin was not due to the presence of other radioactive 
components in the substrate.
In both species the concentrations of metabolite 7 decreased 
rapidly; see FIG. 2.24(c) and (d). This decrease may be due to further 
metabolism or to a rapid removal of the metabolite from the medium 
through binding to the hepatocytes. The fact that the concentrations 
of metabolites 8 and 9 changed in such a way that the combined 
contributions of the three unidentified metabolites to the total radio­
activ ity  remained fa ir ly  constant (8-10% in the ra t, 11-13% in the 
guinea-pig) may be an indication that metabolite 7 was gradually converted 
to metabolites 8 and 9; see FIG. 2.24 (c) and (d).
The guinea-pig hepatocytes produced very l i t t l e  4-hydroxyphenformin 
(1 % at 90 min) and no significant amount of its glucuronide while in the 
rat these compounds accounted for 10% of the radioactivity by 90 min; 
see FIG. 2.24(b). The increase in the concentration of these two metabolites 
corresponded fia r ly  well with the decrease in phenformin levels in both 
species; see FIG. 2.24 (a) and (b).
The results suggest,therefore, that two discrete metabolic sequences 
may have occurred. In it ia lly  a very rapid formation of metabolite 7 was 
observed, followed by the more gradual appearance of metabolites 8 and 
9 which may have been formed from metabolite 7. 4-Hydroxyphenformin was 
produced more slowly and to a significant extent only in rat hepatocytes, 
and was probably formed from [2 '- lttC]phenformin rather than from 
metabolites 7, 8 and 9.
These la tte r three metabolites did not correspond chromatographically 
with any of the radioactive metabolites in urine and faeces of rat and 
guinea-pig after oral or intraperi toneal administration of [2, - lt*C]- 
phenformin.
- 1 2 0 -
FIG. 2.22 - r a t  hepatocytes
FIG. 2.23 - guinea-pig hepatocytes
T . l . c . -autoradiography o f  hepatocyte incubation medium various 
times a f te r  addit ion of [ 2 ' - l h C]phenformin (10~3M).
FIG. 2.24 Metabolism of [2 ' - 14C]phenformin by rat and 
guinea-pig hepatocytes.
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2.3 DISCUSSION
In both rat and guinea-pig the radioactivity was rapidly cleared 
from the blood during the f ir s t  10 min after intravenous administration 
of [21 - lifC]phenformin hydrochloride (10 mg/kg); see FIG. 2 .2 (a ).
Phenformin concentrations measured in guinea-pig plasma were very 
similar to those calculated from the radioactivity in whole blood (see 
TABLE 2.1) indicating that very l i t t l e  metabolism or plasma protein 
binding occurred in the f ir s t  10 min after systemic administration.
A semi logarithmic plot of the combined results for the guinea-pig showed 
that phenformin removal from blood occurred in two distinct phases; 
see FIG. 2.2(b). The second phase followed first-order kinetics.
An in it ia l rapid fa ll in plasma levels of the drug is typical of 
intravascularly administered foreign compounds (Goldstein et a l . ,  1968) 
but the rate of decrease appears to be particularly rapid with phenformin. 
After intravenous administration o f[lt+C]buformin (1.2 mg/kg) in man the 
serum concentrations of radioactivity showed an in it ia l disappearance with 
a h a lf-life  of some 75 min (Beckmann, 1968). In comparison the half- 
l i fe  of the f ir s t  phase in FIG. 2.2(b) is less than 2 min. Extrapolation 
of the linear portion. of the curve in FIG. 2.2(b) to the ordinate gave 
an in it ia l serum concentration for this portion (CQ) of 0.84 yg/ml and 
a h a lf-life  of 120 min. The rate of decrease was slow with an elimination 
rate constant (K ■) of approximately 0.6% per min. The apparent volume 
of distribution (Vd) was 11.9 1/kg indicating that with phenformin the 
parameter does not represent a real anatomical volume and that the drug 
was extensively localised outside the plasma. After intravenous admin­
istration o f[l 4C]buformin (1.2 mg/kg) in man the serum concentrations of 
radioactivity in the linear portion of the curve decreased at about half
-1 2 3 -
the rate shown for phenformin in FIG. 2.2(b), with a h a lf- life  of 230 min 
(K = 0.3% per min) and an in it ia l concentration of 0.42 yg/ml (Beckmann, 
1968). These figures give a value for Vd for buformin of 2.9 1/kg in man 
indicating that this biguanide is also concentrated extravascularly.
The f irs t  portion of the curve in FIG. 2.2(a) and (b) probably 
represents distribution of phenformin in the tissues. This is supported 
by the high value of obtained for the linear section of the graph.
Hal'l-et al_ (1968) have reported that large proportions of an intraperi toneal 
dose of [11+C-biguanide]phenformin to rats (100 mg/kg) and guinea-pigs 
(15 mg/kg) are associated with the live r (20-30%) and intestines (15-20%) 
for 3-4h after administration, and smaller amounts (2-7%) are detected in 
the stomach. This rapid tissue localisation of parenterally administered 
[14C]phenformin may explain why blood levels of radioactivity after in tra - 
peritoneal injection of [2 '- ltfC]phenformin (15-25 mg/kg) did not reach the 
lim it of detection (equivalent to 0.8 yg phenformin/ml blood). The high 
levels in the live r indicate that the drug is rapidly absorbed into the 
portal system and retained by hepatic tissue, presumably for gradual 
metabolism and release into bile and blood. According to Hall et al_. (1968) 
most of the radioactivity associated with rat liv e r and about 60% of that 
associated with guinea-pig liver is accounted for by metabolic products.
The presence of radioactivity in the stomach and intestines 30-60 min 
after parenteral administration (Wick et 1960; Hall et al_., 1968) 
suggests that the biguanide is secreted into the stomach and perhaps the 
gut. This process usually displays first-order kinetics (Goldstein et a l .,  
1968) and is favoured by the basic nature of the drug. Phenformin is a 
di-acidic base with a strongly basic primary dissociation constant (pKb = 
11.8) and a much weaker secondary dissociation constant (pKa = 2.7)
(Ray, 1961). The drug exists in the plasma and gut (effective pH 5.3; 
Schanker, 1971) almost exclusively in the protonated form as an internal, 
6-membered, hydrogen-bonded ring (Shapiro, 1959); see FIG. 2.25.
Although this structure is fa ir ly  polar i t  is readily absorbed through 
the various tissue membranes as the drug is effective after both oral and 
intravenous administration. In the stomach (pH 1.4; Cohn, 1971) phenformin 
exists largely as the di-protonated species which is probably less readily 
reabsorbed into the plasma. Assuming that membrane barriers are relatively  
impermeable to the di-protonated phenformin molecule the stomach juices 
may concentrate large amounts of the drug from the plasma, although the 
values in FIG. 2.25 represent a static equilibrium and should only be 
regarded as indications of the values existing under dynamic equilibrium 
conditions. Wick afh (1960) have shown that the radioactivity in rat 
stomachs 30-60 min after intraperitoneal administration of [2 '- 1kC]phenformin 
is chromatographically identifiable as the parent compound and is associated 
with the gastric juices rather than bound to the tissue. The gastric 
secretion of a number of parenterally administered basic foreign compounds 
such as aniline, aminopyrine and mecamylamine in the rat (Shore et al .,1957) 
and nicotine in rat and mouse (Andersson et a K , 1965) has been reported.
The rapid clearance of radioactivity from the circulation may also 
be due in part to renal excretion. The renal clearance of phenformin in 
man is 567 ml/min (Sterling Winthrop Research Laboratories, personal 
communication, 1977) which is considerably greater than the average 
glomerular f iltra tio n  rate of 120 ml/min (Harper, 1965) and indicates that 
the drug may be actively secreted in the kidney, probably in the proximal 
tubule (Cafruny, 1971). Buformin is actively secreted by the kidneys in 
normal (Beckmann, 1968) and diabetic (Lintz et aK , 1974) human volunteers. 
Active tubular secretion of ionised foreign compounds is extremely rapid
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Chasseaud, 1970) and this may contribute to the precipitous fa ll in 
blood concentrations of phenformin.
The slower rate of decline (K = 0.6%/min) in guinea-pig plasma levels 
of unchanged phenformin in the linear phase of FIG. 2.2(b) may correspond 
to the rate of metabolism of the drug and excretion of the metabolic 
products after distribution equilibrium has been established.
In the rat after oral administration of [2‘ - ll+C] phenformin the 
pattern of excretion and metabolism were different after low and high 
doses. After a 7 mg/kg dose about 88% of the dose was eliminated within 
24h, compared with 63% after 100 mg/kg. Excretion in the 24h-48h period 
was more significant after the high dose than after the low dose (see 
TABLE 2.2) and was predominantly in the faeces. These findings d iffe r  
considerably from those obtained by Wick £ t a]_. (I960), Beckmann (1967.
1968) and Murphy and Wick (1968); see TABLE 1.4. Faecal excretion of 
radioactivity was approximately equal (14-16% of the dose) in the f ir s t  
two 24h periods after a 100 mg/kg dose while after 7 mg/kg doses most of 
the faecal radioactivity appeared in the f irs t  24h. The presence of 
radioactivity in the faeces may not have been due entirely to unabsorbed 
[ 2 phenformin as only 50-70% of the faecal radioactivity was accounted 
for as unchanged drug. Rat caecal microflora did not metabolise [2 '- lttC] 
phenformin under conditions which result in the metabolism of a number of 
foreign compounds (Scheline, 1966) but i t  is s t i l l  possible that metabolism 
of the drug by the intestinal, wall could account for the presence of 
metabolites in the faeces. However, i f  the biguanide was not readily 
absorbed from the gut the proportion of radioactivity excreted in the 24h 
faeces would be greater after a 100 mg/kg dose than after a 7 mg/kg dose.
The equal proportion of the dose in the 24h and 48h faeces after administration 
of [V  - 14C]phenformin (100 mg/kg) may be an indication that the radioactivity
was being eliminated in the bile and that the process was saturated 
and was therefore rate lim iting.
Relatively l i t t l e  is known about the b iliary  excretion of bases 
but studies with some quaternary ammonium compounds have shown that 
these substances are excreted in the bile in large amounts. Such 
molecules usually contain one quaternary nitrogen (Smith, 1966; Hughes 
ja t^ K , 1973). The quaternary ammonium structure may be important in this 
respect as the b iliary  excretion of the tertiary analogue of benzo- 
methamine is negligible whilst quaternary benzomethamine its e lf  is 
extensively eliminated in the bile  by man, rat and rabbit (Levine and 
Clark, 1955). Certain organic cations appear to be excreted into the 
bile by active processes which are different from those for anions. 
Procaineamide ethobromide was rapidly secreted into the bile  of rats 
with bile to plasma concentration ratios of about 80, Ih a fter dosing 
(Schanker and Solomon, 1963). The transfer mechanism could be saturated 
by large doses of the drug and depressed by administration of other 
cations which were eliminated in the b ile , but was unaffected after  
administration of anions. After [2 1 - ltfC]phenformin administration 
intraduodenally (20 mg/kg) more than 27% of the dose in rats was excreted 
in the bile in 6h while in the guinea-pig only about 6% was excreted; 
see FIG. 2.6. In the rat the rate of b ilia ry  excretion was essentially 
constant and the mean concentration of radioactivity for the 6h period 
was equivalent to approximately 250 yg phenformin/ml b ile . This is very 
much greater than the expected blood concentration since intravenous 
administration of [2 phenformin (10 mg/kg) gave a blood level of 
radioactivity after the f ir s t  10 min equivalent to less than 1 yg phenformin/ 
ml; see FIG. 2.2(a). I t  seems lik e ly , therefore, that the rat actively 
eliminates phenformin and probably its  metabolites in the b ile . Pooled
0-6h rat bile contained mainly unchanged phenformin (75%) as well as 
its  metabolites 4-hydroxyphenformin (13%) and 4-hydroxyphenformin 
glucuronide (8%) all of which contain a quaternary nitrogen moiety at 
physiological pH. The glucuronide conjugate probably exists as the 
zwitterion (1) as the pK values of the acid portion of most glucuronides 
are in the range 3-4 and are therefore ionised at physiological pH (Smith 
and Williams, 1966). The other two biguanides probably exist as the 
hydrogen bonded structures [2) described earlie r. These three compounds 
may be actively secreted by the mechanism described by Schanker and 
Solomon (1963) for hepatic transport of cations in the ra t. All three 
compounds have molecular weights greater than the threshold value (200 
+ 50) for appreciable b ilia ry  excretion of monoquaternary organic cations 
in rat and guinea-pig (Hughes et al_., 1973). The pattern of b ilia ry
0 )
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elimination of cations appears to be in contrast to the excretion of 
organic anions which shows a species dependent b iliary  threshold 
for molecular weights, being about 325 +50 in rat and 400 +50  in guinea- 
pig (Abou-el-Makarem et a K , 1967b; Millburn et aQ_., 1967; Hirom et a l .,
1972). The existence of an active transport mechanism for b ilia ry  
elimination of phenformin and its  metabolites could explain the linear 
rate of b iliary  excretion of radioactivity in the rat over the 6h period 
studied.
Although a significant portion of the b ilia ry  radioactivity in rats 
was undoubtedly reabsorbed in the gut (otherwise 100% of a 20 mg/kg dose 
would have been excreted in the faeces) no enterohepatic circulation was 
demonstrated. In view of the large proportion of the dose excreted in the 
48h faeces after oral and intraperi toneal administration of [2 '- llfC] phenformin 
(100 mg/kg), i t  is more like ly  that the failure to demonstrate recycling 
was due to the limitations of the techniques employed. Absorption of basic 
biliary  radioactive components may have been impaired in animals anaesthetised 
with pentobarbitone. Phenobarbitone has been shown to stimulate b ile  acid 
synthesis and b ile -sa lt secretion (Redinger and Small, 1973) and i f  such 
an effect was produced by sodium pentobarbitone the absorption of basic 
drugs might be hindered. Lack of food in the gut, such as would result 
from the'inhibition of gastrie-emptying by anaesthesia also increases the 
flow of bile salts into the intestines. Even though the membrane boundary 
between the blood and bile is extremely porous (Parke, 1968) i t  is doubtful 
that the intestinal epithelium would be permeable to the polar metabolites 
of phenformin and only the parent compound is like ly  to be reabsorbed from 
the gut.
In addition to enterohepatic circulation the secretion of phenformin 
from the plasma into the stomach could contribute to the delayed excretion
of the drug. As the biguanide passes from the stomach to the. intestines 
i t  may be reabsorbed into the plasma and re-excreted either into the 
stomach or in the b ile .
The reason for the profound species difference in the b ilia ry  
excretion of phenformin is not known. Hughes £ t al_. (1973) found no 
significant difference in the excretion of a range of monoquaternary 
ammonium cations in the bile of rat and guinea-pig; a ll were extensively 
excreted provided the molecular weights exceeded 200 + 50. The rate of 
biliary  excretion of radioactivity in the guinea-pig was not constant. 
In it ia lly  the rate of excretion was high, with some 4% of the dose being 
excreted in the f ir s t  hour. During this time the mean concentration of 
radioactivity was equivalent to some 150 yg phenformin/ml b ile . After 
the f ir s t  hour the rate of elimination fe ll such that only about 2% of 
the dose was excreted in the next 5h; see FIG. 2.6. During this period 
the mean concentration of radioactivity was equivalent to less than 2 0 yg 
phenformin/ml b ile . A possible explanation for this variable rate of 
excretion may lie  with the particular sensitivity of the guinea-pig to the 
pharmacological actions of phenformin (see CHAPTER 3). I t  may be that at 
this dose of the drug mitochondrial respiration in guinea-pig live r was 
depressed sufficiently to lower the availab ility  of ATP (see SECTION,1.4) 
and impair the active b ilia ry  excretion of phenformirt and its metabolites.
In view of the low degree of b iliary  elimination of radioactivity in 
the guinea-pig i t  is d iff ic u lt  to explain how a large proportion of the 
dose was excreted in the faeces after 24h (20% of the dose) and 48h (14% 
of the dose); see TABLE 2.2. About 75% of the 24h faecal radioactivity  
(15% of the dose) was due to an unidentified compound (metabolite 6 ) which 
was probably more polar than phenformin (see FIG. 2.17 D) and as [2 '- lltC] 
phenformin was not metabolised on incubation with guinea-pig caecal micro-
flora under conditions which metabolise a variety of foreign compounds 
(Scheline, 1966) i t  would seem that, unless the intestinal epithelium 
is capable of extensively metabolising the drug, unabsorbed [2 1- 1^C]- 
phenformin does not contribute significantly to the presence of radio­
activ ity  in guinea-pig faeces. This suggests that most of the radio­
activ ity  was derived from b ilia ry  excretion and/or gastric secretion.
As the metabolic pattern in guinea-pig bile was not determined i t  is not 
possible to say whether the faecal metabolite originated in the bile or 
stomach juices, but in view of the well-established s tab ility  of the 
biguanides in acid solution (Shapiro, 1959; Wick et a K , 1960; Cohen 
and Costerousse, 1961; Beckmann, 1966, 1967) the metabolite is more 
like ly  to be of hepatic origin. The discrepancy between the rate of 
b iliary  excretion of radioactivity and its  appearance in the faeces may 
only be apparent. I t  has already been suggested that active b ilia ry  
secretion of phenformin and/or its metabolites in the guinea-pig may have 
been impaired by the drug. The depletion of ATP levels by phenformin is 
related to its hypoglycaemic and hyperlactataemic actions(see SECTION 1 .4 ), 
both of which are temporary effects (see CHAPTER 3). I f  the pharmaco­
logical effects diminished at some time after the 6h period of bile  
collection, the active elimination of phenformin and/or its  metabolites 
may have resumed and resulted in higher faecal levels of radioactivity.
A difference in the urinary ratio of phenformin to metabolic 
products occurred in the rat after different oral doses of [ 2 '- lltC]- 
phenformin; see FIGS. 2.19(a) and 2.20 and TABLE 2.3. After oral 
administration of 7 mg/kg an average of only 5% of the urinary radio­
activity (2.5% of the dose) was excreted in the urine as unchanged 
phenformin, the remainder being accounted for as 4-hydroxyphenformin and 
its glucuronic acid conjugate. In some rats receiving this low dose no
parent compound was found in the urine; see FIG. 2.12. After a high 
dose (100 mg/kg) almost a quarter of the radioactivity in the urine 
(12% of the dose)was unchanged phenformin. These findings are in 
contrast to earlier reports which have found that after 50 mg/kg 
[3H]phenformin (Beckmann, 1967, 1968) or 100 mg/kg [2 '- ltfC]phenformin 
(Murphy and Wick, 1968) only 4-hydroxyphenformin and its glucuronide 
were present in rat urine.
The liver is probably the major site of metabolism of phenformin 
in the rat (Hall et jil_., 1968) and Wick £ t al_. (1970) have shown that 
rat liver cytochrome P-450 is involved in the aromatic hydroxylation 
of the drug. The intestinal wall may also contribute to the metabolism 
of the biguanide, particularly in view of the high concentrations which 
arise after oral and intraperitoneal dosing.
Drugs given orally or intraperitoneally (assuming no lymphatic 
absorption) gain access to the peripheral venous circulation almost 
exclusively by way of the hepatic portal system (Gibaidi and Perrier,1975). 
Extensive metabolism and elimination of a drug may occur in the intestinal 
wall and liver during the f irs t  passage of the compound into the circulation 
this is generally referred to as the 'first-pass e ffe c t'. First-pass 
extraction and metabolism of foreign compounds can occur in the liv e r, 
as with lidocaine (Boyes et al_., 1970; Gugler £ t al_., 1975) or in the 
intestinal wall, as with isoproteronol (Dolley et al_., 1971). Both 
tissues have been implicated in the metabolism of acetyl salicylic acid 
(Harris and Riegelman, 1969). Grundin £ t al_. (1974) have suggested that 
hepatic cytochrome P-450 may be, at least partly, responsible for the 
marked first-pass extraction and metabolism of alprenolol in rats.
The presence of unmetabolised phenformin in rat urine after a large
oral dose of [2 ' - 14CJphenformin (100 mg/kg) may reflect the limited 
capacity of the first-pass extraction process in gut and/or ]ive r. The 
extraction of propranolol was shown to be saturable (Evans and Shand,
1973). This explanation is supported by the results obtained after  
intraperitoneal administration of [21- I 4C]phenformin (100 mg/kg); see 
TABLES 2.2 and 2.3. Although a greater percentage of the administered 
radioactivity was eliminated in the 24h urine after the parentera] dose 
than after a similar oral dose, the increase was accounted for as 
unchanged drug rather than as metabolic products; see FIG. 2.26. This 
could be the result of a more rapid absorption of the drug into the 
portal blood supply following intraperitoneal injection and saturation 
of the hepatic extraction capacity for the drug with the result that a 
higher proportion of the dose is eliminated unchanged by the kidneys.
Significant first-pass metabolism reduces the fraction of the dose 
ultimately excreted in the urine as unchanged drug (Gibaldi and Perrier, 
1975) and reduces the availab ility  of the compound in the-peripheral 
tissues. In cases where metabolism results in loss of biological 
activity first-pass elimination may significantly reduce the pharmacological 
effectiveness of a drug. Saturation of the extraction process may lead to 
dose-dependent disposition kinetics of drugs (Grundin £ t al_., 1974). The 
implications of this effect in relation to the hyperlactataemic and hypo- 
glycaemic actions of phenformin and 4-hydroxyphenformin are discussed in 
CHAPTER 3.
Active biliary excretion may be an important route of elimination 
of phenformin in the rat but i f  this process is saturated after 
administration of large enteral or parenteral doses of the biguanides, 
renal excretion of the parent compound could be increased. Urinary and
FIG. 2 .26 Excretion of phenformin and its  metabolites in 24h 
rat urine after oral and intraperitoneal administration 
of £2 1 - ltfCJphenformin [100 mg/kg)
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b ilia ry  pathways of excretion may be complementary to each other in 
the elimination of a number of anionic foreign organic compounds and 
when one of these routes is blocked the other may be increased (Hirom 
et aK , 1976). This interrelationship between the two excretory mechanisms 
may also occur for cations such as phenformin and in circumstances where 
one of the routes is saturated rather than blocked. The relatively  slower 
rate [on a % dose basis) of metabolism and elimination in the ra t of high 
doses of phenformin may have important implications in the pharmacological 
behaviour of the drug (see also CHAPTER 3).
In the guinea-pig excretion of a 25 mg/kg oral dose of [ 2 '-1ItC]-
phenformin was incomplete even after 6 days; see TABLE 2.2. The 96h 
cumulative excretion in this species (86% of the dose) was significantly 
lower (p < 0.01) than in rats after 7 or 100 mg/kg doses. In one guinea- 
pig studied for 144h after dosing the total recovery of radioactivity was 
only 92%. The presence of significant amounts of the dose in the faeces 
at 144h suggests that extensive recycling of radioactivity occurred in 
the guinea-pigs despite the apparently low degree of b ilia ry  excretion.
This possibility has been discussed earlier.
Guinea-pig urine 24h after oral administration of [2*- ltfC]phenformin 
(25 mg/kg) contained about 37% of the dose, half of which was identified  
as unchanged phenformin. 4-Hydroxyphenformin and its  glucuronic acid 
conjugate were not detected. The metabolite 4 which, along with its  
glucuronide (metabolite 5) accounted for the remaining radioactivity in 
the 24h urine was not identified. Mass spectrometric analysis indicated 
that the metabolite was not a phenolic compound. The hydrolysis of 
metabolite 5 by 3-glucuronidase was inhibited by saccharic acid 1,4-lactone 
and the conjugate was stable to acid and a lk a li, indicating that i t  was 
an 0-glucosidiironic acid rather than an N-glucosiduronic acid conjugate 
(Fishman, 1961). The aglycone (metabolite 4 ), therefore, may have been 
hydroxylated on the aliphatic side chain, either a- or 3- to N1 of the 
biguanide moiety. The absence of evidence for the s-triazine grouping in 
the mass spectrum suggests that the biguanide portion of the molecule may 
be incomplete or structurally altered. Beckmann (1967) has reported that 
the guinea-pig excreted only traces of metabolic products, which were 
identified as 4-hydroxyphenformin and its  glucuronide conjugate, and that 
the urine contained almost exclusively unchanged phenformin after oral 
administration of [3H]phenformin (50 mg/kg). This finding was based on the 
result from a single animal and identification relied solely on comparison
of Rp values. In addition the dose used was greater than the oral 
LD50 for phenformin in the guinea-pig (38 mg/kg; Ungar et a]_., 1957; 
see TABLE 1.2). Small amounts of 4-hydroxyphenformin, free and 
conjugated with glucuronic acid, were present in guinea-pig urine 
after intraperitoneal administration of [21- 14C]phenformin (12.5 mg/kg); 
see TABLE 2.3.
The hepatocytes from rat and guinea-pig also produced different
_3
metabolic patterns after incubation with [2‘ - 14C]phenformin (10 M).
Both species rapidly formed three unidentified compounds (metabolites 
7, 8 and 9) which were not present in urine after in vivo administration. 
Some 7-9% of the substrate was converted to metabolite 7 within the 
short space of time required to stop the reaction. This time varies 
with liver cells from different species according to their f ra g ility ,  
but is probably in the order of 2 minutes (Jones, 1978). Rat hepatocytes 
produced 4-hydroxyphenformin, free and conjugated with glucuronic acid 
(10% in 90 min) while guinea-pig hepatocytes produced only a trace amount 
of the phenol ( 1% in 90 min) and no detectable conjugate; see FIGS. 2.23 
and 2.24.
Differences in the metabolic fate of phenformin in the rat and 
guinea-pig are not totally unexpected. Although aromatic hydroxylation 
occurs in most species, there are "considerable species variations in 
the extent to which i t  occurs in a given compound and also in the extent 
to which i t  occurs with different compounds in the same species" (Williams, 
1971). This is illustrated by the metabolism in different species of 
amphetamine, a molecule with some structural sim ilarities to phenformin. 
Aromatic hydroxylation is the major route of metabolism in rats but a 
minor one in guinea-pigs, rabbits and in man. Deamination and subsequent 
oxidation giving benzoic acid and its conjugates is the major route in
guinea-pigs and a significant route in rabbits and in man, but not in 
rats. Rabbit urine also contains acetophenone as the sulphate conjugate 
of the enol form of the molecule and some 1-phenylpropan-2-ol (Dring 
et al_, 1966, 1970); see FIG. 2.27. Similarly, after administration of 
methamphetamine (N-methylamphetamine) the rat excretes mainly products 
of aromatic hydroxylation while the guinea-pig excretes large amounts 
of benzoic acid and its conjugates, but no products of aromatic 
hydroxylation (Caldwell et a [ .,  1972a).
FIG. 2.27 Metabolism of amphetamine (Dring et al_., 1966, 1970)
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Phenethylamine derivatives are hydroxylated on the methylene group 
adjacent to the aromatic ring as an important stage in the anabolism of
biologically active amines, such as the transformation of dopamine to 
noradrenaline. Some exogenous substrates also undergo 3-hydroxylation 
to a limited extent. Dopamine-3—hydroxylase is believed to catalyse 
hydroxylation of both endogenous and exogenous substrates (Testa and 
Jenner, 1976). An example of 3-hydroxylation has also been reported 
with the anticonvulsant drug N-2-[5-(m-chlorophenyl )T ,2,4-oxadiazol-3-yl]- 
ethyl-N-methylacetamide (3) which contains an N-substituted ethylamino 
side chain adjacent to a heterocyclic ring. In man the secondary 
alcohol (4) is one of the major metabolites (Allen et al_„, 1971). As 
the molecular structure of (3) differs greatly from that of the endogenous 
phenethylamines i t  is doubtful whether this drug acts as a substrate for 
dopamine-3-hydroxylase (Testa and Jenner, 1976).
C0CH3
:0CH
Amphetamine in man and rat (Dring £ t £ h ,  1970; Caldwell et a l ., 
1972b) and methamphetamine in man, rat and guinea-pig (Caldwell e t a l . ,  
1972a) are partly metabolised by 3-hydroxylation. In man the products 
in each case are norephedrine (5) and 4-hydroxynorephedrine (6 ) which 
total only some 2-4% of the dose. In rats the major product from 
methamphetamine (16% of a 45 mg/kg oral dose) is 4 -hydroxynorephedrine 
while the guinea-pig excretes only norephedrine. In the guinea-pig the 
3-hydroxylation reaction appears to be dose dependent with norephedrine 
accounting for 1% of a 10 mg/kg dose and 19% of a 45 mg/kg dose of
methamphetamine (Caldwell et aj_.s 1972a).
( 5 )
OH
HO
CH-CH-NH
2
(6 )
Deamination of a number of phenethylamine derivatives occurs 
readily in various species and proceeds via cleavage of the C-N bond.
Thus mescaline (3,4,5-trimethoxyphenethylamine) is metabolised in 
rat and man to give both benzoic acid and phenylethanol derivatives 
(Schreiber, 1970). In a comparative study of the aromatic oxidation 
and deamination of a series of amphetamine-related compounds in 
several species, i t  was shown that the rat demonstrated marked aromatic 
oxidation while the guinea-pig displayed effic ient deamination (Williams 
et al_., 1973).
In the main the guanidine and biguanide groupings appear relatively  
inert to most metabolic processes. No metabolic changes in the biguanide 
moiety of phenformin, buformin or metformin have been reported previously, 
although on heating with alkali phenformin is rapidly degraded to give 
phenethylguanidine, phenethylurea and phenethylamine (Shapiro, 1959).
The guanidine grouping of Guanethidine (7) is unchanged in man while 
N-oxidation of the alicyclic nitrogen occurs to a significant extent 
(McMartin and Simpson, 1971) and the diuretic amiloride hydrochloride (8 ) 
and carcino-chemotherapeutic agent methylglyoxal-bis-guanylhydrazone (9) 
are not biotransformed to a significant extent in several species
- 1 4 0 -
(Chasseaud, 1970). In contrast the guanidino-group of Guanoxan (JO)
W
N-CH2CH2NH-C-NH2 (7 )
Cl
h2n
r
(/ , f
>NH-C-NH,
(8 )
CH.
C=N-I
NH
II
l-C-NH
CH=N-NH-C-NH,
ii ‘
NH
(9 )
undergoes transamidination in dogs in the presence of ornithine and 
glycine to give arginine and guanidino-acetic acid (Cafias-Rodriguez, 
1966).
•ch2nh-c-nh2
CIO)
ornithine
glycine
C O
CH2NH2
NH jJH
+ CH2-NH-£-NH2 + CH«-NH-C-NH,
Cch2)2
CHNHo
co2h
co2h
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CHAPTER 3
STUDIES ON PHENFORMIN-ASSOCIATED LACTIC ACIDOSIS
3 •1 materials and methods
Chemicals
Lithium lactate, lactate dehydrogenase, NAD+ and thiamine 
pyrophosphate were obtained from Sigma (London) Chemical Co. Ltd. 
Guaiacum, peroxidase and glucose oxidase (Fermcozyme 653AM) reagents 
were purchased from Hughes and Hughes (Enzymes) Ltd., Romford, Essex. 
Dichloroacetic acid (reagent grade) was supplied by Fisons, Loughborough, 
Leics. and was converted to the sodium salt by neutralizing the aqueous 
solution with sodium hydroxide and freeze-drying at 30°C. The solid 
was pulverised and stored in a dark glass bottle until used. Phenformin 
hydrochloride, 4-hydroxyphenformin dihydrochloride and chlorpropamide 
were kindly donated by Sterling Winthrop Research Laboratories, Fawdon, 
Newcastle-upon-Tyne. Sodium pentobarbitone anaesthetic solution was 
obtained from Abbot Laboratories, Queenborough, Kent (Nembutal) or 
May and Baker Ltd., Dagenham, Essex (Sagattal). Urethane anaesthetic 
solution was prepared as described in CHAPTER 2 from the reagent grade 
material obtained from British Drug Houses Ltd., Poole, Dorset. All 
other chemicals were purchased from common laboratory suppliers and, 
unless otherwise specified, were of reagent grade.
Materials
Cannula tubing was supplied by Portex Ltd., Hythe, Kent. Neutral 
glass collection tubes (2ml capacity) were obtained from Glass Wholesale 
Supplies Ltd., London and 1ml capacity auto-analyser cups prefilled  
with fluoride-oxalate with concave base (F07/C) from Stayne Laboratories 
Ltd., Marlow, Bucks. Butterfly infusion catheters (short-25 pediatric 
infusion set, 0.5mm ext. diameter, length 9.6mm; 25-G thin wall siliconed
needle] were supplied by Abbot Laboratories, Queenborough, Kent.
Collection of blood
Male Wistar albino rats (200g-300g) and Dunkin-Hartley albino 
guinea-pigs (280g-400g) were anaesthetised as described in CHAPTER 2.
Rat blood samples were collected at Q.5h intervals from the ta il 
vein which was exposed by removing the tip  of the ta il using a scalpel.
The end of the ta il was cleaned to prevent surface contamination of 
the blood and the f ir s t  sample discarded as tissue damage and venous 
stasis may cause an elevation of blood lactate levels. Clotting of the 
ta il vein between collection periods was encouraged by wrapping the 
exposed tip  of the ta il in cotton wool.
Guinea-pig blood samples were collected by cardiac puncture at 
l.Oh intervals, using heparinised syringes and needles.
All blood samples were transferred to fluoride-oxalate treated 
autoanalyser cups containing heparin, mixed and appropriate aliquots 
dispensed for assay of lactic acid and glucose.
Determination of lactate
Lactate concentrations were determined by the method of Hdhorst 
(see Henry £ t aK , 1974) modified for small blood volumes.
Perchloric acid (7%, w/v , 0 . 2ml) was transferred to a neutral glass 
2ml test tube and blood or standard (0 .2ml) added and mixed thoroughly. 
After standing for 5-10 min the tube was centrifuged and 0.1ml supernatant 
dispensed into a similar 2ml tube containing 1ml buffer (0.4M-hydrazine 
sulphate and 0.5M-glycine adjusted to pH 9.0 with 5N-NaOH), 0.1ml NAD+ 
solution (20mg/ml in water] and 0.02 ml lactate dehydrogenase (400U/ml).
Reagent blanks containing 0.1ml 3.5% (W/v) perchloric acid and lactic
-3acid standards (10 and 20mg/100ml 2.5 x 10 M sulphuric acid) were 
prepared. Blood samples which were expected to have a value greater 
than 35 mg/100ml were diluted with water before assay.
The tubes were incubated for lh at 25° and the absorbance measured 
at 340nm in 1ml quartz cuvettes (1cm light path).
Determination of glucose
Blood glucose concentrations were determined by the glucose oxidase 
method of Marks et aK (1968) using 0.1 volumes of heparinised blood.
This method permits determination of glucose over the range 0-200mg/100ml 
blood.
Analysis of data
Significant differences between the blood lactate or glucose 
concentrations in the different groups were determined using a modified 
form of Student's t-te s t for small samples (Bailey, 1959). Where 
variances in the populations were shown by a variance-ratio test to be 
statis tica lly  unequal, a second modified form of t-tes t was used 
(Bailey, 1959).
3.2 RESULTS
(a) Studies in the non-fasted rat
P re lim ina ry  s tud ies  w ith  phenformin
Anaesthetised rats were given phenformin hydrochloride intraperitoneally 
and the lactate and glucose levels in the blood measured at 0.5h intervals 
up to 4 or 5h. The maximum effect upon blood lactate and glucose 
concentrations occurred at approx. 2.5h after administration (see FIG. 3.1).
FIG. 3.1 Blood lactate and glucose concentrations in 
the rat following a single intraperitoneal 
administration of phenformin.
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Points represent the means of 3-9 experiments + S.E.M. 
represented by vertical bars. Phenformin hydrochloride 
administered in saline (0.5 ml)
v , 75 mg/kg; □ , 120 mg/kg; o , saline alone.
After a single dose of phenformin (75mg/kg) lactate levels were increased 
from a resting level of 12mg/100ml (1.3mM) to 17mg/100ml (1.9mM) at 2.5h 
and glucose levels were decreased from some lOOmg/lOOml (5.6mM) to 
70mg/100ml (3.9mM). After a single dose of 120mg phenformin/kg blood 
lactate concentrations reached 24mg/100ml (2.7mM) at 2.5h while glucose 
levels fe ll to 65mg/100ml (3.6mM). Thus while the hyperlactataemic 
responses were significantly different at the two dose levels (p<0.001 
from 1 .Oh) the hypoglycaemic effects were indistinguishable (p>0.1 at 
a l1 time intervals).
Dose-response s tud ies  w ith  phenforrrdn
The dependence of the hyperlactataemic and hypoglycaemic responses 
on the dose of phenformin in the rat was determined in groups of 3 
animals given 50, 75, 90, 105, 120, 135 or 150mg/kg intraperitoneally.
The experiment was performed over a period of 3 days and the doses 
were randomised for each day. Saline injected control animals were 
examined at the beginning and end of each day to allow for any changes 
in the resting levels of lactate and glucose.
Blood samples were taken immediately before and 2.5h after dosing 
and the lactate and glucose concentrations determined. A larger sample 
of blood (-2.0-3.0ml) was removed from each animal by cardiac puncture 
and the plasma sample analysed for phenformin by g .l.c . at Sterling 
Winthrop Research Laboratories, Fawdon.
The mean percentage change in lactate and glucose concentrations 
for each dose and the corresponding mean plasma phenformin level are 
shown in FIG. 3.2. The values obtained were subjected to computer 
analysis in order to calculate the nature of the best curve-fit.
FIG. 3.2 The effect of increasing dose of phenformin on blood
lactate and glucose and plasma phenformin levels in the 
rat at 2.5h.
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Points represent the means of 3 experiments +_ S.E.M. represented by 
vertical bars; blood lactate and glucose concentrations expressed as 
mean % change from individual resting levels. Phenformin hydrochloride 
administered intraperitoneally in saline (0.5 ml).
The blood concentration of lactic acid in the rat did not increase 
dramatically with doses of 50-105mg/kg. Lactate levels after a 50mg/kg 
dose of phenformin were not significantly different from those in the 
control animals, but after doses of 75, 90 and 105mg/kg small but 
significant increases of up to 40% were measured (p<0.05-p<0.001 compared 
to controls). At doses of 120-150mg/kg much greater rises in lactate 
concentrations occurred, ranging from 100% at 120mg/kg to 225% at 
150mg/kg.
The hypoglycaemic response followed a similar pattern although i t  
should be noted that a dose of 50mg/kg produced a 20% decrease in 
blood glucose levels without producing hyperlactataemia. Glucose 
concentrations after doses of 75-120mg/kg showed a fa ir ly  uniform 
reduction to 65-70%, while 135 and 150mg/kg produced a sharp fa ll to 
only some 40% of resting levels.
These findings suggest that the hyperlactataemic and hypoglycaemic 
responses in the rat to increasing doses of phenformin may exhibit a 
biphasic nature with a c ritica l dose level in the region of 120-135mg/kg.
The e ffe c ts  o f  d ich lo ra ce ta te
The effects' of dichloracetate on the hyperlactataemic and hypoglycaemic 
actions of phenformin in the rat were studied. Rats were anaesthetised 
throughout the experiment and the right femoral vein was catheterised 
using a butterfly infusion catheter. Sodium dichloroacetate (50mg/ml 
i s o to n ic  saline, pH7.4) was administered intravenously as boluses at 
10 min intervals (equivalent to 300mg/kg/h) commencing Ih before 
administration of phenformin (12Qmg/kg) or saline (control animals).
Blood lactate and glucose concentrations were determined immediately
before commencing the infusion of dichloroacetate, immediately before 
administration of the challenging dose of phenformin or saline and at 
0.5h intervals for the following 4h.
Dichloroacetate infusion produced a significant (p<0.001) 40% 
reduction in the blood lactate concentrations to 5.6mg/100ml (0.6mM) 
after Ih; see FIG. 3.3. Subsequent administration of phenformin (120mg/kg) 
resulted in an increase in lactate levels of almost 30% in 2h, but the 
concentration did not exceed the normal resting levels. In the absence 
of dichloroacetate the same dose of phenformin produced a 100% increase 
over normal resting concentrations.
Dichloroacetate had a slight but significant effect on resting blood 
glucose concentrations in the non-fasted rat; see FIG. 3.3. In the 
dichloroacetate treated, saline injected animals throughout the 5h 
period of the experiment the mean blood glucose (90mg/100ml, 5.0mM) was 
significantly lower (p<0.001) than that of rats studied for 4h after 
administration of saline alone (103mg/100ml, 5.7mM).
Administration of phenformin (120mg/kg) to dichloroacetate infused 
rats resulted in a severe hyopglycaemia reaching a maximum effect at 2h 
at which time blood glucose levels were reduced to 30% of normal levels 
(27mg/100ml, 1.5mM). In phenformin treated animals not receiving 
dichloroacetate blood glucose levels were reduced to 65-70% of resting 
levels at 2h; see FIG. 3.3. The blood glucose concentrations in rats 
receiving phenformin and dichloroacetate were significantly lower 
(p<0.01-p<0.001) than those in rats given; phenformin alone from 0.5h 
after dosing.
FIG. 3.3 Blood lactate and glucose concentrations in the rat 
following a single intraperitoneal administration of 
phenformin alone or in conjunction with an intravenous 
infusion of dichloroacetate
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Points represent the means of 3-6 experiments + S.E.M. represented 
by vertical bars. Phenformin hydrochloride (170 mg/kg) administered 
in saline (0.5 ml); sodium dichloroaicetate (300 mg/Rg/h) in-saline, 
pH 7.4 infused intravenously (1.2-1.4 ml/h) starting Ih before 
administration of phenformin or saline. □, phenformin alone;
■> phenformin and dichloroacetate; o , saline alone; • ,  saline and 
dichloroacetate.
The e ffe c ts  o f  thiam ine and th iam ine pyrophosphate
The effects of thiamine hydrochloride and thiamine pyrophosphate 
chloride on phenformin-associated hyperlactataemia and of thiamine 
hydrochloride on phenformin-associated hyopglycaemia were investigated. 
The right femoral veins of anaesthetised rats were cannulated with 
polypropylene cannula tubing (PP10 cannula, Portex Ltd.) or butterfly  
infusion catheters. Equimolar doses of thiamine hydrochloride 
(1.8-2.0mg/ml saline, pH 7.4) or thiamine pyrophosphate chloride 
(2.0-3.0mg/ml saline, pH 7.4)were administered intravenously as regular 
boluses at lOmin intervals (equivalent to 7mg/kg/h and lOmg/kg/h 
respectively) commencing Ih before administration of phenformin.
Thiamine hydrochloride had no significant effect on phenformin- 
induced changes in blood lactate or glucose concentrations; see FIG. 3.4
Administration of thiamine pyrophosphate in conjunction with 
phenformin produced small but s ta tis tica lly  significant changes in the 
blood lactate profile compared to that in animals receiving only 
phenformin; see FIG. 3.4. Peak lactate concentrations were slightly  
higher in animals given both compounds (p<0.001) and declined at a 
faster rate so that the 4h concentrations in animals receiving dual 
therapy (14mg/100ml, 1.53mM) were significantly lower (p<0.001) than 
those of rats receiving phenformin alone (18mg/100ml, 2.0mM).
Adjuvant e ffe c ts  o f  phenformin and chlorpropamide
The effects on the blood concentrations of lactic acid and glucose 
of chlorpropamide (150mg/kg) administration alone and in conjunction 
with phenformin (75mg/kg) were investigated.
FIG. 3.4 Blood lactate and glucose concentrations in the rat 
following a single intraperitoneal administration of 
phenformin alone and in conjunction with an intravenous 
infusion of thiamine or thiamine pyrophosphate.
blood 
1actate 
(mg/100 ml)
30
25
20
15
10
5
0
* 3 -
\
blood 
glucose 
(mg/100 ml)
— i — 'H -
- 1 0  1 2  3 4
time after phenformin administration (h)
Points represent the means of 3-8 experiments + S.E.M. represented by 
vertical bars. Phenformin hydrochloride (120 mg/kg) administered in 
saline (0.5 ml); thiamine hydrochloride (7 mg/kg/h) and thiamine pyro­
phosphate chloride (10 mg/kg/h) in saline, pH 7.4, infused intravenously 
(1.0-1.2 ml/h) starting lh before administration of phenformin.□ ,phenformin 
alone; o, saline alone; ▼, thiamine and phenformin; v, thiamine pyro­
phosphate and phenformin.
Chlorpropamide was administered intraperitoneally as a suspension 
in corn-oil (0 .4 -0 .5ml) to two groups of rats and was immediately 
followed by an injection of phenformin (75mg/kg) in saline or saline 
alone. Two other groups of rats received either phenformin alone or 
saline only (controls). Blood lactate and glucose concentrations were 
determined at 0.5h intervals for 4h.
Blood lactate concentrations in rats given chlorpropamide alone 
were significantly lower (p<0.05-P<0.001) than those of control animals 
within 0.5h of administration, decreasing from a resting level of 
llmg/lOOml (1.2mM) to 7.5mg/100ml (0.83mM) at 4h*, see FIG. 3.5. The 
blood lactate profiles in rats receiving chlorpropamide and phenformin 
together and rats given phenformin alone were very similar except the 
hyperlactataemic response appeared to be prolonged in animals on dual 
therapy (see FIG. 3.5) giving rise to significant differences between 
the two groups at 3h-4h (p<0.05).
Chlorpropamide, alone and in conjunction with phenformin, produced 
a marked hypoglycaemia with blood glucose levels fa lling  by some 
60-70% to 30-40mg/100ml (1.7-2.2mM) in 2.5-3h, but the responses of 
the two groups were indistinguishable. Phenformin alone caused a 
reduction of 30-35% in blood glucose concentrations in the same period; 
see FIG. 3.5.
The e ffe c ts  o f  4-hydroxyphenformin
After a single intraperitoneal administration of 4-hydroxyphenformin 
dihydrochloride in saline (150mg/kg or 183mg/kg, the molar equivalent 
of 120mg/kg and 150mg/kg phenformin hydrochloride respectively) blood 
concentrations of lactic acid were unchanged; see FIG. 3.6. Molar 
equivalent doses of phenformin produced 100-225% increases in blood
-1 5 4 -
FIG. 3.5 Blood lactate and glucose concentrations in the 
rat following intraperitoneal administration of 
phenformin alone or in conjunction with chlorpropamide
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Points represent the means of 3-6 experiments ± S.E.M. represented 
by vertical bars. Phenformin hydrochloride (75 mg/kg) administered 
in saline (0.5 ml), chlorpropamide (150 mg/kg) in corn-oil (0.5 ml) 
□ , phenformin alone; ■, phenformin and chlorpropamide1; v, chlor­
propamide alone; o, saline alone.
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FIG. 3.6 Blood lactate and glucose concentrations in the
rat following a single intraperitoneal administration 
of 4-hydroxyphenformin.
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Points represent the means of 4-8 experiments ± S.E.M. represented by 
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lac tic  acid in 2.5h; see FIGS. 3.1 and 3.2.
After a higher dose of 4-hydroxyphenformin (305mg/kg equivalent to 
250mg/kg phenformin) to 5 rats, a ll of the animals died within 1.0-1.5h 
but the cause of death was unknown.
No significant changes in blood glucose concentrations were observed 
in rats given a single dose of 183mg/kg 4-hydroxyphenformin. The 
equivalent dose of phenformin (150mg/kg) produced a 55-60% reduction in 
blood glucose levels in 2.5h; see FIG. 3.2.
(b) Studies in the non-fasted guinea-pig
The e ffe c ts  o f  phenformin
Anaesthetised guinea-pigs were given phenformin hydrochloride 
(12.5mg/kg) intraperitoneally and the lactate and glucose levels in the 
blood measured at Ih intervals for 5h.
Blood lactate concentrations increased very rapidly after phenformin 
administration. After lh lactate concentrations (25mg/100ml, 2.7mM) 
were double the resting levels (12mg/100ml, 1.3mM) and by 5h had reached 
132mg/100ml (14.6mM); see FIG. 3.7.
Blood glucose concentrations increased by 200% from a resting level 
of some 128mg/l00ml (7.1mM) to 392mg/100ml (21.8mM) in 2h. The 
hyperglycaemia decreased rapidly and the animals showed an 80% hypoglycaemia 
at 5h with blood glucose levels of 26mg/100ml (1.4mM); see FIG. 3.7.
The e ffe c ts  o f  4-hydroxyphenformin
Administration of 4-hydroxyphenformin dihydrochloride (15.2mg/kg, 
the molar equivalent of 12.5mg/kg phenformin hydrochloride) caused a
FIG. 3 .7 Blood lactate and glucose concentrations in the 
non-fa£ted guinea-pig following a single intraperitoneal 
administration of phenformin.
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FIG. 3.8 &lood lactate and glucose concentrations in the
non-fasted guinea-pig following a single in tra­
peri toneal administration of 4-hydroxyphenformin.
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140% increase in blood lactic acid levels in 4h (30mg/100ml, 3.!3mM) 
compared to control animals (12mg/100ml, 1.3 mM); see FIG. 3.8.
No significant effects on blood glucose concentrations were seen 
over the 4h period studied; see FIG. 3.8.
(c) Studies in the fasted guinea-pig
The e ffe c ts  o f  phenformin
Guinea-pigs were deprived of food for 24h before use but were 
allowed free access to water. Phenformin hydrochloride (12.5mg/kg) 
was administered intraperitoneally and the blood concentrations of lactic  
acid and glucose determined at lh intervals for 4h.
Blood lactate levels increased rapidly after administration of 
phenformin from a resting level of 9mg/100ml (l.OmM) to 58mg/100ml 
(6.5mM) at 4h; see FIG. 3.9.
The increase in lactic acid levels in the 24h-fasted guinea-pig 
was less marked than in the non-fasted guinea-pig; see FIGS. 3.7 and 
3.9. Lactate levels were significantly different (p<0.01-p<0.001) 
between the two groups from lh.
Phenformin administration in the fasted guinea-pig was accompanied 
by a fa ll in blood glucose concentration from 140mg/100ml (7.8mM) to 
56mg/100ml (3.1mM) at 4h; see FIG. 3.9. This response with no 
hyperglycaemic phase was very different from that observed in the non-fasted 
guinea-pig; see FIG. 3.7. Blood glucose concentrations at 4h in the 
fasted guinea-pig (56mg/l00ml, 3.1mM) were marginally lower (p<0.05) than 
in the non-fasted animal (92mg/100ml, 5.1mM).
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Glucose concentrations in the fasted control animals rose significantly  
during the 4h period of the experiments from some 137mg/l00ml (7.6mM) to 
170mg/100ml (9.4mM); see FIG. 3.9. No significant changes in blood 
glucose levels in non-fasted guinea-pigs were observed; see FIG. 3.8.
The e ffe c ts  o f  d ich lo roace ta te  and phenformin
The effects of an intraperitoneal infusion of sodium dichloroacetate 
on blood lactate and glucose concentrations in the 24h-fasted guinea-pig 
after a single intraperitoneal administration of phenformin (12.5mg/kg) 
were determined.
Sodium dichloroacetate was administered in saline at pH 7.4 
(180-200mg/ml) at a rate of 300mg/kg/h. The solution was infused through 
an in-dwelling intraperitoneal catheter (PP50 cannula tubing, Portex Ltd.) 
which was inserted through a 0.5cm mid-line incision in the abdominal 
wall and fixed with sutures.
Phenformin hydrochloride (12.5mg/kg) was administered in 0.5ml 
saline as a single intraperitoneal injection after lh of infusion with 
dichloroacetate.
In the fasted control guinea-pig dichloroacetate administration had no 
effect on lactate levels compared to untreated control animals; see
FIG. 3.9. Glucose levels, however, were considerably reduced
in animals receiving dichloroacetate (pre-infusion levels 130mg/100ml,
7.3mM, compared with 98mg/100ml, 5.5mM, after 5h infusion) while in
untreated starved control animals the blood glucose concentrations
increased from a resting level of 137mg/100ml (7.6mM) to a 4h level of
170mg/100ml (9.4mM). Comparison of the means at each time interval showed
significant differences from 2h (p<0.05-p<0.002); see FIGS. 3.9 and 3.10.
Dichloroacetate infusion partia lly  prevented the hyperlactataemia 
produced by phenformin (see FIG. 3.9) giving a 4h lactate concentration 
of 38mg/100ml (4.2mM) compared to 58mg/100ml (6.5mM) in animals receiving 
phenformin alone. Differences between the two phenformin-treated groups 
were significant at 2, 3 and 4h (p<0.05-p<0.001).
The hypoglycaemic action of phenformin was considerably enhanced 
after infusion with dichloroacetate. Blood glucose concentrations fe ll 
to 23mg/100ml (1.3mM) at 4h compared with 56mg/100ml (3.1mM) in animals 
receiving only phenformin (<$ 0.05 at 3h and 4h); see FIG. 3.9.
The e ffe c ts  o f  4-hydroxyphenformin
Administration of 4-hydroxyphenformin (15.2mg/kg, the molar 
equivalent of 12.5mg/kg phenformin) produced a significant increase in 
lactate concentrations to 20mg/100ml (2.2mM) at 4h compared to controls 
(llmg/lOOml, 1.2mM; p<0.005); see FIG. 3.10. The increase in lactic  
acid levels in fasted guinea-pigs was significantly lower than in 
non-fasted guinea-pigs (p<0.05 at 3h and 4h); see also FIG. 3.8.
Blood glucose levels in the fasted guinea-pig after administration 
of 4-hydroxyphenforrnin were not s ta tis tica lly  different from those of 
control animals; see FIG. 3.10.
The e ffe c ts  o f  d ich lo roa ce ta te  and 4-hydroxyphenformin
The effects of an intraperitoneal infusion of sodium dichloroacetate 
(300mg/kg/h) on blood lactate and glucose concentrations after 
intraperitoneal administration of 4-hydroxyphenformin (15.2mg/kg) were 
studied. Sodium dichloroacetate was infused as previously described 
and after lh infusion the biguanide was administered in saline (0.5ml approx.).
FIG.3.10 Blood lactate and glucose concentrations in the 24h 
fasted guinea-pig following a single intraperitoneal 
administration of 4-hydroxyphenformin alone or in 
conjunction with an intraperitoneal infusion of 
dichloroacetate
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Points represent the means of 3 experiments + S.E.M. represented by 
vertical bars. 4-Hydroxyphenformin dihydrochloride (15.2 mg/kg) 
administered in saline (0.5 ml); sodium dichloroacetate (300 mg/kg/h) 
in saline, pH 7.4, infused intraperitoneally (0.5-0.6 ml/h) starting 
lh before administration of 4-hydroxyphenformin or saline.
□, 4-hydroxyphenformin alone; ■, 4-hydroxyphenformin and dichloro­
acetate; o , saline alone; • ,  saline and dichloroacetate.
Dichloroacetate completely abolished the hyperlactataemic response 
associated with 4-hydroxyphenformin; see FIG. 3.10. Blood lactate 
levels in guinea-pigs receiving both drugs were not s ta tis tica lly  
different from levels in untreated controls or dichloroacetate treated 
controls.
Administration o f dichloroacetate in conjunction with 4-hydroxyphenformin 
failed to e l ic i t  a hypoglycaemic response. Blood glucose levels appeared 
to decrease at a slightly slower rate than in animals receiving 
dichloroacetate alone (see FIG. 3.10) but the differences are of 
doubtful significance, with 0.05<p<0.10 at 4h.
3.3 DISCUSSION
Because of the d ifficu lties  involved in developing a suitable 
diabetic animal model with which to examine phenformin-associated lactic  
acidosis the present studies were performed using non-diabetic normal 
and fasted animals. The effects of the two commonly used diabetogenic 
agents, alloxan and streptozotocin, result from their cytotoxic actions 
on the pancreatic 3-cells, causing rapid and essentially irreversible  
necrosis (Lukens, 1948; Heilman and Diderholm, 1955; Scherer, 1955;
M iller and Wurster, 1956; Rakieten et al_.s 1963; Brosky and Logothetopoulos, 
1969; Dulin and Wyse, 1969). Treatment with these compounds produces 
insulin deficiency and in severe cases ketoacidosis. As the biguanides 
are not generally recommended for the treatment of insulin-deficient 
diabetic patients, because of the inab ility  of the drugs to suppress 
lipolysis leading to ketosis, the experimentally-induced diabetic animal 
is not wholly representative of the clinical situation. In addition there 
have been several reports of extrapancreatic damage with both of these 
diabetogenic agents which cast doubts on their value in studying biguanide- 
associated lactic  acidosis. In view of the involvement of renal and 
hepatic dysfunction in the aetiology of phenformin-associated lac tic  
acidosis (see SECTION 1.5) the finding that alloxan and streptozotocin 
may cause a number of renal and hepatic lesions in animals and man (Lukens, 
1948; Burwell and Paley, 1955; Scherer, 1955; Webb, 1966; Livingston and 
Carter, 1969; Vargas et al_., 1970; Hohenegger and Rudas, 1971) means that 
careful characterisation of experimentally-induced diabetes in animals is 
essential in pharmacological studies with the biguanides.
In the normal, fed rat the hyperlactataemic and hypoglycaemic effects 
of phenformin were dose related; see FIGS. 3.1 and 3.2. The maximum effect 
on lactate and glucose concentrations occurred at around 2.5h and would
probably have returned to normal after about 6h. The dose-effect
relationships in FIG.3.2 suggest the existence of a c ritica l dose of
phenformin in the normal rat of 120-135 mg/kg at which point lactate
concentrations rise sharply to 200-320% of the normal level and glucose
concentrations fa ll to only 40% of resting levels. The plasma phenformin
level after doses of 120-135 mg/kg was 2-3vg/ml (1.0-1.5 x 10~^M) which
is considerably lower than the concentrations of drug used in most
in v itro  experiments demonstrating glycogen depletion and respiratory 
- 3 - 4inhibition (10 —10 M; Steiner and Williams, 1958), inhibition of
-3enzymes in the c itr ic  acid cycle (2 x 10 M; Wicket al_.9 1958; Kruger
jst.al_.9 1960) and inhibition of oxidative phosphorylation and hepatic
gluconeogenesis (4 x 10”4M; Altschuld and Kruger, 1968). There is ,
however, some dispute as to the concentration of phenformin required to
produce some of these inhibitory effects. Thus while SOIing (1969) has
reported that no evidence of reduced oxidative phosphorylation is seen
-5in rat livers perfused in vitro with biguanides at 2.5 x 10 M, Woods
-5and Alberti (1973) showed that 10 M phenformin causes a 45% inhibition  
of gluconeogenesis in rat liv e r.
I t  remains possible, therefore, that the rapid onset of hyperlactataemia 
and hypoglycaenria as seen in FIG. 3.2 indicates the point at which inhibition  
of oxidative phosphorylation and gluconeogenesis become evident. The 
possible mechanisms by which phenformin exhibits its  hypoglycaemic action 
are discussed in detail in SECTION 1.4. I t  has been reported that at low 
doses (e.g. in therapeutic use) phenformin causes an increased rate of 
anaerobic and oxidative metabolism of glucose and gluconeogenesis may be 
slightly enhanced, possibly as a compensatory mechanism for the increased 
production of lactate (Searle and Cavalieri, 1968; Losert et al_., 1971).
The increase in lactate oxidation may be insufficient to counter the
enhanced production via anaerobic metabolism (Searle and Siperstein, 1975) 
causing blood levels to rise . In the non-diabetic subject only slight 
changes in blood lactate and glucose occur because increased gluconeogenesis 
acts as a regulatory mechanism. Diabetic subjects are probably unable to 
make such a metabolic adjustment as gluconeogenesis is already increased 
or even maximal in diabetes (Forbath and Hetenyi, 1956; Hermann, 1973;
Ray, 1976).
With higher doses of phenformin the inhibition of oxidative phos­
phorylation, such as that seen in in vitro experiments, becomes a distinct 
possibility. Such an effect would prevent the recycling of lactate and 
other gluconeogenic substrates to glucose and produce hypoglycaemia and 
hyperlactataemia in normal and diabetic subjects. A decrease in lactate 
uptake by the live r may cause a drop in hepatic in tracellu lar pH (Lloyd 
£ t  al_., 1973) which in turn could further inh ib it gluconeogenesis due to 
the pH-dependent activation of pyruvate carboxylase by acetyl-CoA (see 
SECTION 1 .5 ). Such a series of events could produce a self-perpetuating 
cycle which might explain the rapid-onset of lactic acidosis once the 
process has started. The data in FIG.3.2 support the current view that 
lactic  acidosis only occurs in the presence of abnormally high plasma 
levels of phenformin (Cohen and Woods, 1976; Alberti and Nattrass, 1977). 
This situation may occur in cases of frank overdose as Represented in 
these animal studies with high doses of biguanide,or in cases of hepatic 
or renal insufficiency where metabolism and excretion of phenformin are
impaired. Karam et a/L (1974) have reported a plasma concentration of 
-51 x 10 M phenformin in a patient with lactic acidosis resulting from 
suicidal self-poisoning and Heuclin et al_. (1975) have demonstrated that 
phenformin accumulation and reduced gluconeogenesis from lactate occurs
in rats with experimentally-induced renal fa ilu re .
Experiments in rats treated with microsomal hydroxylase inhibitors 
have suggested that metabolism of phenformin reduces its pharmacological 
activ ity  (Holloway and A lberti, 1976; Alberti and Holloway, 1977). The 
major metabolite of phenformin in the rat is 4-hydroxyphenformin which, 
together v/ith its  glucuronic acid conjugate, accounts for more than half 
the radioactivity eliminated in the 24h urine (35-40% of the dose) after 
a 100 mg/kg intraperitoneal dose of [2'-^C]phenformin (see CHAPTER 2). 
4-Hydroxyphenformin had no significant effect on blood lactate or glucose 
concentrations in the normal rat (see FIG. 3.6) when administered at doses 
of 150 or 183 mg/kg (the molar equivalents of 120 and 150 mg/kg phenformin 
respectively). The molecule was not without biological activ ity  as a 
higher dose (305 mg/kg, equivalent on a molar basis to 250 mg/kg phenformin) 
was lethal to a ll of 5 rats studied. Beckmann (1967) reported that oral 
administration of 4-hydroxyphenformin (200-400 mg/kg) does not produce 
hypoglycaemia in the mouse and Heuclin jet al_.(1975) found no change in 
blood lactate levels in rats with surgically-induced renal insufficiency 
after administration of 4-hydroxyphenformin (unspecified dose) for 8 days.
In contrast Wick et £l_.(1970) have reported that the 4-hydroxy metabolite 
possesses half the hypoglycaemic activity of phenformin in the ra t, but 
no details of this study were given.
I t  therefore appears that the rat can effectively inactivate phenformin 
by aromatic oxidation and subsequent conjugation of the phenol to a 
varying extent (see CHAPTER 2). After high doses of the biguanide to rats 
the a b ility  of the liv e r to extract and/or metabolise phenformin may be 
saturated and a higher proportion of the dose may be excreted unchanged 
in the urine (see TABLE 2 .3 ). The existence of a first-pass elimination 
process for phenformin in the rat has been discussed in more detail in
SECTION 2.3. The saturation of such a system may lead to dose-dependent 
disposition kinetics (Grundin et al_., 1974) and could explain the relatively  
constant increase in plasma phenformin concentrations with each dose 
increment above 50 mg/kg; see FIG. 3.2. Thus a 50 mg/kg jntraperitoneal 
dose may result in portal blood concentrations which approximate to the 
maximum that can be effectively extracted by the live r and higher doses 
lead to the appearance of the drug in the peripheral circulation and the 
onset of the conditions leading to lactic  acidosis.
Sodium dichloroacetate infusion in the normal rat reduced blood 
lactate levels by almost 50% in Ih . Although subsequent injection of 
phenformin caused a slight elevation, lactate concentrations did not 
exceed those in untreated control rats (see FIG. 3.3) indicating that 
dichloroacetate can effectively prevent the occurrence of phenformin- 
associated lactic  acidosis. Similar findings have been reported in the 
fasted rat treated with SKF525A to prevent the hepatic inactivation of 
phenformin (Holloway and A lberti, 1976)and in streptozotocin-induced 
diabetic rats treated for 28 days with phenformin and dichloroacetate 
(Man and A lberti, 1976). Dichloroacetate can also reverse established 
phenformin-associated lactic  acidosis in the starved rat (Alberti and 
Holloway, 1977).
The slight but significant (p < 0.001) reduction in blood glucose 
levels in dichloroacetate-infused rats is in contrast to a number of 
earlier reports that the compound only lowers blood glucose concentrations 
in diabetic and fasted non-diabetic animals (Lorini and Ciman, 1961; 
Stacpoole and Felts, 1970; Eichner, 1974). In those studies where no 
reduction in blood glucose levels was found, dichloroacetate was
administered orally or intraperitoneally, while in the present studies 
the compound was given intravenously. As the hypoglycaemic effect of 
dichloroacetate is due at least partly to a reduction in the peripheral 
release of gluconeogenic precursors (Blackshear e_t al_., 1974, 1975; 
Stacpoole £ t  al_., 1976) the fa ll in blood glucose levels in rats after  
systemic administration of dichloroacetate may be the the result of an 
enhanced peripheral effect of the compound due to the higher blood 
concentrations and increased tissue distribution which occur after  
intravenous injection.
Administration of phenformin to dichloroacetate-infused rats caused 
a 70% fa ll  in blood glucose levels in 2h to 27 mg/100 ml (1.5 mM) 
compared with 65 mg/100 mi (3.6 mM) after phenformin alone. Hollov/ay 
and Alberti (1976) have reported that simultaneous infusion of phenformin 
and dichloroacetate in SKF525A-treated, starved rats produces a slightly  
greater hypoglycaemic effect than phenformin alone.
The mechanism of action of dichloroacetate has been discussed in 
SECTION 1.5. The compound is believed to activate hepatic and extra- 
hepatic pyruvate dehydrogenase and to decrease the release of gluconeo­
genic precursors from peripheral tissues (Stacpoole et a l .,  1970, 1976; 
Blackshear et aT_., 1974, 1975; Whitehouse et al_., 1974). Dichloroacetate 
probably prevents hyperlactataemia by decreasing the flow of gluconeogenic 
substrates to the live r rather than by directly counteracting the hepatic 
action of high doses of phenformin on gluconeogenesis as Stacpoole (1977) 
has shown that dichloroacetate significantly reduces the rate of glucose 
formation from a range of substrates in isolated parenchymal cells obtained 
from the livers of fasted rats. The fa ll in lactate levels in control 
infused animals may be due to the enhanced activ ity  of pyruvate
dehydrogenase. This is reflected by the observation that after 
treatment with phenformin and dichloroacetate the ketone body concentration 
in rat liv e r is increased (Man and Alberti, 1976; Alberti and Holloway, 
1977) probably due to an increased production of acetyl-CoA and an 
inhibition of c itr ic  acid cycle activity caused by dichloroacetate and 
phenformin respectively. The enhanced glycolytic activ ity  and reduced 
gluconeogenesis which results from the inhibition of oxidative phosphor­
ylation and the activation o f pyruvate dehydrogenase may also account for 
the increased hypoglycaemic effect observed after combined therapy.
The hyperlactataemic and hypoglycaemic responses to phenformin in 
the guinea-pig differed greatly from those in the rat; c f. FIGS 3.1 and 
3.7. Blood lactate levels in the normal, fed guinea-pig appeared to peak 
after 5h, increasing from a resting concentration of 12 mg/100 ml (1.3 mM) 
to 132 mg/100 ml (14.6 mM). Blood glucose levels showed a massive hyper­
glycaemia lasting almost 4h, followed by a severe hypoglycaemia. The 
period of hyperglycaemia after biguanide administration corresponds to the 
mobilisation of the live r glycogen reserves of the animal to combat the 
hypoglycaemic action of the drug (Sterne, 1969). Glycogen depletion in 
the non-fasting animal precedes hypoglycaemia, survives i t  and appears in 
some animals without changes in blood glucose (Sterne, 1969). In the 
normal guinea-pig the blood glucose concentration at 5h (26 mg/100 ml;
1.4 mM) was only 20% of the resting level (128 mg/100 ml; 7.1 mM).
In the 24h-fasted guinea-pig blood lactate levels rose to less than 
50% of the lactate concentration in the non-fasted guinea-pig. Blood 
glucose concentrations showed no hyperglycaemic phase but fe ll steadily 
from 140 mg/100 ml (7.8 mM) to 56 mg/100 ml (3.1 mM) at 4h; see FIG. 3.9.
In the normal guinea-pig the hyperglycaemia which results from phenformin- 
induced glycogenolysis probably triggers the secretion of insulin. Such 
a response could explain the extremely rapid fa ll in blood glucose levels
due to the stimulation by insulin of glycogen synthesis and the glycolytic 
and oxidative pathways of carbohydrate metabolism and the inhibition of 
gluconeogenesis from lactate and glucogenic amino acids (West et aK , 1966; 
Ashmore and Weber, 1968; Felig, 1972; Weber, 1972). Insulin alone may 
cause slight rises in blood lactate concentrations by causing lactate to 
accumulate at a greater rate than i t  can be disposed of by oxidation 
(Alberti and Nattrass, 1977). The combined actions of insulin and toxic 
levels of phenformin (which also causes the accumulation of lactate by 
inhibiting its  elimination by oxidation and gluconeogenesis) could explain 
the exaggerated response in the normal guinea-pig. In the fasted animal 
the absence of hepatic glycogen deposits obviates the occurrence of a 
hyperglycaemic, insulinogenic response.
Dichloroacetate infusion alone did not reduce the normal blood lactate 
concentrations in the fasted guinea-pig but did significantly lower blood 
glucose levels; see FIG. 3.9. The fasted guinea-pig therefore behaves 
differently to the fasted rat in which dichloroacetate lowers blood lactate 
concentrations by 50% (Blackshear et al_., 1974). I t  should also be noted 
that blood lactate concentrations in untreated control fasted guinea-pigs 
were not lower than those in control normal guinea-pigs, while lactate  
levels in cardiac blood of fasted rats (6.8 + 1.7 mg/100 ml) are lower than 
those in normal rats (13.6 1.4 mg/100 ml) (Ramachander et a]_., 1968).
Dichloroacetate increased the hypoglycaemia and decreased the hyper- 
lactataemia associated with phenformin administration in the fasted guinea- 
pig; see FIG. 3.9. Blood lactate levels were not completely prevented from 
rising above normal but i t  should be noted that dichloroacetate was 
administered intraperitoneally in this species and intravenously in the 
ra t. The difference in effect in the two species may therefore re flec t  
only the influence of route of administration on the pharmacological
effectiveness of dichloroacetate. The dose administered (300 mg/kg/h) was
that reported as being effective in preventing the development of lactic
acidosis in fasted, SKF525A-treated rats.infused simultaneously with
phenformin (50 mg/kg/h) and dichloroacetate intravenously (Holloway and
%
Alberti, 1976). In view of the much greater increases in blood lactate 
which occur in phenformin treated guinea-pigs compared with rats, larger 
doses of dichloroacetate may be required to prevent hyperlactataemia in 
the guinea-pig.
Blood lactate levels in both the normal and fasted guinea-pig were 
elevated after administration of 4-hydroxyphenformin (15.2 mg/kg, molar 
equivalent to 12.5 mg phenformin/kg); see FIGS. 3.8 and 3.10. No hypoglycaem 
response was observed. The hyperlactataemia accompanying normoglycaemia is 
unlikely to have arisen from inhibition of oxidative phosphorylation or 
inhibition of gluconeogenesis. A lowering of the ATP/ADP ratio which would 
reduce pyruvate oxidation would also reduce gluconeogenesis and increase 
the rate of glycolysis. These changes would lead to a fa ll in blood glucose 
concentrations in fasted animals. Impaired gluconeogenesis in the presence 
of a normal level of glucose metabolism would also produce hypoglycaemia 
in the fasted animal. The increases in blood lactate after 4-hydroxy- 
phenformin administration could have resulted from an enhanced peripheral 
glycolysis without a corresponding increase in oxidative metabolism, similar 
to the observations of Searle and Siperstein (1975) with phenformin. Glucose 
concentrations may be maintained by gluconeogenesis from lactate and other 
glucogenic substrates and in normal animal by the breakdown of hepatic 
glycogen deposits. The absence of glycogen reserves in the fasted guinea- 
pig is probably reflected by an increased rate of gluconeogenesis. This 
could explain the slower rate of increase in blood lactate concentrations 
in fasted guinea-pigs compared with non-fasted animals.
4-Hydroxyphenformin-associated hyperlactataemia in the fasted
guinea-pig was prevented by dichloroacetate. This could be due to
the enhanced activ ity  of pyruvate dehydrogenase which follows
%
dichloroacetate administration (Whitehouse and Randle, 1973;
Whitehouse _et _al_., 1974).
The absence of an effect of 4-hydroxyphenformin on blood lactate 
and glucose levels in the normal rat may be attributed to a more 
effic ien t hepatic extraction and elimination of the compound, or may 
reflect a species difference in susceptibility to the effects of 
4-hydroxyphenformin on carbohydrate metabolism.
The blood lactate and glucose concentrations in fasted guinea-pigs 
treated with phenformin and 4-hydroxyphenformin alone and in conjunction 
with dichloroacetate are summarised in FIGS. 3.11 and 3.12.
The effect of thiamine pyrophosphate on the hyperlactataemic 
response to phenformin in the ra t was studied in the lig h t of a report 
by Valette et aK.(1975] that intravenous infusion of the compound 
C5nig/kg/h] in the dog counteracted the increase in blood lactate 
produced by intraduodenal administration of phenformin (30mg/kg). In 
the rat thiamine pyrophosphate QOmg/kg/h) did not reduce the increase 
in blood lactate associated with phenformin administration (120mg/kg); 
see FIG. 3.4. Slight changes were seen in the blood lactate profile  
in that the peak level occurred earlier and declined more rapidly. No 
explanation has been found for the s lightly higher lactate levels but 
the more rapid clearance may be due to enhanced activity of pyruvate 
dehydrogenase. Thiamine pyrophosphate is a coenzyme for the pyruvate 
dehydrogenase enzyme complex and thiamine deficiency causes elevations 
in blood lactate levels due to pyruvate accumulation (Harper, 1965;
FIG.3.11 Blood lactate concentration in the 24h-fasted guinea-pig 
receiving phenformin, 4-hydroxyphenformin or saline 
intraperitoneally, alone (a) or in conjunction with 
dichloroacetate (b).
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FIG. 3.12 Blood glucose concentrations in the 24h-fasted
guinea-pig receiving phenformin, 4-hydroxyphenformin 
or saline intraperitoneally, alone (a) or in conjuction 
with dichloroacetate (b ).
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Harken, 1976). The coenzyme is formed in the cell by transfer of
pyrophosphate from ATP to thiamine which is absorbed from the d iet.
I t  would be surprising to find that thiamine pyrophosphate is readily
distributed in the tissues after intravenous administration.
*
Thiamine its e lf  had no effect on the blood lactate or glucose profiles 
following phenformin administration; see FIG. 3.4.
The effects of chlorpropamide and phenformin alone and in conjunction 
with each other on blood lactate and glucose concentrations in the rat 
(see FIG. 3.5) reflec t the independent actions of the drugs on carbohydrate 
metabolism. The sulphonylureas such as chlorpropamide produce 
hypoglycaemia by stimulating the release of insulin from the pancreatic
3-cells (P fe iffer eit aJ_., 1969).
The fa ll in blood lactate concentrations seen after administration 
of chlorpropamide to rats (see FIG. 3.5) probably results from an 
increased oxidation of pyruvate, as gluconeogenesis is inhibited by 
insulin. Insulin alone, or with glucose in patients with hypoglycaemia, 
has been recommended for the treatment of biguanide-associated lac tic  
acidosis (Johnson and Waterhouse, 1968; Dembo et a l . ,  1975; FuTop and 
Hoberman, 1976). The rationale for this is that by activating pyruvate 
dehydrogenase the hormone w ill enhance lactate clearance. However by 
stimulating glycolysis and inhibiting gluconeogenesis insulin may cause 
lactate to accumulate more rapidly than i t  can be oxidised (Alberti and 
Nattrass, 1977). This may explain the prolonged hyperlactataemia produced 
in rats after treatment with both phenformin and chlorpropamide. The 
impaired oxidative phosphorylation caused by phenformin may p artia lly  
counteract the enhanced oxidation of pyruvate associated with insulin
secretion with the result that combined therapy causes accumulation 
of lactate. Bramanti et al_. (1971a) have reported that in blood samples 
taken from guinea-pigs 4h after administration of phenformin (0-40 mg/kg 
orally) and chlorpropamide (50 or 100 mg/kg orally) the blood lactate
I
levels were about double those occurring after phenformin alone.
The increased blood lactate concentrations in the guinea-pig on 
combined therapy were accompanied by an enhanced hypoglycaemic effect 
(Bramanti e t a1_., 1971a, b). This was not seen in the ra t (see FIG.3.5) 
where the hypoglycaemic effect of chlorpropamide alone was as 
great as that measured after combined therapy with phenformin. Such 
contrasts between the rat and guinea-pig are not surprising in view of 
the marked species differences in pharmacological susceptibility to 
phenformin (b'ngar et al_.,1957) and the differences in the metabolism 
and excretion of both phenformin (see CHAPTER 2) and chlorpropamide 
(P fe iffer et a l .,1969).
CHAPTER 4 
FINAL DISCUSSION
The aim of these studies has been to investigate the role of 
the metabolism of phenformin in the species differences in the 
hypoglycaemic and hyper!actataemic responses to the drug and in the 
aetiology of phenformin-associated lactic acidosis. The metabolism 
and excretion of [2‘ - 14C]phenformin in the rat and guinea-pig have 
been studied and the effects of phenformin and 4-hydroxyphenformin 
on blood lactate and glucose concentrations have been determined.
The view widely expressed in the literature  is that the 
differences in hypoglycaemic response to phenformin in the rat and 
guinea-pig arise from differences in the degree of metabolism of 
the drug in the two species. This belie f stems from the reports of 
Beckman (1967, 1968) that rat urine after a 50 mg/kg oral dose of 
[3H]phenformin contained only 4-hydroxyphenformin (and its  glucuronide) 
while guinea-pig urine contained almost exclusively parent compound 
with only traces of the metabolites. In contrast, the present studies 
have shown that although the drug was less extensively metabolised 
by the guinea-pig, guinea-pig urine contained approximately equal amounts 
of unchanged phenformin and metabolites a fter oral dosing and that
4-hydroxyphenformin was not excreted; see TABLE 2.3 and FIG. 2.9. 
Guinea-pig faeces also contained large amounts of a novel metabolite, 
but as neither the faecal nor the urinary metabolite have been identified  
i t  is not possible to state whether these are biologically active 
metabolites or inactive. Beckmann (1966)has reported that an inverse 
correlation exists for buformin between the hypoglycaemic activ ity  in 
different species and the degree of metabolism. The present findings, 
together with the report that phenformin (50 mg/kg) produced hypoglycaemi 
in the mouse which excreted predominantly 4-hydroxyphenformin glucuronide 
but not in the rabbit which excreted large amounts of the parent compound
along with the same metabolites (Beckmann, 1967) indicate that with 
phenformin such a simple relationship does not hold.
In contrast to the report of Beckmann (1967) the guinea-pig 
showed a slower rate of excretion of radioactivity than the rat after  
low oral doses of [21—14C]phenformin; see TABLE 2.2. The differences 
in the urinary excretion of unchanged parent compound (see TABLE 2.3) 
suggest a slower rate of metabolism in the guinea-pig and this is 
supported by the differences in the rate o f metabolism in isolated 
hepatocytes; see FIG. 2.24a. These metabolic and dispositional 
differences may contribute significantly to the increased pharmacological 
response of the guinea-pig to a given dose of the drug.
Differences in the rates of metabolism and excretion, however, 
are unlikely to account entirely for the species differences in the 
hypoglycaemic and hyperlactataemic responses. The effects of phenformin 
on blood glucose and lactate concentrations were more pronounced in 
the guinea-pig after administration of 12.5 mg/kg intraperitoneally 
than in the rat after doses of 100-120 mg/kg (see CHAPTER 3) although 
in both cases most of the dose was rapidly eliminated in the urine as 
an approximately equal mixture of the parent compound and metabolites.
As some 22% of the guinea-pig urinary radioactivity (16% of the dose) 
was accounted for as the unidentified metabolite (metabolite 4) and its  
glucuronide i t  remains possible that the sensitivity of this species 
to the pharmacological actions of phenformin may be due to the formation 
of a biologically active metabolite.
y  .
The variations in pharmacological response to phenformin in 
different animals may be the result of differences in the mechanism of 
glucose regulation. Species differences exist in the regulation of 
hepatic gluconeogenesis, partly due to the in tracellu lar distribution
of the enzyme phosphoenolpyruvate carboxykinase. This enzyme is 
present in the mitochondria and cytosol in varying proportions in 
different animals (Nordlie and Lardy, 1963). The two forms of 
the enzyme are separate proteins regulated in different manners 
(Ballard and Hanson, 1969). Guinea-pig and man fa ll into the same 
group with the enzyme equally distributed between the cytosol and 
mitochondria while the rat enzyme is predominantly cytosolic (Nordlie 
and Lardy, 1963; Hanson and Garber, 1972).
In comparison to rat live r the cytosolic redox state (calculated 
from the lactate dehydrogenase couple) is more reduced in the guinea- 
pig and the mitochondrial redox state (calculated from the 3-hydroxy- 
butyrate dehydrogenase couple) is more oxidised (Willms jet a/h, 1970; 
Garber and Hanson, 1971a,b; Sflling and Kleineke, 1976). In species 
with mitochondrial phosphoenol pyruvate carboxykinase activ ity  (e.g. 
guinea-pig and man) conditions which lead to oxidation of the 
mitochondrial NAD /NADH system, such as fasting (Garber and Hanson, 
1971a,b) favour mitochondrial synthesis of phosphoenol pyruvate by 
increasing the mitochondrial concentration of oxaloacetate. Similarly, 
conditions which lead to reduction of the mitochondrial NAD+/NADH 
system, such as fatty  acid oxidation, impair mitochondrial synthesis 
of phosphoenolpyruvate by increasing the mitochondrial concentration 
of malate at the expense of oxaloacetate (Garber and Hanson, 1971 a,b; 
Arinze et aJL, 1973). This may explain the fact that fa tty  acids have 
an inhibitory effect on gluconeogenesis from lactate in guinea-pig 
liv e r. In rat liv e r on the other hand, fatty  acids stimulate gluconeo­
genesis mainly by causing an increase in the activ ity  of pyruvate 
carboxylase due to an.increased level of acetyl-CoA and by decreasing 
the activity of pyruvate dehydrogenase (Sdling e t al_., 1970; Arinze
J -iiL l*9 1973; SOIing and Kleineke, 1976).
Alternatively, hepatic gluconeogenesis in the guinea-pig may 
be inhibited by fatty acid oxidation due to a decrease in the 
concentration of pyruvate resulting from an increased reduction of 
the cytosolic NAD+/NADH system (Sflling and Kleineke, 1976). The 
lactate/pyruvate ratio in-guinea-pig live r is considerably higher than 
in rat liv e r and increases further in the presence of fa tty  acids 
(Willms jit  a1_., 1970). For a given concentration of lactate the 
concentration of pyruvate is always less with isolated, perfused 
guinea-pig livers than with rat livers under the same conditions 
(Willms et a l . ,  1970.).
The susceptibility of the gluconeogenic enzymes in guinea-pig
liv e r to inhibition by changes in the cytosolic or mitochondrial
redox states may explain the particular sensitivity of this animal
to the pharmacological effects of phenformin. Haeckel and Haeckel (1972)
have shown that in perfused livers from guinea-pigs pretreated with
phenformin the ATP/ADP ratio was lowered but gluconeogenesis was
unaffected. At the same time small increases in the 3-hydroxybutyrate/
acetoacetate and lactate/pyruvate ratios were measured, and the
concentration of malate but not oxaloacetate was increased. Addition
-5of phenformin (2 x 10 M) to the perfusate produced a 60% inhibition  
of gluconeogenesis without further depressing the ATP/ADP ratio but with 
further increases in the cytosolic and mitochondrial redox couples.
These results suggest that in the guinea-pig a small decrease in the 
liver ATP/ADP ratio , which is insufficient to inh ib it gluconeogenesis 
by directly limiting the supply of ATP, may s t i l l  be suffic ien t to 
increase the reductive state of the cytosolic and mitochondrial NAD+/
NADH systems which in turn would impair glucose synthesis by lim iting
the substrate available for either or both of the key enzymes, 
pyruvate carboxylase and phosphoenolpyruvate carboxykinase.
Rat liv e r, on the other hand, is less susceptible to these 
reductive changes (as shown by the effects of fatty  acid administration) 
and in this species phenformin probably has l i t t l e  effect on gluconeo­
genesis until high doses of the drug are administered which cause a 
substantial depletion of hepatic ATP levels. As human live r is 
similar to guinea-pig live r in the intracellu lar distribution of 
phosphoenolpyruvate carboxykinase i t  is possible that a similar series 
of changes may occur in man in response to intermediate doses of 
phenformin.
The present studies indicate that a number of factors are involved 
in the species differences in response to phenformin and that the widely 
held view that the rate of metabolism is the controlling factor in the 
pharmacological activ ity  of the drug in different species (Beckmann, 1967; 
Cook et. afL, 1973a) is an oversimplification.
The differences in pharmacological activity  in the rat and guinea-pig 
can be explained by the results in this thesis, which show a slower rate 
of metabolism and excretion in the guinea-pig, together with the established 
biochemical differences in the mechanisms of carbohydrate regulation in 
these species. Contrary to the report of Beckmann (1967) the guinea-pig 
was found partly to metabolise phenformin but excreted an oral dose more 
slowly than the ra t. B iliary excretion was also shown to be less significant 
in the guinea-pig. Although in trinsically  this may be an important route 
for the elimination of phenformin in the guinea-pig, i t  appears to be 
easily inhibited, at least by the dose level used in this study. At lower 
dose levels i t  may be that b ilia ry  excretion is more e ffic ie n t as i t  may 
not be inhibited.
The possibility that the guinea-pig may produce a biologically 
active metabolite has not been resolved. The previously unreported 
metabolites have been detected in guinea-pig urine and faeces after 
oral dosing. The urinary metabolite is probably the product of 
aliphatic hydroxylation rather than aromatic hydroxylation and both 
metabolites have modified biguanide portions (see APPENDIX), but their 
complete characterisation and pharmacological properties remain to be 
determined.
The hyperlactataemic activity of 4-hydroxyphenformin in the guinea- 
pig is of interest. Man reportedly excretes equal quantities of 4- 
hydroxyphenformin and parent compound after administration of [3H]phenformin 
(Beckmann, 1967). The pharmacological activ ity  of this metabolite in man 
requires investigation.
The existence of a critica l dose level for the hypoglycaemic and 
hyperlactataemic actions of phenformin together with the dose-related 
degree of metabolism (see SECTION 2.3) of the drug provide further 
indications that the toxic actions of phenformin are related to 
accumulation of the active drug. These findings may explain the 
predisposition to Tacticacidosis of patients with renal and hepatic 
dysfunction.
Sodium dichloroacetate was shown to be effective in controlling 
phenformin-associated hyperlactataemia and enhanced the hypoglycaemic 
action of the drug. A combination of sodium dichloroacetate and a 
reduced dose of phenformin may therefore be valuable in the treatment 
of some forms of diabetes. However, more extensive biochemical and 
toxicological studies are required to determine the therapeutic potential 
of the combined treatment. The risks of ketosis are increased (see 
SECTION 3.3) but this may cause less d iffic u lty  in ketoacidosis-resistant 
diabetes.
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APPENDIX 
INTERPRETATION OF MASS SPECTRA
APPENDIX
Confirmation of the structures of metabolites 1 and 2 in rat urine 
and metabolite 1 in guinea-pig urine was obtained by mass spectrometry 
as described in CHAPTER 2. Examples of the positive-ion distribution  
spectra for authentic and isolated samples of phenfomiin and 4-hydroxy­
phenformin are presented in FIGS. 2.13-2.16.
The biguanides are insufficiently volatile  to produce spectra until
subjected to high temperatures when they form triazine derivatives by
internal condensation. Suggested structural assignments for the major
positive ions in the electron-irnpact spectra of phenformin and 4-hydroxy-
m*
phenformin are given in Fig. 1. The symbol /e  is used to denote the 
occurrence of a rnetastable ion accompanying a particular transition. The 
position of m* accompanying the transition of ion nix to m2 is given by 
equation (1) (Budzikiewicz e t  al_.s 1967). In FIG. 1 homolytic bond fission
involving one-electron movements are signified using the "fishhook" symbol 
( —^  ) introduced by Budzikiewicz et al_.(1964, 1967). For the sake of 
simplicity only one "fishhook" is written whem homolvsis of a bond is 
indicated so that the expressions in (2) are synonymous. The usual arrow 
( — **.) denotes a two-electron sh ift as in (3 ).
O )
\ (2 )
(3 )
Wickramasinghe and Shaw (1972) have reported that after mass spectro- 
metric analysis of the single g .l .c . peak produced by phenformin at 225-230°
produced a t 220-230 (70eV)
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the parent ion occurred at m/e 230 and prominent peaks were found at
m/e  values of 139, 110, 91 and 68. The mass spectrum of 4-hydroxyphenformin
does not appear to have been reported previously.
After direct insertion mass spectrometry at 220-230°«the parent 
ion for phenformin occurred at m/e  334 corresponding to the disubstituted 
triamino-s-triazine ion ( I ) .  Cleavage at the C-C bond adjacent to a 
nitrogen atom (a-cleavage) whose non-bonding electrons provide resonance 
stabilisation (Silverstein and Bassler, 1967) resulted in the base peak 
at m/e 243 ( I I ) ;  see FIG. l.b . Under the same conditions the parent ion 
for 4-hydroxyphenformin occurred at m/e  246 and corresponded to the mono­
substituted triamino-s-triazine (XVI) while the base peak was due to the 
fragment at m/e 43 (XV); see FIG. l . i .  When 4-hydroxyphenformin was heated
at 220-230° for several minutes the ions (XXI) and (XXII) corresponding
/
to ( I )  and ( I I )  from phenformin could also be detected and the spectrum 
resembled that of phenformin more closely.
CH2CH NH
ra/e  366 Q(XI1
T
NH^ cT ) ch2
m*/e  obs. 183.3 
calc .183.28
ch2ch2nh
m/e 259 (M U )
ry-
f
nh=ch2
The ions ( I I I ) ,  (V.)9 (VI) and (IX) appear to be produced by 
McLafferty rearrangements which involve the transfer of y-hydrogen 
radicals in six-membered transition states (Budzikiewicz et aT_., 1967). 
Styrene (IX) may retain the charge i f  the nitrogen containing fragment 
is eliminated as a neutral molecule (FIG. l.h ) or may its e lf  be expelled 
as a neutral fragment (FIG. l .c ,  d and g).
The ions at m/e  139 (V) and ra/e  126 (VI) or 127 (X V III) appear to 
be characteristic of the fragmentation of the triazine structures formed 
by phenformin and 4-hydroxyphenformin. The ion (V) may be formed by 
a-cleavage (FIG. 1.e and m) or by McLafferty rearrangement (FIG. 1 .d) 
and produces a number of smaller fragments by successive elimination of 
small neutral molecules (FIG. l . f ,  i and j ) .
The phenolic portion of 4-hydroxyphenformin gives rise to the hydroxy-
m +tropylium ion (XIX) at /e  107 which fragments further to give the
ion (m/e 77). Whether this occurs by the elimination of formaldehyde as
depicted in FIG. l.n , or by successive elimination of CO and two hydrogens
as shown below (Budzikiewicz et al_., 1967) is a matter for conjecture.
The appearance of a metastable ion is generally regarded as evidence that
the neutral atoms are ejected in a one-step process as a single entity .
However, a number of examples of decomposition reactions which occur with
appropriate metastable peaks, but are like ly  to correspond to two-step
roA> 107 (XIX)
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processes have been reported (Budzikiewicz jet aj[., 1967) .
The mass spectra of guinea-pig metabolites 4 and 6 contained 
no evidence of the positive ions characteristic of phenolic or 
triazine groupings. As metabolite 4 is also excreted as an 0- 
glucosiduronic acid conjugate [metabolite 5) the absence of the 
hydroxytropylium ion (XIX) in the mass spectrum suggests that 
hydroxylation has occurred on the aliphatic side chain of the 
molecule. The absence of the ions (V), (V I), (X II) and (X II I)  
which characterise the triazine structures formed by phenformin 
and 4-hydroxyphenformin may be an indication that the biguanide 
portions of metabolites 4 and 6 have been modified. The spectra 
of both metabolites contained ions at m/e values of 77 (XX) and 
65 (XIV) which were related by the presence of metastable ions. This 
transition indicates the presence of the aromatic phenyl moiety 
(Budzikiewicz et al_., 1967; Silverstein and Bassler, 1967).
Treatment of the urinary aglycone with acetic anhydride in 
pyridine did not result in the appearance in the mass spectrum of positive 
ions characteristic of the triazine structure which would be expected 
to form in the presence of an intact biguanide grouping; see FIG. 1.3.
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